Sentence,class,file
NIH grant to Redell JB: NIH #R21NS078596- 01; MiR-223 regulation of blood brain barrier function after traumatic brain injury 2012; Uni-versity of Texas health Sc ience Center Houston; http://projectreporter.nih.gov/project_info_ description.cfm?projectnumber=1R21NS078596- 01 123.,Non-OADS,/arxiv_data1/oa_pdf/a6/66/ktib-02-e944446.PMC4292042.pdf
Tissue Barriers 2014; 2:e28320; PMID: 24843843; http://dx.doi.org/10.4161/tisb.28320 124.,Non-OADS,/arxiv_data1/oa_pdf/a6/66/ktib-02-e944446.PMC4292042.pdf
"org Submitted: 04/16/2014; Revised: 06/08/2014; Accepted: 06/22/2014http://dx.doi.org/10.4161/21688362.2014.944449 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
NeuroRx2005; 2:3-14; PMID:15717053; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
FEMS Immunol Med Microbiol 2011; 63:297-318; PMID:22092557; http://dx.doi.org/ 10.1111/j.1574-695X.2011.00867.x 4.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nat Rev Microbiol 2010; 8:645-55; PMID:20706281; http://dx.doi.org/ 10.1038/nrmicro2395 6.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nat Rev Microbiol 2010;8:231-41; PMID:20125087; http://dx.doi.org/ 10.1038/nrmicro2296 7.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Mass Spectrom Rev2008; 27:575-95; PMID:18498137; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Adv Exp Med Biol 2013; 790:1-23; PMID:23884583; http://dx.doi.org/10.1007/978-1-4614-7651-1_1 10.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Structure 2000; 8:R157-62; PMID:10997898; http://dx.doi.org/10.1016/S0969-2126(00)00181-7 12.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nat Rev Immunol2011; 11:318-29; PMID:21508982; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Med Microbiol 2006;55:785-90; PMID:16687600; http://dx.doi.org/ 10.1099/jmm.0.46370-0 16.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J BiolChem 2002; 277:37655-62; PMID:12163480; http://dx.doi.org/10.1074/jbc.M201374200 18.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Gen Virol 1984;65(Pt 4):781-9; PMID:6423770; http://dx.doi.org/ 10.1099/0022-1317-65-4-781 21.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Neurovirol 2009; 15:111-22; PMID:19306229;http://dx.doi.org/10.1080/13550280902769764 22.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Brain Res 2011; 1399:96-115; PMID:21641584; http://dx.doi.org/ 10.1016/j.brainres.2011.05.015 23.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Microbes Infect 2006;8:1347-57; PMID:16697675; http://dx.doi.org/ 10.1016/j.micinf.2005.11.014 24.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Exp Neurol 2005; 193:218-27; PMID:15817280; http://dx.doi.org/10.1016/j.expneurol.2004.11.019 26.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Drug Target 2012; 20:235-45; PMID:22188312; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Angiogenesis 2002; 5:141-51; PMID:12831055; http://dx.doi.org/10.1023/ A:1023892223074 28.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Cell Microbiol 2001; 3:277-87; PMID:11298651; http://dx.doi.org/10.1046/j.1462-5822.2001.00116.x 31.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Toxins 2010; 2:2622-44; PMID:22069568; http://dx.doi.org/ 10.3390/toxins2112622 32.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Toxicon: Off J Int Soc Tox- inol 2013; 66:59-63; PMID:23419592; http://dx.doi.org/10.1016/j.toxicon.2012.12.027 33.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Physiol 2013; 591:1031-43; PMID:23109108; http://dx.doi.org/10.1113/jphysiol.2012.242131 37.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
"Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botuli- num neurotoxin A. J Neurosci: Off J Soc Neurosci 2008; 28:3689-96; PMID:18385327; http://dx.doi.org/10.1523/JNEUROSCI.0375-08.2008 38.",Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Mol Microbiol 2012; 86:1116-31; PMID:23095033;http://dx.doi.org/10.1111/mmi.12045 41.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Biol Chem 2000; 275:36769-74; PMID:10973983; http://dx.doi.org/10.1074/jbc.M007382200 43.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nature1997; 387:725-9; PMID:9192900; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Microb Pathogenesis 2003; 35:35-42; PMID:12860457;http://dx.doi.org/10.1016/S0882-4010(03)00090-1 45.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Clin Investi 2009; 119:1638-46; PMID:19436113;http://dx.doi.org/10.1172/JCI36759 48.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nat Rev Immunol 2003; 3:569-81; PMID:12876559; http://dx.doi.org/ 10.1038/nri1130 49.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Immunol2004; 172:4418-24; http://dx.doi.org/10.4049/ jimmunol.172.7.4418 50.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Infect Immun 2003; 71:95-100; PMID:12496153; http://dx.doi.org/10.1128/IAI.71.1.95-100.2003 51.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Glia 2013; 61:611-22; PMID:23322603; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Toxicon: Off J Int Soc Toxinol 2012; 60:478-91; PMID:22543187; http://dx.doi.org/10.1016/j.toxicon.2012.04.337 54.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Expert OpinBiol Ther 2011; 11:1469-84; PMID:21939428; http://dx.doi.org/10.1517/14712598.2011.621940 55.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Tox- icon: Off J Int Soc Toxinol 1998; 36:1573-83;PMID:9792173; http://dx.doi.org/10.1016/S0041- 0101(98)00149-4 56.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biochem J 2004; 378:717-26; PMID:14674883; http://dx.doi.org/10.1042/BJ20031860 57.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
JMol Biol 2000; 297:771-80; PMID:10731427; http://dx.doi.org/10.1006/jmbi.2000.3609 58.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Protein Sci 2004; 13:1197-208;PMID:15096626; http://dx.doi.org/10.1110/ ps.03584304 59.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
"Neurochem Res 2012;37:1967-81; PMID:22684283; http://dx.doi.org/ 10.1007/s11064-012-0817-y 60. de Paula Le Sueur L, Kalapothakis E, da Cruz- Hoﬂing MA.",OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Trends Pharmacol Sci 2006; 27:482- 91; PMID:16876883; http://dx.doi.org/10.1016/j.tips.2006.07.004 62.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Toxicon: Off J Int Soc Toxinol 2010; 56:855-67; PMID:20670641; http://dx.doi.org/ 10.1016/j.toxicon.2010.07.010 64.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Biol Chem 2012; 287:6725-34; PMID:22223648; http://dx.doi.org/ 10.1074/jbc.M111.32231366.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biophys J 2009; 97:2089-97; PMID:19804741; http://dx.doi.org/10.1016/j.bpj.2009.07.037 68.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Immunoassay Immunochem 2009; 30:262-90; PMID:19591041; http://dx.doi.org/ 10.1080/15321810903084400 70.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Marine drugs 2012; 10:1244-65; PMID:22822370; http://dx.doi.org/10.3390/md10061244 71.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Pharmacol Rev 2012; 64:259-98; PMID:22407615; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Biol Chem 2013; 288:25428-39; PMID:23846688; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Centers for Disease Control; 2013; http://www.selectagents.gov/Select %20Agents%20and%20Toxins%20List.html 74.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Glia 2002; 39:162-73; PMID:12112367; http://dx.doi.org/10.1002/glia.10083 76.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Toxicon: Off J Int Soc Toxinol 2003; 41:125-8; PMID:12565730; http://dx.doi.org/10.1016/ S0041-0101(02)00294-5 77.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Toxicon 2006; 47:348-55; PMID:16387337; http://dx.doi.org/10.1016/j.toxicon.2005.11.013 78.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nat Bio- technol 2011; 29:341-5; PMID:21423189; http://dx.doi.org/10.1038/nbt.1807 79.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nature 2007; 448:39- 43; PMID:17572664; http://dx.doi.org/10.1038/ nature05901 80.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Cancer Res 2007; 67:6882-8; PMID:17638899; http://dx.doi.org/ 10.1158/0008-5472.CAN-06-3948 82.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Clin Oncol 2006; 24:3644-50; PMID:16877732; http://dx.doi.org/10.1200/JCO.2005.05.4569 83.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biomaterials 2011; 32:2399-406; PMID:21185076; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
ACS Nano 2010; 4:4587-94; PMID:20731441; http://dx.doi.org/10.1021/nn1008512 86.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Mol Pharm 2010; 7:1930-9; PMID:20722417; http://dx.doi.org/ 10.1021/mp100221h 87.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biomaterials 2010; 31:8032-42;PMID:20673683; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Drug Del 2012; 2012:975763; PMID:23304519; http://dx.doi.org/ 10.1155/2012/975763 90.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Adv Healthc Mater 2012; 1:342-7; PMID:23184752; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Drug Target 2012; 20:67-75; PMID:22149216; http://dx.doi.org/10.3109/ 1061186X.2011.595490 9 3 .,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biomaterials 2011;32:5177-86; PMID:21531455; http://dx.doi.org/ 10.1016/j.biomaterials.2011.03.075 94.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Control Release: Off J Control Release Soc 2011; 152:402-10; PMID:21435361; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nanomedicine 2010; 5:1357-69; PMID:21128719; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Acta Pharmacol Sinic 2007; 28:2019-26;PMID:18031618; http://dx.doi.org/10.1111/ j.1745-7254.2007.00661.x 98.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
ACS Nano 2010; 4:2402-10; PMID:20232826; http://dx.doi.org/10.1021/nn100190v 99.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nanomedicine 2008; 3:495-505; PMID:18694312; http://dx.doi.org/10.2217/17435889.3.4.495 100.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Small2008; 4:372-9; PMID:18232053; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Small 2009; 5:256-64; PMID:19089837; http://dx.doi.org/10.1002/smll.200800646 102.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Cancer Res 2009; 69:6200-7; PMID:19638572; http://dx.doi.org/ 10.1158/0008-5472.CAN-09-1157 103.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nanotechnology 2010; 21:235104; PMID:20472942; http://dx.doi.org/10.1088/0957-4484/21/23/235104 104.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nano Letters 2009; 9:2589-99; PMID:19507837; http://dx.doi.org/10.1021/nl900789e 105.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biotechnol Bioeng 2013; 110:1211-20; PMID:23125026; http://dx.doi.org/10.1002/bit.24775106.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Mol Pharm 2010; 7:1940-7; PMID:20964364; http://dx.doi.org/10.1021/mp100238j 107.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
ACS Nano 2010; 4:6617-28; PMID:20939520;http://dx.doi.org/10.1021/nn101867w 108.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Brain Res 2004; 995:84-96; PMID:14644474; http://dx.doi.org/10.1016/j.brainres.2003.09.063 109.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Exp Neurol 1997; 145:546-54; PMID:9217090; http://dx.doi.org/10.1006/exnr.1997.6490 112.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Control Release: Off J Control Release Soc 2014; 180C:81-90; http://dx.doi.org/ 10.1016/j.jconrel.2014.02.011 113.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biomaterials 2009;30:951-8; PMID:19046764; http://dx.doi.org/ 10.1016/j.biomaterials.2008.10.059 114.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Adv Mater 2013; 25:6233-7; PMID:23946251; http://dx.doi.org/ 10.1002/adma.201302737 115.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nat Rev Neurol 2012; 8:307-18; PMID:22526003; http://dx.doi.org/10.1038/nrneurol.2012.76 116.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Neurovirol 2003; 9:247-52; PMID:12707855; http://dx.doi.org/10.1080/13550280390193993 117.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Cell 2006; 127:305-16; PMID:17055432; http://dx.doi.org/ 10.1016/j.cell.2006.08.046 119.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Cell 2004; 119:915-26; PMID:15620351; http://dx.doi.org/ 10.1016/j.cell.2004.11.007 www.landesbioscience.com e944449-11 Tissue Barriers,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Curr HIV Res 2006; 4:267-78; PMID:16842080; http://dx.doi.org/10.2174/157016206777709500 121.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nat Med 2004; 10:1366-73; PMID:15558055;http://dx.doi.org/10.1038/nm1140 122.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
JBiol Chem 2004; 279:54533-41; PMID:15475343; http://dx.doi.org/10.1074/jbc.M410208200 123.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Biol Chem 2003; 278:16857-62; PMID:12615923; http://dx.doi.org/10.1074/jbc.M301028200 125.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
"Thepparit C, Smith DR. Serotype-speciﬁc entry of dengue virus into liver cells: identiﬁcation of the 37- kilodalton/67-kilodalton high-afﬁnity laminin receptor as a dengue virus serotype 1 receptor.J Virol 2004; 78:12647-56; PMID:15507651; http://dx.doi.org/10.1128/JVI.78.22.12647-12656.",Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Mol Recognit 2008; 21:55-62; PMID:18061925; http://dx.doi.org/ 10.1002/jmr.866 127.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Mol Ther: J Am Soc Gene Ther 2005; 12:813-23; PMID:16109508; http://dx.doi.org/10.1016/j.ymthe.2005.06.476 129.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Mol Pharm 2010; 7:1940-7; PMID:20964364; http://dx.doi.org/10.1021/mp100238j 132.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Pharmacological characterization of alpha-elapitoxin-Al2a from the venom of the Australian pygmy copperhead (Austrelaps labialis): an atypical long-chain alpha-neurotoxin with only weak afﬁnity for alpha7 nicotinic receptors.Biochem Pharmacol 2012; 84:851-63; PMID:22771828; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Toxicon: Off J Int Soc Toxinol 2009; 54:295-301; PMID:19393680; http://dx.doi.org/10.1016/j.toxicon.2009.04.016 134.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biochemistry 2007; 46:6628-38; PMID:17497892; http://dx.doi.org/ 10.1021/bi7004202 135.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
EMBO J 2007; 26:3858-67; PMID: 17660751; http://dx.doi.org/10.1038/sj.emboj.7601785 136.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biochem Pharmacol 2013; 86:791-9; PMID:23924607; http://dx.doi.org/ 10.1016/j.bcp.2013.07.016 137.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Nat Bio- technol 2011; 29:341-5; PMID:21423189; http://dx.doi.org/10.1038/nbt.1807 140.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biomaterials 2011; 32:4968-75; PMID:21489620;http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Phar-maceut Res 2012; 29:1562-9; PMID:22231987; http://dx.doi.org/10.1007/s11095-012-0667-y 142.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biomaterials 2013; 34:1170-8; PMID:23122677; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Drug Target 2011; 19:228-34; PMID:20540685; http://dx.doi.org/10.3109/1061186X.2010.492523 144.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
C h e m b i o c h e m :E u rJC h e mB i o l2 0 0 8 ;9 : 2 1 9 - 31; PMID:18076008; http://dx.doi.org/10.1002/ cbic.200700277 146.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Targeted gene delivery into peripheral sensorial neurons mediated by self-assembled vectors composed of poly(ethyleneimine) and tetanus toxin fragment c. J Control Release: Off J Control Release Soc 2010; 143:350- 8; PMID:20093157; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Biol Chem 1995; 270:15434-42; PMID:7797532; http://dx.doi.org/ 10.1074/jbc.270.25.15434 152.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
J Drug Target 2013; 21:662-74; PMID:23697582; http://dx.doi.org/ 10.3109/1061186X.2013.796954 153.,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Brain Res 2006; 1120:1-12; PMID:17020749; http://dx.doi.org/ 10.1016/j.brainres.2006.08.079 154.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biochem Biophys Res Commun 2009; 390:947-51; PMID:19852934;http://dx.doi.org/10.1016/j.bbrc.2009.10.083 155.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
Biomaterials 2007; 28:5176- 84; PMID:17854886; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5e/b3/ktib-02-e944449.PMC4292043.pdf
"5,6Keywords: cell motility, E-cadherin, Epi- thelial to Mesenchymal Transition,MUC1, P120 catenin, Pancreatic cancermetastasis Abbreviations: EMT, epithelial to mesen- chymal transition; Mucin 1, MUC1; ctn,catenin © Xiang Liu, Huocong Huang, Neeley Remmers, and Michael A Hollingsworth*Correspondence to: Michael A Hollingsworth;Email: mahollin@unmc.edu Submitted: 09/05/2014 Revised: 09/18/2014Accepted: 09/19/2014http://dx.doi.org/10.4161/21688362.2014.969112 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/43/65/ktib-02-e969112.PMC4292045.pdf
Dev Dyn 2005; 232:685-94; PMID:15712202; http://dx.doi.org/10.1002/dvdy.20334 2.,OADS,/arxiv_data1/oa_pdf/43/65/ktib-02-e969112.PMC4292045.pdf
Dev Cell 2008; 14:570-81; PMID:18410732; http://dx.doi.org/10.1016/j.devcel.2008.03.003 3.,OADS,/arxiv_data1/oa_pdf/43/65/ktib-02-e969112.PMC4292045.pdf
Int J Cancer 2013; 132:1487-95; PMID:22833228; http://dx.doi.org/ 10.1002/ijc.27745 6.,Non-OADS,/arxiv_data1/oa_pdf/43/65/ktib-02-e969112.PMC4292045.pdf
Oncogenesis2014; 3:e107; PMID:24979278; http://dx.doi.org/ 10.1038/oncsis.2014.19 10.,Non-OADS,/arxiv_data1/oa_pdf/43/65/ktib-02-e969112.PMC4292045.pdf
PLoS One 2012; 7:e37864; PMID:22662240; http://dx.doi.org/10.1371/journal.pone.0037864 11.,Non-OADS,/arxiv_data1/oa_pdf/43/65/ktib-02-e969112.PMC4292045.pdf
Cells Tissues Organs 2011; 193:23-40; PMID:21051859;http://dx.doi.org/10.1159/000320174 13.,Non-OADS,/arxiv_data1/oa_pdf/43/65/ktib-02-e969112.PMC4292045.pdf
Cell 2014; 158:1110-22; PMID:25171411; http://dx.doi.org/ 10.1016/j.cell.2014.07.013 21.,OADS,/arxiv_data1/oa_pdf/43/65/ktib-02-e969112.PMC4292045.pdf
Annu Rev Cell Dev Biol 2009; 25:407-29; PMID:19575657; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/43/65/ktib-02-e969112.PMC4292045.pdf
Cell 2014; 157:1146-59; PMID:24855950; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/43/65/ktib-02-e969112.PMC4292045.pdf
Clin Cancer Res 2013; 19:1981-93; PMID:23446997; http://dx.doi.org/10.1158/1078-0432.CCR-12-2662 e969112-6 Volume 2 Issue 4 Tissue Barriers,Non-OADS,/arxiv_data1/oa_pdf/43/65/ktib-02-e969112.PMC4292045.pdf
"Tumor necrosis factor (TNF) receptor- associated factor 4 (TRAF4), a gene origi-nally identiﬁed in breast cancer, isKeywords: breast cancer, cell migration, tight junction, TRAF domain, phospho-inositide Abbreviations: TRAF4, tumor necrosis factor (TNF) receptor-associated factor 4;TJ, tight junction; PIP, phosphoinositide;MEC, mammary epithelial cell; TGF- b, transforming growth factor b; EMT, epi- thelial-mesenchymal transition; ZF, zincﬁnger © Adrien Rousseau, Lea P Wilhelm, Catherine Tomasetto, and Fabien Alpy*Correspondence to: Fabien Alpy;Email: Fabien.Alpy@igbmc.fr Submitted: 09/01/2014 Revised: 10/07/2014Accepted: 10/07/2014http://dx.doi.org/10.4161/21688370.2014.975597 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
"Semin Cell Dev Biol [Internet] [cited 2014 Sep 30]; Available from: ""http://www.sciencedirect.comsciencearticlepiiS1084952114002511""; PMID: 25171873 2.",OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Curr Opin Cell Biol 2005;17:453-8; PMID:16098725; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Oncogene 2008; 27:6939-57; PMID: 19029936; http://dx.doi.org/10.1038/onc.2008.345 4.,Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Nat Cell Biol 2006; 8:963-70; PMID:16921364; http://dx.doi.org/10.1038/ncb1461 5.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Cell 2007; 128:383- 97; PMID:17254974; http://dx.doi.org/10.1016/j.cell.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Science 2013; 340:1185-9; PMID:23744939; http://dx.doi.org/ 10.1126/science.1235249 7.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Trends Cell Biol 2010; 20:142-9;PMID:20061152; http://dx.doi.org/10.1016/j.tcb.2009.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Onco- gene 2007; 26:142-7; PMID:16799635; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
J Biol Chem 1995; 270:25715-21; PMID:7592751; http://dx.doi.org/10.1074/jbc.270.43.25715 10.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Proc Natl Acad Sci USA 2004; 101:9309-14; http://dx.doi.org/ 10.1073/pnas.0401994101 11.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Mol Cell 2013; 51:559-72; PMID:23973329; http://dx.doi.org/ 10.1016/j.molcel.2013.07.014 13.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Oncogene 2001; 20:6482- 91; PMID:11607847; http://dx.doi.org/10.1038/sj.onc.1204788 14.,Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
J Cell Physiol 2012; 227:1280-4;PMID:22105767; http://dx.doi.org/10.1002/jcp.24011 15.,Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Cancers 2011; 3:2734-49; PMID:24212830; http://dx.doi.org/ 10.3390/cancers3022734 16.,Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
PLoS ONE 2008; 3:e3518; PMID:18953416; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
PLoS Biol 2013; 11:e1001726; PMID:24311986;http://dx.doi.org/10.1371/journal.pbio.1001726 18.,Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
J Biol Chem1995; 270:25715-21; http://dx.doi.org/10.1074/ jbc.270.43.25715 20.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Genes Dev 2013; 27:274-87; PMID: 23388826; http://dx.doi.org/10.1101/gad.203760.112 21.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Nature 1999; 398:533-8; PMID:10206649; http://dx.doi.org/10.1038/19110 22.,Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Nat Struct Mol Biol 2009; 16:658-66; PMID:19465916; http://dx.doi.org/10.1038/nsmb.1605 23.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Mol Cell 2007; 28:886-98; PMID:18082612; http://dx.doi.org/10.1016/j.molcel.2007.10.028 24.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Science 2005; 307:1603-9; PMID:15761148;http://dx.doi.org/10.1126/science.1105718 26.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Mol Cell Biochem 2010; 338:11-7; PMID:19937093;http://dx.doi.org/10.1007/s11010-009-0315-y 27.,Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
J Biol Chem 2013; 288:21784-92; PMID: 23760265; http://dx.doi.org/10.1074/jbc.M113.472704 28.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Cancer Biol Ther 2006; 5:1228-35; PMID: 16969126; http://dx.doi.org/10.4161/cbt.5.9.3295 29.,Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
J Biol Chem 2003; 278:36435-44; PMID:12788948; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Adv Exp Med Biol 2007; 597:1-24; PMID:17633013; http://dx.doi.org/10.1007/978-0-387-70630-6_1 31.,Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Mol Cell Biol 2011; 31:4978- 93; PMID:21986496; http://dx.doi.org/10.1128/ MCB.05542-11 32.,Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
J Biol Chem 2004; 279:17278- 82; PMID:15001576; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Annu Rev Biophys 2013; 42:443-68; PMID:23495970; http://dx.doi.org/10.1146/annurev- biophys-083012-130338 34.,Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
Mol Cell 1999; 4:321-30; PMID:10518213; http://dx.doi.org/10.1016/S1097-2765(00)80334-2 35.,OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
"San Carlos, USA: Delano Sientiﬁc; 2002.Available from: ""http://www.pymol.org"" e975597-6 Volume 2 Issue 4 Tissue Barriers",Non-OADS,/arxiv_data1/oa_pdf/71/55/ktib-02-e975597.PMC4292048.pdf
"If heart failure is suspected, consider the following diagnostic tests (adapted from http://www.chfn.ca/is-it-heart-f ailure).",Non-OADS,/arxiv_data1/oa_pdf/cf/83/jgc-11-04-329.PMC4292097.pdf
"This subcellular © Bilgi Gungor, Fuat Cem Yagci, Ihsan Gursel, and Mayda Gursel *Correspondence to: Mayda Gursel; Email: mgursel@metu.edu.trSubmitted: 06/24/2014; Accepted: 07/02/2014 http://dx.doi.org/10.4161/21624011.2014.950166 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f2/bb/koni-03-e950166.PMC4292235.pdf
Nat Rev Immunol 2004;4: 249-58; PMID:15057783; http://dx.doi.org/ 10.1038/nri1329 2.,Non-OADS,/arxiv_data1/oa_pdf/f2/bb/koni-03-e950166.PMC4292235.pdf
Int J Nanomedicine 2012;7:2181- 95; PMID:22619554; http://dx.doi.org/10.2147/ IJN.S30197 3.,OADS,/arxiv_data1/oa_pdf/f2/bb/koni-03-e950166.PMC4292235.pdf
J Immunol 2001;166:2372-7; PMID:11160295; http://dx.doi.org/10.4049/jimmunol.166.4.2372 4.,Non-OADS,/arxiv_data1/oa_pdf/f2/bb/koni-03-e950166.PMC4292235.pdf
Eur J Immunol 2002;32:2617-22; PMID:12207346; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f2/bb/koni-03-e950166.PMC4292235.pdf
Nucleic Acid Ther 2012;22:77-89; PMID:22352814; http://dx.doi.or g/10.1089/nat.2012.0340 7.,OADS,/arxiv_data1/oa_pdf/f2/bb/koni-03-e950166.PMC4292235.pdf
J Biol Chem 2005;280:8086-93; PMID:15591070; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f2/bb/koni-03-e950166.PMC4292235.pdf
J Immunol2006;177:1575-80; PMID:16849465; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f2/bb/koni-03-e950166.PMC4292235.pdf
Nature 2005;434: 1035-40; PMID:15815647; http://dx.doi.org/10.1038/ nature03547 10.,Non-OADS,/arxiv_data1/oa_pdf/f2/bb/koni-03-e950166.PMC4292235.pdf
Sci Transl Med 2014;6:235ra61; PMID:24807558; http://dx.doi.org/10.1126/scitranslmed.,Non-OADS,/arxiv_data1/oa_pdf/f2/bb/koni-03-e950166.PMC4292235.pdf
"A model experiment was thus pre- formed based on a new concept, namely,local antitumor treatment that inducesinﬂammation at the tumor-bearing sitefollowed by enhancement of the host- © Shiro Kanegasaki and Tomoko Tsuchiya *Correspondence to: Tomoko Tsuchiya; Email: ttsuchiy-tky@umin.ac.jpSubmitted: 08/20/2014; Accepted: 08/23/2014 http://dx.doi.org/10.4161/21624011.2014.958956 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/17/49/koni-03-e958956.PMC4292266.pdf
J Antibiotics 1982; 35:1086-92; PMID:6815146; http://dx.doi.org/10.7164/antibiotics.35.1086 3.,Non-OADS,/arxiv_data1/oa_pdf/17/49/koni-03-e958956.PMC4292266.pdf
"Shiraishi K, Ishiwata Y, Nakagawa K, Yokochi S, Tar- uki C, Akuta T, Ohtomo K, Matsushima K, Tamatani T, Kanegasaki S. Enhancement of antitumor radiation efﬁcacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of MIP-1 a.Clinical Cancer Res 2008; 14:1159-66; PMID:18281550; http://dx.doi.org/10.1158/1078- 0432.CCR-07-4485 4.",Non-OADS,/arxiv_data1/oa_pdf/17/49/koni-03-e958956.PMC4292266.pdf
PMID:10914676; http://dx.doi.org/10.1007/s004390 000288 5.,Non-OADS,/arxiv_data1/oa_pdf/17/49/koni-03-e958956.PMC4292266.pdf
Proc Natl Acad Sci U S A 1999; 96:8693-98; PMID:10411937; http://dx.doi.org/ 10.1073/pnas.96.15.8693 6.,OADS,/arxiv_data1/oa_pdf/17/49/koni-03-e958956.PMC4292266.pdf
Microbiol Immunol 1993; 37:563-71;PMID:7694055; http://dx.doi.org/10.1111/j.1348- 0421.1993.tb01678.x 7.,Non-OADS,/arxiv_data1/oa_pdf/17/49/koni-03-e958956.PMC4292266.pdf
Cancer Res 2010; 70:6556-66; PMID:20663902; http://dx.doi.org/10.1158/0008-5472.CAN-10-0096 10.,Non-OADS,/arxiv_data1/oa_pdf/17/49/koni-03-e958956.PMC4292266.pdf
Cancer Res2014 74:5070-78; PMID:25038226; http://dx.doi.org/ 10.1158/0008-5472.CAN-14-0551 www.landesbioscience.com e958956-3 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/17/49/koni-03-e958956.PMC4292266.pdf
"Fur-thermore, transplantation of human © Shicheng Su, Wei Wu, Chonghua He, Qiang Liu, and Erwei Song *Correspondence to: Erwei Song; Email: songew@mail.sysu.edu.cnSubmitted: 06/23/2014; Accepted: 07/02/2014 http://dx.doi.org/10.4161/21624011.2014.953418 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/28/b7/koni-03-e953418.PMC4292267.pdf
CancerCell 2014; 25:605-20; PMID:24823638; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/28/b7/koni-03-e953418.PMC4292267.pdf
Cell 2006; 124:263-6; PMID:16439202; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/28/b7/koni-03-e953418.PMC4292267.pdf
Nat Rev Immu- nol 2012; 12:786-98; PMID:23059428; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/28/b7/koni-03-e953418.PMC4292267.pdf
Annu Rev Immunol 2009; 27:451-83; PMID:19105661; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/28/b7/koni-03-e953418.PMC4292267.pdf
Cancer Cell 2011; 19:541-55; PMID:21481794; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/28/b7/koni-03-e953418.PMC4292267.pdf
Immu- nity 2010; 32:790-802; PMID:20605485; http://dx.doi.org/10.1016/j.immuni.2010.05.010 7.,OADS,/arxiv_data1/oa_pdf/28/b7/koni-03-e953418.PMC4292267.pdf
J Clin Oncol 2007; 25:2546-53; PMID:17577033; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/28/b7/koni-03-e953418.PMC4292267.pdf
Clin Cancer Res 2009; 15:6745-7; PMID:19903779; http://dx.doi.org/10.1158/1078-0432.CCR-09-2377 9.,Non-OADS,/arxiv_data1/oa_pdf/28/b7/koni-03-e953418.PMC4292267.pdf
Cancer Res 2011; 71:6921-5; PMID:22084445; http://dx.doi.org/ 10.1158/0008-5472.CAN-11-1457 10.,Non-OADS,/arxiv_data1/oa_pdf/28/b7/koni-03-e953418.PMC4292267.pdf
Nat Biotechnol 2012; 30:671-8; PMID:22781696;http://dx.doi.org/10.1038/nbt.2285 www.landesbioscience.com e953418-3 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/28/b7/koni-03-e953418.PMC4292267.pdf
Available from: http://www.who.int/tb/ publications/global_report/en/.,Non-OADS,/arxiv_data1/oa_pdf/bf/46/IJOrtho-49-1.PMC4292318.pdf
Available from: http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/70/d7/IJOrtho-49-56.PMC4292327.pdf
"We found that whereas P3 cellswere resistant to CTLs, P3 cells with © Chih-Ping Mao, TC Wu, Kwon-Ho Song, and Tae Woo Kim *Correspondence to: Tae Woo Kim; Email: twkim0421@korea.ac.krSubmitted: 06/15/2014; Accepted: 06/16/2014 http://dx.doi.org/10.4161/21624011.2014.947871 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/bd/26/koni-03-e947871.PMC4292413.pdf
Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013 2.,OADS,/arxiv_data1/oa_pdf/bd/26/koni-03-e947871.PMC4292413.pdf
Cancer Res 2012; 72:1717-27.; PMID:22337995; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/bd/26/koni-03-e947871.PMC4292413.pdf
Cell 2003; 113:643-55; PMID:12787505; http://dx.doi.org/10.1016/S0092-8674(03)00392-1 5.,OADS,/arxiv_data1/oa_pdf/bd/26/koni-03-e947871.PMC4292413.pdf
J Clin Invest 2012; 122:4077-93; PMID:23093782; http://dx.doi.org/ 10.1172/JCI64057 6.,Non-OADS,/arxiv_data1/oa_pdf/bd/26/koni-03-e947871.PMC4292413.pdf
Cell1999; 96:857-68; PMID:10102273; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/bd/26/koni-03-e947871.PMC4292413.pdf
Nature 2004; 428:332-7; PMID:15029198;http://dx.doi.org/10.1038/nature02369 www.landesbioscience.com e947871-3 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/bd/26/koni-03-e947871.PMC4292413.pdf
"Thus, advanced melanoma patients with sufﬁcient num-bers of (activated) T cells in the tumor at © Esther P M Tjin and Rosalie M Luiten *Correspondence to: Esther P M Tjin; Email: e.p.tjin@amc.uva.nlSubmitted: 07/07/2014; Accepted: 07/09/2014 http://dx.doi.org/10.4161/21624011.2014.954862 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ 3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4d/61/koni-03-e954862.PMC4292520.pdf
Blood 2009; 114:1537-44; PMID:19423728; http://dx.doi.org/10.1182/blood- 2008-12-195792 2.,Non-OADS,/arxiv_data1/oa_pdf/4d/61/koni-03-e954862.PMC4292520.pdf
Nature 1995; 378:736-9; PMID:7501023; http://dx.doi.org/ 10.1038/378736a0 3.,Non-OADS,/arxiv_data1/oa_pdf/4d/61/koni-03-e954862.PMC4292520.pdf
Cancer Immunol Res 2014; 2:538-46; PMID:24894091; http://dx.doi.org/10.1158/2326- 6066.CIR-13-0097 6.,Non-OADS,/arxiv_data1/oa_pdf/4d/61/koni-03-e954862.PMC4292520.pdf
J Clin Oncol 2007; 25:869-75; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4d/61/koni-03-e954862.PMC4292520.pdf
Clin Cancer Res 2013; 19:4792- 800; PMID:23690483; http://dx.doi.org/10.1158/1078-0432.CCR-13-0380 9.,Non-OADS,/arxiv_data1/oa_pdf/4d/61/koni-03-e954862.PMC4292520.pdf
"6Over- expression of IRF4 conferred partial lena- lidomide-resistance to multiple myeloma © Jan Kr €onke, Slater N Hurst, and Benjamin L Ebert *Correspondence to: Benjamin L Ebert; Email: Benjamin_Ebert@dfci.harvard.eduSubmitted: 05/14/2014; Accepted: 05/21/2014 http://dx.doi.org/10.4161/21624011.2014.941742 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/be/17/koni-03-e941742.PMC4292522.pdf
Br J Haematol 2014; 164:811-21; PMID:24328678; http://dx.doi.org/10.1111/bjh.12708 5.,Non-OADS,/arxiv_data1/oa_pdf/be/17/koni-03-e941742.PMC4292522.pdf
Cell 1995; 83:289-99; PMID: 7585946; http://dx.doi.org/ 10.1016/0092-8674(95)90170-1 6.,OADS,/arxiv_data1/oa_pdf/be/17/koni-03-e941742.PMC4292522.pdf
Cancer Cell 2012; 21:723-37; PMID: 22698399;http://dx.doi.org/10.1016/j.ccr.2012.05.024 7.,Non-OADS,/arxiv_data1/oa_pdf/be/17/koni-03-e941742.PMC4292522.pdf
Nat Immunol 2010; 11:846-53; PMID: 20676092; http://dx.doi.org/10.1038/ ni.1915 8.,Non-OADS,/arxiv_data1/oa_pdf/be/17/koni-03-e941742.PMC4292522.pdf
J Exp Med2004; 199:209-19; PMID: 14718515; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/be/17/koni-03-e941742.PMC4292522.pdf
Nature 2007; 446:640-5; PMID: 17410169; http://dx.doi.org/10.1038/nature05731 www.landesbioscience.com e941742-3 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/be/17/koni-03-e941742.PMC4292522.pdf
"Pancreatic cancer follows the rules: immune activation triggers immunosuppressive mechanisms FOXP3 Cputative regulatory T cells (Tregs) have previously been shown toinﬁltrate PDA tumors, 6and we conﬁrmed the presence of CD4CFOXP3CCD25C © Venu G Pillarisetty *Correspondence to: Dr Venu G Pillarisetty; Email: vgp@uw.eduSubmitted: 06/25/2014; Accepted: 07/02/2014 http://dx.doi.org/10.4161/21624011.2014.950171 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9c/ac/koni-03-e950171.PMC4292569.pdf
Curr Opin Immunol 2013; 25:200-5; PMID:23422836; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9c/ac/koni-03-e950171.PMC4292569.pdf
Science 2011; 331:1612-6; PMID:21436454; http://dx.doi.org/ 10.1126/science.1198443 3.,Non-OADS,/arxiv_data1/oa_pdf/9c/ac/koni-03-e950171.PMC4292569.pdf
J Exp Med 2011; 208:469-78; PMID:21339327; http://dx.doi.org/10.1084/jem.201018764.,Non-OADS,/arxiv_data1/oa_pdf/9c/ac/koni-03-e950171.PMC4292569.pdf
Br J Cancer 2013; 108:914-23; PMID:23385730; http://dx.doi.org/ 10.1038/bjc.2013.32 5.,Non-OADS,/arxiv_data1/oa_pdf/9c/ac/koni-03-e950171.PMC4292569.pdf
PD-1 identiﬁes the patient-speciﬁc CD8 C tumor-reactive repertoire inﬁltrating human tumors.J Clin Invest 2014; 124:2246-59; PMID:24667641; http://dx.doi.org/10.1172/JCI73639 8.,Non-OADS,/arxiv_data1/oa_pdf/9c/ac/koni-03-e950171.PMC4292569.pdf
Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/ 10.1126/scitranslmed.3003689 9.,Non-OADS,/arxiv_data1/oa_pdf/9c/ac/koni-03-e950171.PMC4292569.pdf
N Engl J Med 2012; 366:2455-65; PMID:22658128;http://dx.doi.org/10.1056/NEJMoa1200694 www.landesbioscience.com e950171-3 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/9c/ac/koni-03-e950171.PMC4292569.pdf
"Models have grown in complexity as new experimental evidence hasemerged: from the early minimal models that included a fewionic channels and a basic representation of Ca 2Chandling and metabolism, to the current complex models that incorporatedetailed representations of glycolysis and ATP production, andthe recent appearance of models of human b-cells.© Gerardo J F /C19elix-Mart /C19ınez and J Rafael God /C19ınez-Fern /C19andez *Correspondence to: Gerardo J F /C19elix-Mart /C19ınez; Email: gjfelix2005@gmail.com Submitted: 04/06/2014; Revised: 07/21/2014; Accepted: 07/23/2014http://dx.doi.org/10.4161/19382014.2014.949195 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabe- tologia 1983; 24:231-7; PMID:6345247; http://dx.doi.org/10.1007/BF00282705 2.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Ups J Med Sci 2009; 114:193-205; PMID:19961265; http://dx.doi.org/ 10.3109/03009730903366075 3.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabe-tes 1981; 30:435-9; PMID:7014311; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 2007; 56:1277-88; PMID:17317765; http://dx.doi.org/10.2337/db06-0367 5.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Eur J Clin Invest 2003; 33:742-50; PMID:12925032; http://dx.doi.org/ 10.1046/j.1365-2362.2003.01207.x 6.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes Res Clin PR 2011; 93: S27-31; http://dx.doi.org/10.1016/S0168-8227(11) 70010-9 7.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetologia 2009; 52:739-51; PMID:19288076;http://dx.doi.org/10.1007/s00125-009-1314-y8.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 2012; 61:270-1; PMID:22275083; http://dx.doi.org/10.2337/db11- 1677 9.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Rev Endocr Metab Disord 2010; 11:157-63; PMID:20878482; http://dx.doi.org/10.1007/s11154- 010-9144-2 10.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 2012; 61:1726-33; PMID:22492527; http://dx.doi.org/ 10.2337/db11-1516 12.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Cell Cal- cium 2012; 52:28-35; PMID:22502861; http://dx.doi.org/10.1016/j.ceca.2012.03.003 13.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 2012; 61:447-53; PMID:22275086; http://dx.doi.org/10.2337/db11-0995 14.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
B Math Biol 2004; 66:1313-44; http://dx.doi.org/10.1016/j.bulm.2003.12.005 17.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Adv Exp Med Biol 2010;654:115-63; PMID:20217497; http://dx.doi.org/ 10.1007/978-90-481-3271-3_7 18.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Prog Biophys Molec Biol 1989; 54:87-143; http://dx.doi.org/10.1016/0079-6107 (89)90013-8 19.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Pﬂugers Arch 1974;351:195-206; PMID:4608967; http://dx.doi.org/ 10.1007/BF00586918 20.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
PMID:24042324; http://dx.doi.org/10.1038/nrendo.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 2008; 57:1618- 28; PMID:18390794; http://dx.doi.org/10.2337/ db07-0991 23.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 1992; 41:1221-8; PMID:1397696; http://dx.doi.org/10.2337/diab.41.10.1221 24.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Islets 2013; 5:1-15; PMID:23624892; http://dx.doi.org/10.4161/isl.24166 25.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys J 2000; 79:2880-92; PMID: 11106596; http://dx.doi.org/10.1016/S0006-3495(00) 76525-8 26.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys J 2010; 99:3200- 7; PMID:21081067; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
PLoS Comp Biol 2014; 10(1):e1003389; http://dx.doi.org/10.1371/jour- nal.pcbi.1003389 29.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Pﬂugers Arch 1991; 418:417-22; PMID:1876486; http://dx.doi.org/ 10.1007/BF00550880 30.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
FEBS Lett 1989; 259:19-23; PMID: 2689228; http://dx.doi.org/10.1016/0014-5793(89)81484-X 31.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Pﬂug ArchEur J Phy 1995; 431:272-82; http://dx.doi.org/ 10.1007/BF00410201 32.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Membrane Biol 1990; 116:273-80; http://dx.doi.org/10.1007/BF01868466 33.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
"Hellman B, Gylfe E, Bergsten P, Grapengiesser E, Lund PE, Berts A, Tengholm A, Pipeleers DG, Ling Z. Glucose induces oscillatory Ca2Csignalling and insulin release in human pancreatic beta cells.Diabetologia 1994; 37:S11-20; PMID:7821725; http://dx.doi.org/10.1007/BF00400821 37.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Ann NY Acad Sci 2007; 1099:456-67; PMID: 17446486; http://dx.doi.org/10.1196/annals.1387.048 39.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Nat Rev Mol Cell Biol 2003; 4 (7):517-29; PMID: 12838335; http://dx.doi.org/10.1038/nrm1155 40.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Biol Chem 1999; 274:20197-205; PMID:10400636; http://dx.doi.org/10.1074/jbc.274.29.20197 42.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 2005; 54:3073-81; PMID:16249428; http://dx.doi.org/10.2337/diabetes.54.11.3073 43.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 2002; 51:1299-309; PMID: 11978625; http://dx.doi.org/10.2337/diabetes.51.5.1299 44.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Pharmacology1986; 32:257-67; PMID:3086908; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Am J Cell Physiol 2006; 290:C1503-11; http://dx.doi.org/10.1152/ajpcell.00400.2005 46.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
FEBS Lett 1980; 119:1-8;PMID:7000543; http://dx.doi.org/10.1016/0014- 5793(80)80986-0 47.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
PloS ONE 2012; 7:e39722; PMID:22829870; http://dx.doi.org/10.1371/jour- nal.pone.0039722 50.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Proc Nat Acad Sci U S A 2010; 107:436-41;PMID:20018762; http://dx.doi.org/10.1073/ pnas.0908099107 51.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Mol Cell Endocrinol 2013; 379:12-8;PMID:23792187; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Mol Cell Endocrinol 2012; 353:128-37; PMID:21784130; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Cell Metab 2013; 18:162-85; PMID:23791483; http://dx.doi.org/10.1016/j.cmet.2013.05.018 55.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Dia- betologia 2013; 56:1577-86; PMID:23536115;http://dx.doi.org/10.1007/s00125-013-2894-0 56.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Proc Natl Acad Sci U S A 1999; 96:760- 5; PMID:9892707; http://dx.doi.org/10.1073/ pnas.96.2.760 57.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Cell Metab2011; 13:601-11; PMID:21531342; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biochem Biophys Res Commun2000; 267:179-83; PMID:10623595; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Biol Chem 2001; 276:34530-6; PMID:11445566; http://dx.doi.org/10.1074/jbc.M102492200 63.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Theor Biol Med Model 2010; 7:15;PMID:20497556; http://dx.doi.org/10.1186/1742- 4682-7-15 67.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Islets 2011; 3:224-30; PMID:21814042; http://dx.doi.org/10.4161/isl.3.5.16409 68.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
EMBO J 1997; 16:3833-41; PMID:9233793; http://dx.doi.org/10.1093/emboj/16.13.3833 69.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Biol Chem 1999; 274 (19):13281-91; PMID:10224088; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 2002; 51 (Suppl 1):S152-61; http://dx.doi.org/10.2337/dia-betes.51.2007.S152 72.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 2002; 51(Suppl 1): S162-70; PMID:11815476; http://dx.doi.org/ 10.2337/diabetes.51.2007.S162 73.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Physiol 2006; 572:379- 92; PMID:16455690; http://dx.doi.org/10.1113/jphysiol.2005.101766 74.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biochem Bio- phys Res Commun 1999; 259:331-5; PMID:10362508; http://dx.doi.org/10.1006/bbrc.1999.0784 75.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Mol Cell Endocrinol 2009; 297:58-72;PMID:18706473; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Theor Biol 1995; 174:137-48; PMID:7643610;http://dx.doi.org/10.1006/jtbi.1995.0087 77.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Biol Chem 2014; 289:2205-16; PMID:24302735; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
"Int J BiochemCell B 2006; 38(5-6), 696-709; http://dx.doi.org/ 10.1016/j.biocel.2005.12.006 81.",OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biochim Biophys Acta 2014; 1840:1404-12;PMID:24246956; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Antioxid Redox Sign 2010; 12:537-77; http://dx.doi.org/10.1089/ars.2009.253183.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetologia 2005; 48:282-9; PMID:15654602; http://dx.doi.org/ 10.1007/s00125-004-1627-9 84.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Nature 1968; 219:389-90; PMID:4873864; http://dx.doi.org/10.1038/219389a0 86.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys J 1999; 76:1423-35; PMID:10049324; http://dx.doi.org/10.1016/S0006-3495(99)77303-0 88.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 2002; 51 (Suppl 1):S144-51; PMID:11815474; http://dx.doi.org/10.2337/diabetes.51.2007.S144 89.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys J 1983; 42:181-9; PMID:6305437; http://dx.doi.org/ 10.1016/S0006-3495(83)84384-7 90.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Cell Cal- cium 1983; 4:451-61; PMID:6323007; http://dx.doi.org/10.1016/0143-4160(83)90021-0 91.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Membrane Biol 1991; 119:187-95; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Physiol 2010; 588:3511-23; PMID:20643769; http://dx.doi.org/10.1113/jphysiol.2009.184341 93.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Cell Biophys 1987; 11(1): 77-90; PMID:2450671; http://dx.doi.org/10.1007/ BF02797114 95.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Nature 1984; 311:271-3;PMID:6090930; http://dx.doi.org/10.1038/ 311271a0 97.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Nature 1984; 312:446- 8; PMID:6095103; http://dx.doi.org/10.1038/ 312446a0 98.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Prog Biophys Mol Biol 2011; 107:224-35; PMID:21762719; http://dx.doi.org/10.1016/j.pbiomolbio.2011.06.009 99.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys J 1989; 56:229-42;PMID:2673420; http://dx.doi.org/10.1016/S0006- 3495(89)82669-4 100.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Membrane Biol 1992; 127:9-19; http://dx.doi.org/10.1007/BF00232754 103.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetologia 2004; 47:488-98; PMID:14872319; http://dx.doi.org/10.1007/ s00125-004-1348-0 105.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Endocrinology 2009; 150:33-45;PMID:18787024; http://dx.doi.org/10.1210/en.2008- 0617 106.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys Chem 2008; 134:119-43; PMID:18321634; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
FEBS Lett 1990; 261:187-90; PMID:2407553; http://dx.doi.org/10.1016/0014- 5793(90)80667-8 110.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys J 1995; 2323-32; PMID:7647236; http://dx.doi.org/10.1016/S0006-3495(95)80414-5 111.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biol Cybern 1996; 75:419-31; PMID:8983163; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Math Biosci 2010; 227:12-9; PMID:20580727; http://dx.doi.org/10.1016/j.mbs.2010.05.005 113.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Gen Physiol 1999; 114:759-69; PMID:10578013; http://dx.doi.org/10.1085/jgp.114.6.759 115.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Gen Phys- iol 2002; 120:307-22; PMID:12198088; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biochem Biophys Res Commun 1996; 226:830-5; PMID:8831697; http://dx.doi.org/10.1006/bbrc.1996.1436 118.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Gen Physiol 2011; 138:21-37;PMID:21708953; http://dx.doi.org/10.1085/ jgp.201110611 119.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Gen Physiol 2011; 138:39-47; PMID:21708954; http://dx.doi.org/10.1085/jgp.201110612 120.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys J 2004; 87:3074-87; PMID:15347584; http://dx.doi.org/ 10.1529/biophysj.104.049262 122.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Biol Chem 2013; 288(46):33312-22; PMID:24100037; http://dx.doi.org/10.1074/jbc.M113.508127 124.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys J 2010; 99:76-84; PMID:20655835; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
SIAM J Appl Dyn Syst 2014; 13(2):683-703; http://dx.doi.org/10.1137/130920198 127.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys J 2009; 96:3126-39; PMID:19383458; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Histochem Cytochem 2005; 53:1087-97; PMID:15923354; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Islets 2009; 1:129-36; PMID:20606719; http://dx.doi.org/10.4161/isl.1.2.9480 131.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Diabetes 2006; 55:3470-7; PMID:17130494; http://dx.doi.org/10.2337/db06-0868 133.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Ann NY Acad Sci 2009; 1152:187-93; PMID:19161389; http://dx.doi.org/10.1111/j.1749-6632.2008.03992.x 134.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
FASEB J 2000; 14:2601;PMID:11099479; http://dx.doi.org/10.1096/fj.00- 0077com 135.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
J Physiol 2005; 567:159-75; PMID:15932888; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Adv Exp Med Biol 2010; 654:261-79; PMID:20217502; http://dx.doi.org/10.1007/ 978-90-481-3271-3_12 137.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Prog Biophys Mol Biol 2011; 107:257-64; PMID:21839108; http://dx.doi.org/ 10.1016/j.pbiomolbio.2011.07.012 138.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys J 2005; 89:107-19;PMID:15834002; http://dx.doi.org/10.1529/ biophysj.104.055681 139.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Biophys J 1991; 59:547-59; PMID:1646657; http://dx.doi.org/10.1016/S0006-3495(91)82271-8 140.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Mol Cell Endocrinol 2009; 307:57-67; PMID:19524127; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
IEEE Trans Biomed Circuits Syst 2007; 1:39-49; PMID:23851519; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2b/f1/kisl-06-e949195.PMC4292577.pdf
Disponível em: http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/8c/97/rlae-22-02-0286.PMC4292591.pdf
Disponível em:  http://pepsic.bvsalud.org/scielo.php?script=sci_ arttext&pid=S1809-52672010000100013&lng=pt 9.,Non-OADS,/arxiv_data1/oa_pdf/8c/97/rlae-22-02-0286.PMC4292591.pdf
Disponível em: http://portal.anvisa.gov.br/wps/ wcm/connect/aa863580492e0b81b23ab314d16287af/ manual_neonatologia-%2B03-09-2010-%2Bnovo.,Non-OADS,/arxiv_data1/oa_pdf/56/64/rlae-22-02-0255.PMC4292594.pdf
Disponível em: http://www.sciencedirect.,Non-OADS,/arxiv_data1/oa_pdf/56/64/rlae-22-02-0255.PMC4292594.pdf
Disponível em: http://novo.portalcofen.gov.br/ resoluo-cofen-3582009_4384.html 8.,Non-OADS,/arxiv_data1/oa_pdf/56/64/rlae-22-02-0255.PMC4292594.pdf
Disponível em: http://www.ncbi.nlm.nih.gov/ pubmed/12774877  10.,Non-OADS,/arxiv_data1/oa_pdf/56/64/rlae-22-02-0255.PMC4292594.pdf
Disponível  em: http://www.scielo.br/scielo.php?script=sci_arttext &pid=S0100-72032007000800002 18.,Non-OADS,/arxiv_data1/oa_pdf/56/64/rlae-22-02-0255.PMC4292594.pdf
Disponível em: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2675425/ 19.,Non-OADS,/arxiv_data1/oa_pdf/56/64/rlae-22-02-0255.PMC4292594.pdf
Disponível em: http://www.nejm.,Non-OADS,/arxiv_data1/oa_pdf/56/64/rlae-22-02-0255.PMC4292594.pdf
Disponível em:  http://pediatriasaopaulo.usp.br/upload/pdf/1265.pdf  22.,Non-OADS,/arxiv_data1/oa_pdf/56/64/rlae-22-02-0255.PMC4292594.pdf
Disponível em: <http://congreso.pucp.edu.pe/ cibim8/pdf/03/03-29.pdf 9.,Non-OADS,/arxiv_data1/oa_pdf/0a/3b/rlae-22-02-0277.PMC4292597.pdf
Disponível  em: http://www.head-face-med.com/content/ 3/1/17 10.,Non-OADS,/arxiv_data1/oa_pdf/0a/3b/rlae-22-02-0277.PMC4292597.pdf
Disponível em: http://www.llli.,Non-OADS,/arxiv_data1/oa_pdf/0a/3b/rlae-22-02-0277.PMC4292597.pdf
Disponível em: http://www.soperj.org.br/ revista/detalhes.asp?id=22,Non-OADS,/arxiv_data1/oa_pdf/0a/3b/rlae-22-02-0277.PMC4292597.pdf
Disponível  em: http://www.capes.gov.br/images/stories/download/ legislacao/Parecer_CESU_977_1965.pdf 2.,Non-OADS,/arxiv_data1/oa_pdf/da/70/rlae-22-02-0204.PMC4292598.pdf
Disponível em:  http://www.capes.gov.br/images/stories/download/ legislacao/Portaria_CAPES_080_1998.pdf 3.,Non-OADS,/arxiv_data1/oa_pdf/da/70/rlae-22-02-0204.PMC4292598.pdf
Disponível  em: http://www.capes.gov.br/images/stories/download/ legislacao/PortariaNormativa_17MP.pdf 4.,Non-OADS,/arxiv_data1/oa_pdf/da/70/rlae-22-02-0204.PMC4292598.pdf
Disponível em: http://www.capes.,Non-OADS,/arxiv_data1/oa_pdf/da/70/rlae-22-02-0204.PMC4292598.pdf
Disponível em: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2842849/pdf/182e250.pdf 5.,Non-OADS,/arxiv_data1/oa_pdf/a5/59/rlae-22-02-0234.PMC4292599.pdf
Disponível em: http://www.scielo.,Non-OADS,/arxiv_data1/oa_pdf/a5/59/rlae-22-02-0234.PMC4292599.pdf
Disponível em:  http://www.scielo.br/pdf/ape/v23n1/02.pdf 7.,Non-OADS,/arxiv_data1/oa_pdf/a5/59/rlae-22-02-0234.PMC4292599.pdf
Disponível  em: http://www.journalofnursingstudies.com/article/ S0020-7489(11)00301-4/fulltext 9.,Non-OADS,/arxiv_data1/oa_pdf/a5/59/rlae-22-02-0234.PMC4292599.pdf
Disponível em:  http://socialresearchmethods.net/kb/ 12.,Non-OADS,/arxiv_data1/oa_pdf/a5/59/rlae-22-02-0234.PMC4292599.pdf
Disponível em: http://core.ecu.,Non-OADS,/arxiv_data1/oa_pdf/a5/59/rlae-22-02-0234.PMC4292599.pdf
Disponível em: http://www.scielo.br/pdf/reeusp/ v43n2/en_a24v43n2.pdf 14.,Non-OADS,/arxiv_data1/oa_pdf/a5/59/rlae-22-02-0234.PMC4292599.pdf
Disponível em:  http://www.scielo.br/scielo.php?script=sci_arttext&pid =S0080-62342003000100009 23.,Non-OADS,/arxiv_data1/oa_pdf/a5/59/rlae-22-02-0234.PMC4292599.pdf
Disponível em: http://cnr.sagepub.com/ content/19/2/144 2.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em: http://www.hqlo.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em:  http://www.biomedcentral.com/1471-2407/8/226  5.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em: http://www.scielo.br/ pdf/reeusp/v46n4/32.pdf 6.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em: http://www.biomedcentral.com/1472- 6963/13/128 11.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em: http://bhvh.cardiologydomain.com/ images/uploaded/BHVH/Naffe.pdf 12.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em : http://www.cochrane.org/sites/default/ files/uploads/glossary.pdf  14.,OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em: http://www.sciencedirect.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em: http://www.goldjournal.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em:  http://www.medscape.com/viewarticle/746332 17.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em: http://onlinelibrary.wiley.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em: http://jco.ascopubs.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível  em: http://onlinelibrary.wiley.com/doi/10.1111/j.1464- 410X.2007.06913.x/pdf 22.,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível  em: http://www.ejoncologynursing.com/article/S1462- 3889%2812%2900053-1/pdf,Non-OADS,/arxiv_data1/oa_pdf/1c/bb/rlae-22-02-0337.PMC4292600.pdf
Disponível em: http://scielo.isciii.es/scielo.php?script=sci_ arttext&pid=S1575-18132009000500001&lng=es.,Non-OADS,/arxiv_data1/oa_pdf/b7/13/rlae-22-02-0187.PMC4292601.pdf
http://dx.doi.org/10.4067/ S0717-73482008000200008 12.,Non-OADS,/arxiv_data1/oa_pdf/b7/13/rlae-22-02-0187.PMC4292601.pdf
Disponivel em: http://www.scielo.cl/scielo.php?script=sci_ arttext&pid=S0717-95532010000100003&lng=es.,Non-OADS,/arxiv_data1/oa_pdf/b7/13/rlae-22-02-0187.PMC4292601.pdf
http://dx.doi.org/10.4067/S0717-95532010000100003,Non-OADS,/arxiv_data1/oa_pdf/b7/13/rlae-22-02-0187.PMC4292601.pdf
Disponível em: http://novo.portalcofen.gov.br/resoluo- cofen-3582009_4384.html 6.,Non-OADS,/arxiv_data1/oa_pdf/8d/9d/rlae-22-02-0197.PMC4292602.pdf
Disponível em: http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/bb/4d/rlae-22-02-0241.PMC4292603.pdf
Disponível em: http://portal.mec.gov.br/cne/arquivos/ pdf/CES03.pdf 10.,Non-OADS,/arxiv_data1/oa_pdf/eb/09/rlae-22-02-0179.PMC4292604.pdf
Disponível em: http://www.scielo.,Non-OADS,/arxiv_data1/oa_pdf/eb/09/rlae-22-02-0179.PMC4292604.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/09/rlae-22-02-0179.PMC4292604.pdf
Disponível  em: http://www.novo.portalcofen.gov.br.,Non-OADS,/arxiv_data1/oa_pdf/df/04/rlae-22-02-0218.PMC4292606.pdf
http://www.saude.sp.gov.br/resources/ humanizacao/docs/revista_hob_mai06_versao_5.pdf15.,OADS,/arxiv_data1/oa_pdf/df/04/rlae-22-02-0218.PMC4292606.pdf
"Available at: http://www.sbn.org.br/equacoes/link/nefrocalc.htmRenal Failure Algorithm Physical examination Action Description Observe oliguria (volume of urine <400mL in 24 hours) hypovolemia, arterial hypotension, urinary tract obstruction, urinary retention.",Non-OADS,/arxiv_data1/oa_pdf/04/34/rlae-22-02-0211.PMC4292608.pdf
[acesso 28  julho 2011]; Disponível em: http://www.jbn.org.br/ diretrizes.asp 3.,Non-OADS,/arxiv_data1/oa_pdf/04/34/rlae-22-02-0211.PMC4292608.pdf
Disponível  em: http://www.scielo.br/pdf/reeusp/v44n2/07.pdf 3.,Non-OADS,/arxiv_data1/oa_pdf/ca/f4/rlae-22-02-0262.PMC4292613.pdf
Disponível em:  http://www.facenf.uerj.br/v19n2/v19n2a06.pdf 4.,Non-OADS,/arxiv_data1/oa_pdf/ca/f4/rlae-22-02-0262.PMC4292613.pdf
Disponível em:  http://www.scielo.br/pdf/reeusp/v46n1/v46n1a09.pdf 7.,Non-OADS,/arxiv_data1/oa_pdf/ca/f4/rlae-22-02-0262.PMC4292613.pdf
Atlanta: CDC [Internet] 2011  [acesso 23 out 2012] Disponível em: http://www.cdc.,Non-OADS,/arxiv_data1/oa_pdf/ca/f4/rlae-22-02-0262.PMC4292613.pdf
Disponível em: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2856055/pdf/bcp0069-0535.pdf 15.,Non-OADS,/arxiv_data1/oa_pdf/ca/f4/rlae-22-02-0262.PMC4292613.pdf
Disponível em:  http://www.scielo.br/pdf/csp/v26n1/04.pdf 16.,Non-OADS,/arxiv_data1/oa_pdf/ca/f4/rlae-22-02-0262.PMC4292613.pdf
Disponível  em: http://www.scielo.br/pdf/rbepid/v13n4/04.pdf 17.,Non-OADS,/arxiv_data1/oa_pdf/ca/f4/rlae-22-02-0262.PMC4292613.pdf
Disponível em: http://www.scielo.br/pdf/reben/v57n5/ a09v57n5.pdf 18.,Non-OADS,/arxiv_data1/oa_pdf/ca/f4/rlae-22-02-0262.PMC4292613.pdf
Disponível em: http://www.revistarene.,Non-OADS,/arxiv_data1/oa_pdf/ca/f4/rlae-22-02-0262.PMC4292613.pdf
Disponível em:  http://www.scielo.br/pdf/ean/v14n4/v14n4a05.pdf 21.,Non-OADS,/arxiv_data1/oa_pdf/ca/f4/rlae-22-02-0262.PMC4292613.pdf
Disponível em: http://www.who.int/mediacentre/ factsheets/fs297/en/print.html 2.,Non-OADS,/arxiv_data1/oa_pdf/a2/e2/rlae-22-03-0408.PMC4292614.pdf
Disponível em: http://motorgrowth.canchild.ca/en/GMFCS/ resources/PORTUGUESE_corrigido-FINALMay12.pdf 16.,Non-OADS,/arxiv_data1/oa_pdf/e7/a2/rlae-22-03-0440.PMC4292615.pdf
Disponível em:  http://www.planalto.gov.br/ccivil_03/leis/l8069.htm 19.,Non-OADS,/arxiv_data1/oa_pdf/98/a7/rlae-22-03-0448.PMC4292616.pdf
Disponível em:  http://www.index-f.com/index-enfermeria/42revista/42_ sumario.php 14.,Non-OADS,/arxiv_data1/oa_pdf/36/fe/rlae-22-03-0476.PMC4292617.pdf
Disponível em:  http://enfeps.blogspot.com.es/2009/04/la-apasionante- historia-de-la-medicina.html 17.,Non-OADS,/arxiv_data1/oa_pdf/36/fe/rlae-22-03-0476.PMC4292617.pdf
Disponível em: http://www.euskonews.com/0227zbk/   gaia22702es.html 18.,Non-OADS,/arxiv_data1/oa_pdf/36/fe/rlae-22-03-0476.PMC4292617.pdf
Disponível em:  http://www.abep.org/novo/FileGenerate.ashx?id=250 14.,OADS,/arxiv_data1/oa_pdf/4f/68/rlae-22-03-0484.PMC4292619.pdf
"As human beings were not  * Available at: http://www.icn.ch/pillarsprograms/international-classification-for-nursing-practice-icnpr/ ** This study further consulted three studies from unpublished master dissertations, which complement the article cited as reference #9.",Non-OADS,/arxiv_data1/oa_pdf/e2/59/rlae-22-03-0499.PMC4292624.pdf
"In regard to the concept “Potential”, its preferential  expression, i.e., the name commonly known by users(3),  * Free-access software available at: <http://protege.stanford.edu/download/registered.html>",Non-OADS,/arxiv_data1/oa_pdf/e2/59/rlae-22-03-0499.PMC4292624.pdf
2012 [acesso 12 dez 2012]; Disponível em:  http://www.who.int/classifications/icd/adaptations/ icnp/en/index.html 2.,Non-OADS,/arxiv_data1/oa_pdf/e2/59/rlae-22-03-0499.PMC4292624.pdf
Disponível em:  http://ac.els-cdn.com/S1042814383710083/1-s2.0- S1042814383710083-main.pdf?_tid=5838380c-234c- 11e2-8a7f-00000aacb35e&acdnat=1351682337_ d968a75211adca0edf138c2889263351 5.,Non-OADS,/arxiv_data1/oa_pdf/e2/59/rlae-22-03-0499.PMC4292624.pdf
[acesso  13 dez 2012]; Disponível em: http://doc.utwente.,Non-OADS,/arxiv_data1/oa_pdf/e2/59/rlae-22-03-0499.PMC4292624.pdf
Disponível em: http://www.it.iitb.ac.in/~palwencha/ ES/Knowledge%20engineering%20-%20Principles%20 and%20methods.pdf,Non-OADS,/arxiv_data1/oa_pdf/e2/59/rlae-22-03-0499.PMC4292624.pdf
[acesso 12 jan  2013]; Disponível em: http://www.w3.org/TR/owl-ref/ 9.,Non-OADS,/arxiv_data1/oa_pdf/e2/59/rlae-22-03-0499.PMC4292624.pdf
Disponível em:  http://www.jhi-sbis.saude.ws/ojs-jhi/index.php/jhi- sbis/article/view/89/74 10.,Non-OADS,/arxiv_data1/oa_pdf/e2/59/rlae-22-03-0499.PMC4292624.pdf
Disponível em:  http://www.sciweavers.org/publications/semantic- precision-and-recall-ontology-alignment-evaluation 13.,Non-OADS,/arxiv_data1/oa_pdf/e2/59/rlae-22-03-0499.PMC4292624.pdf
Disponível em: http://www.loa.istc.cnr.,Non-OADS,/arxiv_data1/oa_pdf/e2/59/rlae-22-03-0499.PMC4292624.pdf
Disponível em: http://bmir.stanford.edu/ file_asset/index.php/1763/BMIR-2011-1474.pdf Received: Aug 15th 2013 Accepted: Mar.,Non-OADS,/arxiv_data1/oa_pdf/e2/59/rlae-22-03-0499.PMC4292624.pdf
Disponível em:  http://www.donantesdesangre.net/ 2.,Non-OADS,/arxiv_data1/oa_pdf/8e/8d/rlae-22-03-0467.PMC4292625.pdf
Disponível  em: http://www.donarsang.gencat.cat/media/upload/ pdf/com_sou_els_donants_de_sang_motivacions_ satisfaccio_editora_7_6_1_editora_8_12_1.pdf 20.,Non-OADS,/arxiv_data1/oa_pdf/8e/8d/rlae-22-03-0467.PMC4292625.pdf
"Disponível em:  http://www.ocu.org/nt/nc/nota-prensa/donacion-de- sangre-urge-mejorar-la-informacion392844/stampa 22. WHO, Blood Transfusion Safety [Internet].",Non-OADS,/arxiv_data1/oa_pdf/8e/8d/rlae-22-03-0467.PMC4292625.pdf
Disponível em: http://www.who.int/ bloodsafety/voluntary_donation/en/ 23.,Non-OADS,/arxiv_data1/oa_pdf/8e/8d/rlae-22-03-0467.PMC4292625.pdf
Disponível em: http://www.marketingsource.,Non-OADS,/arxiv_data1/oa_pdf/8e/8d/rlae-22-03-0467.PMC4292625.pdf
Disponível em:  http://www.saude.rio.rj.gov.br/saude/pubsms/media/   aidsenvelhecimento.doc 5.,Non-OADS,/arxiv_data1/oa_pdf/84/0e/rlae-22-03-0355.PMC4292626.pdf
[acesso 10 dez 2012] Disponível em:  http://www.unaids.org/en/media/unaids/contentassets/ documents/epidemiology/2012/gr2012/20121120_ UNAIDS_Global_Report_2012_en.pdf 8.,Non-OADS,/arxiv_data1/oa_pdf/84/0e/rlae-22-03-0355.PMC4292626.pdf
Disponível em: http://www.aidsinfonet.org/   fact_sheets/view/616 9.,Non-OADS,/arxiv_data1/oa_pdf/84/0e/rlae-22-03-0355.PMC4292626.pdf
Disponível em: http://www.phac-aspc.,Non-OADS,/arxiv_data1/oa_pdf/84/0e/rlae-22-03-0355.PMC4292626.pdf
[acesso 30 mar  2013] Disponível em: http://www.ibge.gov.br 15.,Non-OADS,/arxiv_data1/oa_pdf/84/0e/rlae-22-03-0355.PMC4292626.pdf
[acesso  20 mai 2012] Disponível em: http://sistemas.aids.gov.,Non-OADS,/arxiv_data1/oa_pdf/84/0e/rlae-22-03-0355.PMC4292626.pdf
Disponível em: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível  em: http://www.ncbi.nlm.nih.gov/pubmed/21941879 5.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.scielo.br/scielo.php?pid=   S1808-86942012000300013&script=sci_arttext&tlng=en 9.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.ncbi.nlm.nih.gov/ pubmed/12580686 12.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.scielo.br/scielo.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://bases.bireme.br/cgi-bin/wxislind.,OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível  em: http://www.scielo.br/scielo.php?pid=S0102- 37722010000300009&script=sci_arttext 19.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://bases.bireme.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.ncbi.nlm.nih.gov/ pubmed/19230035,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://www.scielo.br/scielo.,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível  em: http://www.scielo.br/scielo.php?pid=S0103- 21002012000900013&script=sci_arttext,Non-OADS,/arxiv_data1/oa_pdf/60/00/rlae-22-03-0415.PMC4292629.pdf
Disponível em: http://revistas.um.es/eglobal/article/view/5402.,Non-OADS,/arxiv_data1/oa_pdf/8b/8b/rlae-22-03-0371.PMC4292631.pdf
Disponível em: http://site.portalcofen.gov.br/node/541415.,Non-OADS,/arxiv_data1/oa_pdf/8b/8b/rlae-22-03-0371.PMC4292631.pdf
Disponível em: https://uspdigital.usp.br/siicusp/cdOnlin eTrabalhoVisualizarResumo?numeroInscricaoTrabalho= 1763&numeroEdicao=16 18.,Non-OADS,/arxiv_data1/oa_pdf/8b/8b/rlae-22-03-0371.PMC4292631.pdf
Disponível em: http://www.monografias.com/trabajos41/ auriculoterapia/auriculoterapia.shtml.,Non-OADS,/arxiv_data1/oa_pdf/8b/8b/rlae-22-03-0371.PMC4292631.pdf
[acesso 15 nov 2012]; Disponível em:  http://www.stats.gov.cn/was40/gjtjj_detail.jsp?search word=%C8%AB%B9%FA%C5%A9%C3%F1%B9%A4 %D7%DC%C1%BF&presearchword=%C5%A9%B4%E 5&channelid=6697&record=2 3.,Non-OADS,/arxiv_data1/oa_pdf/6b/6c/rlae-22-03-0364.PMC4292632.pdf
Disponível em: http://www.chinadatacenter.org/ Data/Services.aspx 13.,Non-OADS,/arxiv_data1/oa_pdf/6b/6c/rlae-22-03-0364.PMC4292632.pdf
Disponível em: http://www.who.int/patientsafety/ patients_for_patient/en/ 14.,Non-OADS,/arxiv_data1/oa_pdf/50/45/rlae-22-03-0454.PMC4292634.pdf
Disponível em: http://www.nursingworld.org/ MainMenuCategories/ThePracticeofProfessionalNursing/ PatientSafetyQuality/Research-Measurement/The- National-Database/Nursing-Sensitive-Indicators_1/ ANA-Indicator-History 26.,Non-OADS,/arxiv_data1/oa_pdf/50/45/rlae-22-03-0454.PMC4292634.pdf
Disponível em:  http://www.fen.ufg.br/revista/v10/n4/v10n4a05.htm 2.,Non-OADS,/arxiv_data1/oa_pdf/1f/fe/rlae-22-03-0394.PMC4292636.pdf
Disponível em: http://www.index-f. com/memoria/6/mc30863.php 14.,Non-OADS,/arxiv_data1/oa_pdf/1f/fe/rlae-22-03-0394.PMC4292636.pdf
Disponível em:  http://www.fen.,Non-OADS,/arxiv_data1/oa_pdf/1f/fe/rlae-22-03-0394.PMC4292636.pdf
Disponível  em: http://www.scielo.br/scielo.php?script=sci_arttext&   pid=S0080-62342013000200005&lng=pt 6.,Non-OADS,/arxiv_data1/oa_pdf/d7/95/rlae-22-01-0085.PMC4292685.pdf
Disponível em:  http://www.biomedcentral.com/1472-6874/11/19 7.,Non-OADS,/arxiv_data1/oa_pdf/d7/95/rlae-22-01-0085.PMC4292685.pdf
Disponível em:  http://www.biomedcentral.com/1471-2458/9/129 9.,Non-OADS,/arxiv_data1/oa_pdf/d7/95/rlae-22-01-0085.PMC4292685.pdf
Disponível em:  http://www.scielo.br/scielo.php?pid=S2237-60892011   000300006&script=sci_arttext 12.,Non-OADS,/arxiv_data1/oa_pdf/d7/95/rlae-22-01-0085.PMC4292685.pdf
Disponível em:  http://www.biomedcentral.com/1471-2458/11/109 14.,Non-OADS,/arxiv_data1/oa_pdf/d7/95/rlae-22-01-0085.PMC4292685.pdf
Disponível em: http://www.planalto.gov.br/ccivil_03/ decreto-lei/del2848compilado.htm 19.,Non-OADS,/arxiv_data1/oa_pdf/d7/95/rlae-22-01-0085.PMC4292685.pdf
Disponível em: http://www.scielo.br/ pdf/physis/v22n1/v22n1a14.pdf22.,Non-OADS,/arxiv_data1/oa_pdf/d7/95/rlae-22-01-0085.PMC4292685.pdf
Disponível em: http://www.scielo.br/scielo.,Non-OADS,/arxiv_data1/oa_pdf/d7/95/rlae-22-01-0085.PMC4292685.pdf
Disponível em:  http://www.scielo.br/scielo.php?pid=S0034-89102011   000400013&script=sci_arttext 26.,Non-OADS,/arxiv_data1/oa_pdf/d7/95/rlae-22-01-0085.PMC4292685.pdf
Disponível em: http://www.who.int/topics/ chronic_diseases/en/ 2.,Non-OADS,/arxiv_data1/oa_pdf/33/0c/rlae-22-01-0115.PMC4292687.pdf
Disponível em: http://www.fen.ufg.br/ revista/v11/n4/v11n4a20.htm 8.,Non-OADS,/arxiv_data1/oa_pdf/33/0c/rlae-22-01-0115.PMC4292687.pdf
Disponível em:http://www.scielo.br/ scielo.php?script=sci_arttext&pid=S0103166X2009000 200004&lng=en&nrm=iso  13.,Non-OADS,/arxiv_data1/oa_pdf/03/2a/rlae-22-01-0059.PMC4292688.pdf
Disponível em: http://www.planalto.gov.br/ccivil_03/ constituicao/ConstituicaoCompilado.htm#adct 14.,Non-OADS,/arxiv_data1/oa_pdf/03/2a/rlae-22-01-0059.PMC4292688.pdf
Disponível em: http://www.planalto.gov.br/ ccivil_03/leis/l8080.htm 17.,Non-OADS,/arxiv_data1/oa_pdf/03/2a/rlae-22-01-0059.PMC4292688.pdf
Disponível em: http://www.marktest.com/ wap/a/n/id~17f1.aspx 15.,Non-OADS,/arxiv_data1/oa_pdf/bf/88/rlae-22-01-0144.PMC4292690.pdf
Disponível em: http://www.obercom.pt/ client/?newsId=548&fileName=fr_sr_julho_2011_ imprensa.pdf 16.,Non-OADS,/arxiv_data1/oa_pdf/bf/88/rlae-22-01-0144.PMC4292690.pdf
Disponível em: http://conferencias.ulusofona.pt/   index.php/lusocom 19.,Non-OADS,/arxiv_data1/oa_pdf/bf/88/rlae-22-01-0144.PMC4292690.pdf
Disponível em:  http://www.ordemenfermeiros.pt/membros/Documents/ OE%20Dados%20Estat%C3%ADsticos%20-%202000- 2010.pdf 22.,Non-OADS,/arxiv_data1/oa_pdf/bf/88/rlae-22-01-0144.PMC4292690.pdf
Disponível em: http://www.ee.usp.br/pesq/doc/ resolucao_196-96.pdf 13.,Non-OADS,/arxiv_data1/oa_pdf/b4/b8/rlae-22-01-0093.PMC4292692.pdf
Disponível em: http://www.demet.ufmg.br/grad/ disciplinas/emt019/processo.pdf 2.,Non-OADS,/arxiv_data1/oa_pdf/ab/d0/rlae-22-01-0043.PMC4292694.pdf
Disponível em: http://www.ilo.org/wcmsp5/ groups/public/---ed_protect/---protrav/---ilo_aids/ documents/legaldocument/wcms_127474.pdf 13.,Non-OADS,/arxiv_data1/oa_pdf/ab/d0/rlae-22-01-0043.PMC4292694.pdf
Disponível em: <http://www.scielo.br/ scielo.php?script=sci_arttext&pid=S0080-6234200   7000100012&lng=pt&nrm=iso>.,Non-OADS,/arxiv_data1/oa_pdf/15/b2/rlae-22-01-0158.PMC4292695.pdf
http://dx.doi.org/   10.1590/S0080-62342007000100012 12.,Non-OADS,/arxiv_data1/oa_pdf/15/b2/rlae-22-01-0158.PMC4292695.pdf
Disponível em:  http://www.scielo.br/scielo.php?script=sci_arttext&pid=   S0080-62342007000300021&lng=pt.,Non-OADS,/arxiv_data1/oa_pdf/15/b2/rlae-22-01-0158.PMC4292695.pdf
http://dx.doi.org/   10.1590/S0080-62342007000300021 13.,Non-OADS,/arxiv_data1/oa_pdf/15/b2/rlae-22-01-0158.PMC4292695.pdf
http://dx.doi.org/10.1590   /S0104-11692013000100007,Non-OADS,/arxiv_data1/oa_pdf/8c/90/rlae-22-01-0136.PMC4292697.pdf
"Adoption of international guidelines for manuscript elaboration – to improve the quality of the information  contained in the articles it publishes and reduce the processing time between submission and publication, the  journal has adopted guidelines for the elaboration of manuscripts deriving from randomized controlled studies  (CONSORT – http://www.consort-statement.org/), systematic reviews and meta-analyses (PRISMA – http:// prisma-statement.org/), observational studies in epidemiology (STROBE – http://strobe-statement.org/) and  qualitative studies (COREQ – http://intqhc.oxfordjournals.org/content/19/6/349.long).",Non-OADS,/arxiv_data1/oa_pdf/e7/a3/rlae-22-01-0001.PMC4292698.pdf
Disponivel em: http://www.bvs-sp.fsp.usp.br/tecom/docs/2013/muc2013001.pdf Copyright © 2014 Revista Latino-Americana de Enfermagem This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (CC BY-NC).,Non-OADS,/arxiv_data1/oa_pdf/e7/a3/rlae-22-01-0001.PMC4292698.pdf
Disponível em: http://www.scielo.br/   scielo.php?script=sci_arttext&pid=S0102-86501999000   400010&lng=en&nrm=iso 09.,Non-OADS,/arxiv_data1/oa_pdf/9a/42/rlae-22-01-0165.PMC4292699.pdf
Disponível em: http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/a6/74/rlae-22-01-0011.PMC4292700.pdf
Disponível em:  http://www.scielo.br/scielo.php?pid=S0080-62342011   000100031&script=sci_arttext 2.,Non-OADS,/arxiv_data1/oa_pdf/69/33/rlae-22-01-0150.PMC4292703.pdf
Disponível em:  http://www.scielo.br/scielo.php?pid=S0080-6234200   9000500004&script=sci_arttext 4.,Non-OADS,/arxiv_data1/oa_pdf/69/33/rlae-22-01-0150.PMC4292703.pdf
228 p. Disponível em:  http://www.teses.usp.br/teses/disponiveis/7/7140/tde- 25082011-095746/pt-br.php 19.,Non-OADS,/arxiv_data1/oa_pdf/69/33/rlae-22-01-0150.PMC4292703.pdf
Disponível em: http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/69/33/rlae-22-01-0150.PMC4292703.pdf
Disponível em:  http://www.scielo.br/scielo.php?script=sci_arttext&pid =S0104-0707200900030002,Non-OADS,/arxiv_data1/oa_pdf/69/33/rlae-22-01-0150.PMC4292703.pdf
Disponível em:  http://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/ prt0529_01_04_2013.html 25.,Non-OADS,/arxiv_data1/oa_pdf/4c/4f/rlae-22-01-0129.PMC4292706.pdf
2010 [acesso 19 nov 2010]; Disponível em:  http://www.who.int/cancer/detection/variouscancer/en/ 4.,Non-OADS,/arxiv_data1/oa_pdf/00/c4/rlae-22-01-0100.PMC4292707.pdf
Disponível em  http://www.inca.gov.br/estimativa/2012 8.,Non-OADS,/arxiv_data1/oa_pdf/00/c4/rlae-22-01-0100.PMC4292707.pdf
"Thus, cancer cells that areunable to mount a premortem autophagic response are unable tosecrete ATP 6,23,31,32and hence have a reduced ability to attract myeloid cells into the tumor bed after chemotherapy.29,33As a result, tumors from which essential autophagy genes (such asAtg5 orAtg7) have been deleted, can exhibit a reduced anticancer *Correspondence to: Guido Kroemer; Email: kroemer@orange.fr; Micka €el Michaud; Email: mickael_michaud@yahoo.fr Submitted: 03/12/2014; Revised: 05/30/2014; Accepted: 06/02/2014 http://dx.doi.org/10.4161/21624011.2014.944047 www.landesbioscience.com e944047-1 OncoImmunologyOncoImmunology 3:7, e944047; July 1, 2014; © 2014 Taylor & Francis Group, LLCBRIEF REPORT",Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Nat Rev Drug Discov 2012; 11:215-33; PMID: 22301798; http://dx.doi.org/10.1038/nrd3626 2.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Nat Rev Cancer 2012; 12:860-75; PMID: 23151605; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
"Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.Immunity 2013; 39:74-88; PMID: 23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014 4.",OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Nat Rev Clin Oncol 2011; 8:151-60; PMID:21364688; http://dx.doi.org/10.1038/ nrclinonc.2010.223 5.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
J Exp Med 2005; 202:1691-701; PMID: 16365148; http://dx.doi.org/10.1084/jem.20050915 6.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Science 2011; 334:1573-7; PMID: 22174255; http://dx.doi.org/10.1126/ science.1208347 7.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Nat Med 2007; 13:1050-9; PMID: 17704786; http://dx.doi.org/10.1038/nm1622 9.,OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Oncogene 2009; 29:482-91; PMID: 19881547; http://dx.doi.org/ 10.1038/onc.2009.356 10.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Cancer Res 2010; 71:768-78; PMID:21156650; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Sci Transl Med 2012; 4:143ra99; PMID: 22814852; http://dx.doi.org/10.1126/scitranslmed.3003807 13.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Oncoimmunology 2013; 2:e23082; PMID: 23525565; http://dx.doi.org/10.4161/onci.23082 14.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Science 2012; 337:1678-84; PMID: 23019653; http://dx.doi.org/ 10.1126/science.1224922 15.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
"Kepp O, Galluzzi L, Kroemer G. Immune effectors required for the therapeutic activity of vorinostat.Oncoimmunology 2014; 2:e27157; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Cancer Res2013; 73:7265-76; PMID: 24158093; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Oncoimmunology 2014; 2:e26536; http://dx.doi.org/10.4161/onci.26536 18.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Cell Death Differ 2013; 21:92-9; PMID: 24037090; http://dx.doi.org/ 10.1038/cdd.2013.124 19.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Cell Death Differ 2007; 14:1848-50; PMID: 17657249; http://dx.doi.org/10.1038/sj.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Oncoimmunology 2012; 1:786-8; PMID: 22934283; http://dx.doi.org/10.4161/ onci.19750 21.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
EMBO J 2012;31:1062-79; PMID: 22252128; http://dx.doi.org/ 10.1038/emboj.2011.497 22.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Oncogene 2010; 30:1147-58; PMID: 21151176; http://dx.doi.org/10.1038/onc.2010.500 23.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Cell Death Differ 2008; 15:1499-509; PMID: 18464797; http://dx.doi.org/ 10.1038/cdd.2008.67 25.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
EMBO J 2009; 28:578-90; PMID:19165151; http://dx.doi.org/10.1038/emboj.2009.1 26.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Cell Death Differ 2013; 21:69-78; PMID: 23811849; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Annu Rev Immunol 2012; 31:51-72; PMID: 23157435; http://dx.doi.org/10.1146/annurev-immunol-032712- 100008 28.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Curr Opin Immunol 2008; 20:504-11; PMID: 18573340; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Cancer Res 2013; 74:436-45; PMID: 24302580; http://dx.doi.org/ 10.1158/0008-5472.CAN-13-1265 31.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Oncoimmunology 2012; 1:393- 5; PMID: 22737627; http://dx.doi.org/10.4161/ onci.19070 32.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Immunity 2013; 39:211-27; PMID: 23973220; http://dx.doi.org/ 10.1016/j.immuni.2013.07.017 34.,OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Nat Med 2012; 18:344-6; author reply 6; PMID: 22395693; http://dx.doi.org/ 10.1038/nm.2652 35.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Cancer Res 2011; 71:4809-20; PMID:21646474; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Eur J Immunol 2013; 43:2718-29; PMID: 23843024; http://dx.doi.org/10.1002/eji.20124250538.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Cancer Res 2011; 71:5601-5; PMID: 21846822;http://dx.doi.org/10.1158/0008-5472.CAN-11- 1316 39.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Oncoimmunology 2012; 1:1323-43; PMID: 23243596; http://dx.doi.org/10.4161/onci.22009 41.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
J Clin Oncol 2009; 28:105-13; PMID: 19917869; http://dx.doi.org/10.1200/JCO.2009.23.7370 42.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
J Pathol 2011; 224:389-400; PMID: 21437909; http://dx.doi.org/10.1002/path.2866 43.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Oncoimmunology 2013; 2:e24720; PMID: 24073365; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
J Clin Oncol 2013; 31:860-7; PMID: 23341518; http://dx.doi.org/ 10.1200/JCO.2011.41.0902 45.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Cell Death Differ 2009; 16:87-93; PMID:18806760; http://dx.doi.org/10.1038/cdd.2008.131 47.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Cell Cycle 2011; 10:2763-9; PMID: 21775823; http://dx.doi.org/10.4161/ cc.10.16.16868 48.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
Pigment Cell Melanoma Res 2008; 21:534-44; PMID: 18715233; http://dx.doi.org/10.1111/j.1755-148X.2008.00491.x 50.,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
J Cell Biol 2005; 169:425-34; PMID: 15866887; http://dx.doi.org/10.1083/jcb.200412022 e944047-6 Volume 3 Issue 7 OncoImmunology,Non-OADS,/arxiv_data1/oa_pdf/f7/32/koni-03-e944047.PMC4292732.pdf
"Human SRP9 exons, exon –intron boundaries and promoter region (5 kb upstream) were sequenced with nested PCR.22Primers (Table S4) were chosen using LIMSTILL (http://limstill.niob.knaw.nl/).22All sequenced SNPs with an allele frequency >0.05 were selected for association analysis.",OADS,/arxiv_data1/oa_pdf/3a/19/acn30001-0239.PMC4292741.pdf
Database analysis (WebQTL: http://www.genenetwork.org/) revealed a strong cisQTLfor Srp9 mRNA regulation in the AXB eye tissue (LOD =12.1) and BXD brain (LOD =11.7).,OADS,/arxiv_data1/oa_pdf/3a/19/acn30001-0239.PMC4292741.pdf
Newly identiﬁed polymorphisms are in bold and underlined(known polymorphisms http://www.ensembl.org).,Non-OADS,/arxiv_data1/oa_pdf/3a/19/acn30001-0239.PMC4292741.pdf
"Data discussed here were deposited in NCBI’s Gene Expression Omnibus, 14and are accessible through GEO Series accession number GSE49160 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49160).",OADS,/arxiv_data1/oa_pdf/df/b7/acn30001-0284.PMC4292745.pdf
http://dx.doi.org/10.1016/j.ymgmr.2013.11.002 Contents lists available at ScienceDirect Molecular Genetics and Metabolism Reports journal homepage: http://www.journals.elsevier.com/ molecular-genetics-and-metabolism-reports/,Non-OADS,/arxiv_data1/oa_pdf/23/12/main.PMC4292891.pdf
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.ymgmr.2013.11.002 .,OADS,/arxiv_data1/oa_pdf/23/12/main.PMC4292891.pdf
"2091 –2116, http://dx.doi.org/10.1007/978-1-4419-1795-9_126 .",Non-OADS,/arxiv_data1/oa_pdf/23/12/main.PMC4292891.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b0/7c/main.PMC4292909.pdf
http://dx.doi.org/10.1016/j.pmedr.2014.11.001 2211-3355/© 2014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/b0/7c/main.PMC4292909.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b0/7c/main.PMC4292909.pdf
Contents lists available at ScienceDirect Preventive Medicine Reports journal homepage: http://ees.elsevier.com/pmedr,Non-OADS,/arxiv_data1/oa_pdf/b0/7c/main.PMC4292909.pdf
To view the other articles in thissection visit http://dx.doi.org/10.1111/bph.2015.172.issue-2BJPBritish Journal of PharmacologyDOI:10.1111/bph.12687 www.brjpharmacol.org British Journal of Pharmacology (2015) 172 501–514 501 © 2014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d6/3c/bph0172-0501.PMC4292964.pdf
Supporting information Additional Supporting Information may be found in the online version of this article at the publisher’s web-site: http://dx.doi.org/10.1111/bph.12687 Figure S1 β-catenin distribution is affected by δ-opioid receptor (DOPr) expression.,Non-OADS,/arxiv_data1/oa_pdf/d6/3c/bph0172-0501.PMC4292964.pdf
To view the other articles in thissection visit http://dx.doi.org/10.1111/bph.2015.172.issue-2BJPBritish Journal of PharmacologyDOI:10.1111/bph.12753 www.brjpharmacol.org 606 British Journal of Pharmacology (2015) 172 606–614 © 2014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/70/bb/bph0172-0606.PMC4292972.pdf
To view the other articles in thissection visit http://dx.doi.org/10.1111/bph.2015.172.issue-2BJPBritish Journal of PharmacologyDOI:10.1111/bph.12761 www.brjpharmacol.org British Journal of Pharmacology (2015) 172 615–629 615 © 2014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/94/c4/bph0172-0615.PMC4292973.pdf
"Supporting information Additional Supporting Information may be found in the online version of this article at the publisher’s web-site: http://dx.doi.org/10.1111/bph.12761 Figure S1 Original image, Figure 5A, upper left.",Non-OADS,/arxiv_data1/oa_pdf/94/c4/bph0172-0615.PMC4292973.pdf
"To view the other articles in thissection visit http://dx.doi.org/10.1111/bph.2015.172.issue-2 Abbreviations CRF, corticotropin releasing factor; DOP, δopioid; HPA, hypothalamic-pituitary-adrenal axis; KO, knockout; KOP, κ opioid; MOP, μopioid; NOP, nociceptin/orphanin FQ; norBNI, nor-binaltorphimine; WT, wild typeBJPBritish Journal of PharmacologyDOI:10.1111/bph.12810 www.brjpharmacol.org British Journal of Pharmacology (2015) 172 691–703 691 © 2014 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/01/44/bph0172-0691.PMC4292979.pdf
"Supporting information Additional Supporting Information may be found in the online version of this article at the publisher’s web-site:http://dx.doi.org/10.1111/bph.12810 Figure S1 U50,488H antinociceptive response across sex and genotype.",Non-OADS,/arxiv_data1/oa_pdf/01/44/bph0172-0691.PMC4292979.pdf
"The UPPER institutional review board reviewed the study, which was conducted incompliance with its requirements (http://www.uu.nl/vkc/ upper).",Non-OADS,/arxiv_data1/oa_pdf/82/d7/jgs0062-2339.PMC4293156.pdf
"Available at http://www.gundersenhealth.org/respect- ing-choices Accessed January 29, 2014.2424 WILSON ET AL.",Non-OADS,/arxiv_data1/oa_pdf/08/94/jgs0062-2420.PMC4293157.pdf
"Available at http://www.amedisys.com/our-company/blog/June-2012/hav-ing-your-own-say —getting-the-right-care-when-i Accessed June 26, 2014.",Non-OADS,/arxiv_data1/oa_pdf/08/94/jgs0062-2420.PMC4293157.pdf
"Available at http://www.dartmouthatlas.org/ Accessed January 29, 2014.",Non-OADS,/arxiv_data1/oa_pdf/08/94/jgs0062-2420.PMC4293157.pdf
"Available at http://www.mnchurches.org/respectfulcommunities/endoﬂife.html Accessed January 29, 2014.",Non-OADS,/arxiv_data1/oa_pdf/08/94/jgs0062-2420.PMC4293157.pdf
"Available at http://www.mnhealthscores.org/?p=our_reports_landing&landing=1 Accessed May 13, 2014.",Non-OADS,/arxiv_data1/oa_pdf/08/94/jgs0062-2420.PMC4293157.pdf
Prev Chronic Dis 2012;9:110179. doi: http://dx.doi.org/10.5888/pcd9.110179JAGS DECEMBER 2014–VOL.,Non-OADS,/arxiv_data1/oa_pdf/08/94/jgs0062-2420.PMC4293157.pdf
"169Editorial http://dx.doi.org/10.9758/cpn.2014.12.3.169 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):169 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                                                               Corresponding author: Young-Chul Chung, MD, PhD Department of Psychiatry, Chonbuk National University Medical S chool, 20 Geonji-ro, Deokjin-gu, Jeonju 561-712, Korea Tel: +82-63-250-1390, Fax: +82-63-275-3157, E-mail: chungyc@jbn u.ac.kr  This is an Open-Access article distributed under the terms of t he Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, an d reproduction in any medium, provided the original work is pro perly cited.Friends Who Have the Same Dream Walk Together On October 8, 2014, Clinical Psychopharmacology and Neuroscience (Clin Psychopharmacol Neurosci ) was selected  for coverage in Science Citation Index Expanded (SCIE), 11 years after it was launched in 2003.",Non-OADS,/arxiv_data1/oa_pdf/a3/5d/cpn-12-169.PMC4293159.pdf
"170Editorial http://dx.doi.org/10.9758/cpn.2014.12.3.170 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):170 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                                                               Corresponding author: Xin Yu, MD, PhD Institute of Mental Health, Peking University, No.51 Hua Yuan B ei Road, Haidian District, Beijing, 100191, P. R. China Tel: +86-10-82801999, Fax: +86-10-62026310, E-mail: yuxin@bjmu.",Non-OADS,/arxiv_data1/oa_pdf/ba/e7/cpn-12-170.PMC4293160.pdf
"171Review http://dx.doi.org/10.9758/cpn.2014.12.3.171 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):171-179 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  February 21, 2014/ Revised:  April 7, 2014 Accepted:  April 9, 2014 Address for correspondence: Vedat Şar, MD Amerikan Hastanesi Psikiyatri B ölümü, Güzelbahce Sok.",Non-OADS,/arxiv_data1/oa_pdf/17/b2/cpn-12-171.PMC4293161.pdf
"180Review http://dx.doi.org/10.9758/cpn.2014.12.3.180 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):180-188 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  March 21, 2014/ Revised:  April 29, 2014 Accepted:  April 30, 2014 Address for correspondence: Olivia May Dean, PhD Innovations in Mental and Physical Health and Clinical Treatmen ts  Strategic Research Centre, Deakin University, School of Medicin e,  Kitchener House, P.O.",Non-OADS,/arxiv_data1/oa_pdf/52/dd/cpn-12-180.PMC4293162.pdf
"189Review http://dx.doi.org/10.9758/cpn.2014.12.3.189 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):189-195 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  April 14, 2014/ Revised:  June 19, 2014 Accepted:  June 23, 2014 Address for correspondence: Georg Northoff, MD, PhD Research Unit Director, Mind, Brain Imaging and Neuroethics  Institute of Mental Health Research (IMHR), 1145 Carling Avenue ,  Ottawa, ON K1Z 7K4, CanadaTel: +1-613-7226521 ext.",Non-OADS,/arxiv_data1/oa_pdf/c0/19/cpn-12-189.PMC4293163.pdf
"196Review http://dx.doi.org/10.9758/cpn.2014.12.3.196 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):196-202 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  April 15, 2014/ Revised:  June 26, 2014 Accepted:  August 21, 2014 Address for correspondence: Lan-Ting Lee, MD Department of Psychiatry, National Cheng Kung University Hospit al,  138 Sheng Li Road, North Dist., Tainan 70403, TaiwanTel: +886-6-2353535 ext.4200, Fax: +886-6-2759259E-mail: bce2369@hotmail.com  This is an Open-Access article distributed under the terms of t he Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, an d reproduction in any medium, provided the original work is pro perly cited.Table 1.",Non-OADS,/arxiv_data1/oa_pdf/2a/c7/cpn-12-196.PMC4293164.pdf
"203Original Article http://dx.doi.org/10.9758/cpn.2014.12.3.203 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):203-208 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  January 3, 2014/ Revised:  April 7, 2014 Accepted:  April 9, 2014 Address for correspondence: Tjhin Wiguna, MD, MIMH, PhD Child and Adolescent Psychiatry Division, Department of Psychia try, University of Indonesia, Jl.",Non-OADS,/arxiv_data1/oa_pdf/a6/78/cpn-12-203.PMC4293165.pdf
"209Original Article http://dx.doi.org/10.9758/cpn.2014.12.3.209 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):209-214 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  May 7, 2014/ Revised:  July 4, 2014 Accepted:  August 11, 2014 Address for correspondence: Jimmy Lee, MBBS, MMed (Psychiatry), MCI Research Division, Institute of Mental Health, 10 Buangkok View ,  539747, SingaporeTel: +65-63892000, Fax: +65-63891050E-mail: jimmy_lee@imh.com.sg  This is an Open-Access article distributed under the terms of t he Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, an d reproduction in any medium, provided the original work is pro perly cited.Regulation of Interleukin-6 and Leptin in Schizophrenia Patients: A Preliminary  Analysis  Sasi Neelamekam1, Milawaty Nurjono1, Jimmy Lee1,2,3 1Research Division, Institute of Mental Health, 2Department of General Psychiatry 1, Institute of Mental Health,  3Office of Clinical Sciences,  Duke-NUS Graduate Medical School, Singapore Objective: Immune-inflammatory mediators play a pivotal role in brain sign aling and have been increasingly associated with  the pathophysiology of schizophrenia.",Non-OADS,/arxiv_data1/oa_pdf/8b/f6/cpn-12-209.PMC4293166.pdf
"215Original Article http://dx.doi.org/10.9758/cpn.2014.12.3.215 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):215-217 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  June 24, 2014/ Revised:  September 12, 2014 Accepted:  September 15, 2014 Address for correspondence: Yukihiko Shirayama, MD, PhD Department of Psychiatry, Teikyo University Chiba Medical Cente r,  3426-3 Anesaki, Ichihara 299-0111, JapanTel: +81-436-62-1211, Fax: +81-436-62-1511E-mail: shirayama@rapid.ocn.ne.jp  This is an Open-Access article distributed under the terms of t he Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, an d reproduction in any medium, provided the original work is pro perly cited.Effects of Add-on Ramelteon on Cogni tive Impairment in Patients with  Schizophrenia: An Open-label Pilot Trial Yukihiko Shirayama, Michio Takahashi, Masatoshi Suzuki, Yoshiak i Tsuruoka, Koichi Sato Department of Psychiatry, Teikyo University Chiba Medical Cente r, Ichihara, Japan Objective: This open-label study examined the effects of ramelteon on cogn itive functions in 10 outpatients with schizophrenia.",Non-OADS,/arxiv_data1/oa_pdf/17/9f/cpn-12-215.PMC4293167.pdf
"218Original Article http://dx.doi.org/10.9758/cpn.2014.12.3.218 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):218-221 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  June 29, 2014/ Revised:  August 27, 2014 Accepted:  September 20, 2014 Address for correspondence: Kazuki Hirao, OT, PhD Department of Occupational Therapy, School of Health Science  and Social Welfare, Kibi International University, 8 Iga-machi Takahashi, Okayama 716-8508, JapanTel: +81-866-22-4044, Fax: +81-866-22-4044E-mail: hirao-k@kiui.ac.jp  This is an Open-Access article distributed under the terms of t he Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, an d reproduction in any medium, provided the original work is pro perly cited.Two-channel Near-infrared Spectroscopic Analysis of Association of Paranoia  Symptoms with Prefrontal Activation  Kazuki Hirao Department of Occupational Therapy, School of Health Science an d Social Welfare, Kibi International University, Okayama, Japan Objective: The relationship between paranoia symptoms and underlying prefr ontal cortex mechanisms among healthy subjects  was analyzed using near-infrared spectroscopy.",Non-OADS,/arxiv_data1/oa_pdf/3e/71/cpn-12-218.PMC4293168.pdf
"222Original Article http://dx.doi.org/10.9758/cpn.2014.12.3.222 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):222-228 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  May 9, 2014/ Revised:  September 6, 2014 Accepted:  September 28, 2014 Address for correspondence: Young-Chul Chung, MD, PhD Department of Psychiatry, Chonbuk National University Medical  School, 20 Geonji-ro, Deokjin-gu, Jeonju 561-712, KoreaTel: +82-63-250-1390, Fax: +82-63-275-3157E-mail: chungyc@jbnu.ac.kr  This is an Open-Access article distributed under the terms of t he Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, an d reproduction in any medium, provided the original work is pro perly cited.Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations  in Patients with Schizophrenia: A Ra ndomized Controlled, Cross-over Study Eun-Ji Kim1, Seonguk Yeo1, Inho Hwang1, Jong-Il Park1, Yin Cui2,3, Hong-Mei Jin2,3, Hyung Tae Kim4, Tae-Young Hwang4,  Young-Chul Chung1,2,3 1Department of Psychiatry, Chonbuk National University Hospital,  2Department of Psychiatry, Chonbuk National University Medical S chool,  3Research Institute of Clinical Medicine of Chonbuk National Uni versity-Biomedical Research Institute of Chonbuk National Unive rsity  Hospital, Jeonju, 4Department of Psychiatry, Chonbuk Provincial Maeumsarang Hospit al, Wanju, Korea Objective: A randomized double-blind cross-over trial was conducted in pat ients with persistent auditory hallucinations (AHs)  to investigate whether bilateral repetitive transcranial magnet ic stimulation (rTMS) at the temporoparietal area or Broca ’s area  is more effective at high- or low-frequencies compared to a sha m condition.",Non-OADS,/arxiv_data1/oa_pdf/5a/f1/cpn-12-222.PMC4293169.pdf
"229Original Article http://dx.doi.org/10.9758/cpn.2014.12.3.229 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):229-234 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  September 26, 2014/ Revised:  November 21, 2014 Accepted:  November 29, 2014 Address for correspondence: Ik-Seung Chee, MD, PhD Department of Psychiatry, Chungnam National University Hospital ,  Chungnam National University School of Medicine, 282 Munwha-ro, Jung-gu, Daejeon 301-747, KoreaTel: +82-42-280-8291, Fax: +82-42-280-7886E-mail: ischee@cnu.ac.kr  This is an Open-Access article distributed under the terms of t he Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, an d reproduction in any medium, provided the original work is pro perly cited.No Effect on Body Dissatisfaction of an Interaction between 5-HTTLPR  Genotype and Neuroticism in a Young Adult Korean Population Seung-Keun Wang1,3, Young-Ho Lee2,3, Jeong-Lan Kim1,3, Ik-Seung Chee1,3 1Department of Psychiatry, Chungnam National University Hospital , 2Department of Anatomy, Chungnam National University School of  Medicine, Daejeon, 3Institute of Brain Research, Chungnam National University, Daej eon, Korea Objective: Many studies suggest an association between the serotonin trans porter gene-linked polymorphic region (5-HTTLPR)  and anxiety-related personality traits (e.g., neuroticism) in h ealthy subjects.",Non-OADS,/arxiv_data1/oa_pdf/44/bb/cpn-12-229.PMC4293170.pdf
"235Case Report http://dx.doi.org/10.9758/cpn.2014.12.3.235 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):235-239 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  February 24, 2014/ Revised:  May 19, 2014 Accepted:  May 26, 2014 Address for correspondence: Se-Hoon Shim, MD, PhD Department of Psychiatry, Soonchunhyang University Cheonan  Hospital, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan 330-903, KoreaTel: +82-41-570-2280, Fax: +82-41-570-3878E-mail: shshim2k@naver.com  This is an Open-Access article distributed under the terms of t he Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, an d reproduction in any medium, provided the original work is pro perly cited.Adolescent with Tourette Syndrome and Bipolar Disorder: A Case Report Se-Hoon Shim, Young-Joon Kwon Department of Psychiatry, Soonch unhyang University Cheonan Hosp ital, College of Medicine, Soonchunhyang University, Cheonan, K orea  Tourette syndrome consists of multiple motor tics and one or mo re vocal tics.",Non-OADS,/arxiv_data1/oa_pdf/f2/e3/cpn-12-235.PMC4293171.pdf
"240Case Report http://dx.doi.org/10.9758/cpn.2014.12.3.240 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):240-242 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Received:  April 25, 2014/ Revised:  June 21, 2014 Accepted:  July 14, 2014 Address for correspondence: Akira Kishimoto, MD, PhD  Yonago Medical Corporation, Yonago Clinic, 80-1 Bakuro-machi  3-Chome, Yonago 683-0052, JapanTel: +81-859-34-1201, Fax: +81-859-35-5023E-mail: ak-feb8@sea.chukai.ne.jp  This is an Open-Access article distributed under the terms of t he Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, an d reproduction in any medium, provided the original work is pro perly cited.Post-traumatic Stress Disorder Symptoms in a Female Patient Following Repeated  Teasing: Treatment with Gabapentin an d Lamotrigine and the Possible Role of  Sensitization Akira Kishimoto1, Yurie Goto1, Kenji Hashimoto2 1Yonago Medical Corporation, Yonago Clinic, Yonago, 2Division of Clinical Neuroscience, Chiba University Center for Forensic Mental  Health, Chiba, Japan Post-traumatic stress disorder (PTSD) is a pathological respons e to trauma characterized by frequent recollections, recurrent  nightmares, and flashbacks of the traumatic event(s).",Non-OADS,/arxiv_data1/oa_pdf/cf/05/cpn-12-240.PMC4293172.pdf
"243Correction http://dx.doi.org/10.9758/cpn.2014.12.3.243 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2014;12(3):243 Copyrightⓒ 2014, Korean College of Neuropsychopharmacology                       Address for correspondence: Kenji Hashimoto, PhD Division of Clinical Neuroscience, Chiba University Center for  Forensic Mental Health, 1-8-1 Inohara, Chiba 260-8670, Japan Tel: +81-43-226-2517, Fax: +81-43-226-2561E-mail: hashimoto@faculty.chiba-u.jp  This is an Open-Access article distributed under the terms of t he Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, an d reproduction in any medium, provided the original work is pro perly cited.Erratum: Figure Correction Su-Xia Li1,2, Ji-Chun Zhang1, Jin Wu1, Kenji Hashimoto1 1Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan, 2National Institute on Drug  Dependence, Peking University, Beijing, P.R.",Non-OADS,/arxiv_data1/oa_pdf/2d/af/cpn-12-243.PMC4293173.pdf
"Clin Psychopharmacol Neurosci  2014;12(2):124-127. http://dx.doi.org/  10.9758/cpn.2014.12.2.124,” the Figure 1A was given incorrectly.",Non-OADS,/arxiv_data1/oa_pdf/2d/af/cpn-12-243.PMC4293173.pdf
"12       http://www.medsci.org  92  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2015;  12(2):  92-99. doi: 10.7150/ ijms.10497   Research Paper   Syndecan- 1 Expression Is Associated with Tumor Size  and EGFR Expression in Colorectal Carcinoma: A  Clinicopathological Study o f 230 Cases   Su Young Kim1, Eun Ji Choi1, Jeong A Yun1, Eun Sun Jung2, Seung Taek Oh3, Jun Gi Kim3, Won Kyung  Kang3, Sung Hak Lee2  1.",Non-OADS,/arxiv_data1/oa_pdf/0a/60/ijmsv12p0092.PMC4293174.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/0a/60/ijmsv12p0092.PMC4293174.pdf
12     http://www.medsci.org  93  by epithelial cells and plasma cells in adult tissues.,Non-OADS,/arxiv_data1/oa_pdf/0a/60/ijmsv12p0092.PMC4293174.pdf
12     http://www.medsci.org  94  tissue blocks were then sectioned at a thickness of 10  μm.,Non-OADS,/arxiv_data1/oa_pdf/0a/60/ijmsv12p0092.PMC4293174.pdf
12     http://www.medsci.org  95    Fig.,Non-OADS,/arxiv_data1/oa_pdf/0a/60/ijmsv12p0092.PMC4293174.pdf
12     http://www.medsci.org  96  Table 1.,Non-OADS,/arxiv_data1/oa_pdf/0a/60/ijmsv12p0092.PMC4293174.pdf
"12     http://www.medsci.org  97  addition, release of the SDC1 ectodomain from the cell  surface could play an important role.",Non-OADS,/arxiv_data1/oa_pdf/0a/60/ijmsv12p0092.PMC4293174.pdf
"12     http://www.medsci.org  98  branous SDC1 expression, which is significantly cor- related with advanced primary tumors and EGFR immunohistochemical positivity.",Non-OADS,/arxiv_data1/oa_pdf/0a/60/ijmsv12p0092.PMC4293174.pdf
12     http://www.medsci.org  99  4.,Non-OADS,/arxiv_data1/oa_pdf/0a/60/ijmsv12p0092.PMC4293174.pdf
"1 2      http://www.medsci.org  100  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2015;  12(2):  100-115.  doi: 10.7150/ ijms.10696   Research Paper   Liver Function Parameters in Hip Fracture Patients:  Relations to Age, Adipokines, Comorbidities and  Outcomes   Leon Fis her1, Wichat Srikusalanukul2, Alexander Fisher2,4 and Paul Smith3,4   1.",Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
"1 2    http://www.medsci.org  101  all liver cells, accumulation of ageing pigments at the  cytoplasm and pseudocapillarization of the sinusoid .",Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
"1 2    http://www.medsci.org  102  chemical au toanalyzer Abbott Architect CI16200  (Abbott Laboratories, IL 60064, USA).",Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
1 2    http://www.medsci.org  103  function abnormalities were small in magnitude and  not associated with clinically apparent hepatic dis-ease.,Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
1 2    http://www.medsci.org  104  Links between liv er markers and  comorbidities   Parameters of liver function were compared  between patients with and without specific co- morbid  conditions.,Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
"1 2    http://www.medsci.org  105  range (n=124) demonstrated a significantly higher  mean adiponectin concentration (19.8± 7.3 vs. 16.0±7.1 ng/ml, p=0.001), while 25(OH)D levels were similar (29.0 ± 11.96 vs. 31.3 ± 11.83 nmol/L, p=0.194).",Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
"1 2    http://www.medsci.org  106    The prognostic value of GGT>30U/L for pr o- longed LOS [accuracy  60.4%, 95%CI 54.7 – 66.1%,  sensitivity 48.9%, 95%CI 39.9 –  57.8%; specificity  65.8%, 95%CI 61.6 – 69.9%; PPV 39.8%, 95%CI 32.5 –  47.1%; NPV 73.5%, 95%CI 68.9 –  78.1%] was comp a- rable with that of higher adiponectin level (cut -off  17.14 ng/ml) [accuracy 57.",Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
"1 2    http://www.medsci.org  107  levels,87, 88 and with the well -recognized fact that both  these adipokines are higher in women than in men.",Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
"1 2    http://www.medsci.org  108  correlations between GGT and ALT,5, 8, 138, 139  ALP140  and bilirubin.141 These bidirectional links indicate that  GGT activity represents an integral component of  liver function.",Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
1 2    http://www.medsci.org  109  of adiponectin on serum GGT activity.,Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
"1 2    http://www.medsci.org  110  ponectin inhibits oxidative stress, but oxidative stress  suppresses adiponectin production and its powerful protective antioxidant properties.",Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
1 2    http://www.medsci.org  111  measured in parallel are more informative for pre- dicting LOS.,Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
1 2    http://www.medsci.org  112  17.,Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
1 2    http://www.medsci.org  113  77.,Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
1 2    http://www.medsci.org  114  131.,Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
1 2    http://www.medsci.org  115  191.,Non-OADS,/arxiv_data1/oa_pdf/d7/d9/ijmsv12p0100.PMC4293175.pdf
"12       http://www.medsci.org  116  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2015;  12(2):  116-125.  doi: 10.7150/ ijms.10322   Research Paper   Effect of the Hand Antiseptic Agents Benzalkonium  Chloride, Povidone -Iodine, Ethanol, and Chlorhexidine  Gluconate on Atopic Dermatitis in NC/Nga Mice   Kaori Sadakane and Takamichi Ichinose   Department of Health Sciences, Oita University of Nursing and Health Sciences, 2944 -9 Megusuno, Oita Ci ty, Oita 870- 1201, Japan     Corresponding author : Kaori Sadakane.",Non-OADS,/arxiv_data1/oa_pdf/02/45/ijmsv12p0116.PMC4293176.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/  licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/02/45/ijmsv12p0116.PMC4293176.pdf
"12     http://www.medsci.org  117  Another well -known antiseptic, povidone -iodine  (PVP -I), is widely used in mouthwash and in disin- fection before surgery.",Non-OADS,/arxiv_data1/oa_pdf/02/45/ijmsv12p0116.PMC4293176.pdf
12       http://www.medsci.org  118    Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/02/45/ijmsv12p0116.PMC4293176.pdf
12     http://www.medsci.org  119  respectively.,Non-OADS,/arxiv_data1/oa_pdf/02/45/ijmsv12p0116.PMC4293176.pdf
12       http://www.medsci.org  120    Figure 3.,Non-OADS,/arxiv_data1/oa_pdf/02/45/ijmsv12p0116.PMC4293176.pdf
12     http://www.medsci.org  121  3.5.,Non-OADS,/arxiv_data1/oa_pdf/02/45/ijmsv12p0116.PMC4293176.pdf
12     http://www.medsci.org  122    Figure 5.,Non-OADS,/arxiv_data1/oa_pdf/02/45/ijmsv12p0116.PMC4293176.pdf
12       http://www.medsci.org  123  4.,Non-OADS,/arxiv_data1/oa_pdf/02/45/ijmsv12p0116.PMC4293176.pdf
12     http://www.medsci.org  124  promote infection by Staphylococcus aureus  [37].,Non-OADS,/arxiv_data1/oa_pdf/02/45/ijmsv12p0116.PMC4293176.pdf
12     http://www.medsci.org  125  17.,Non-OADS,/arxiv_data1/oa_pdf/02/45/ijmsv12p0116.PMC4293176.pdf
"1 2      http://www.medsci.org  126  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2015;  12(2):  126-134.  doi: 10.7150/ ijms.9951   Research Paper   Single Nucleotide Polymorphism  in Ag85 Genes  of  Mycobacterium Tuberculosis Complex : Analysis  of 178  Clinical Isolates from China and 13 BCG strains   Yi Jiang1,2*, Haican Liu1,2*, Machao Li1,2*, Guilian Li1,2, Hui Pang3, Xiangfeng Dou4, Xiuqin Zhao1,2, Kanglin  Wan1,2  1.",Non-OADS,/arxiv_data1/oa_pdf/41/bd/ijmsv12p0126.PMC4293177.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/41/bd/ijmsv12p0126.PMC4293177.pdf
"1 2    http://www.medsci.org  127  were polymorphisms existing  in two important ant i- gens, MPT64 (4) and PstS1 ( 5) in clinical M. tubercul o- sis strains isolated from China.",Non-OADS,/arxiv_data1/oa_pdf/41/bd/ijmsv12p0126.PMC4293177.pdf
"1 2    http://www.medsci.org  128  These strains were cultured using the standard  Löwenstein -Jensen medium method, the genomic  DNA were prepared according to previously reported  and then used directly in polymerase chain reactions  (PCRs).",Non-OADS,/arxiv_data1/oa_pdf/41/bd/ijmsv12p0126.PMC4293177.pdf
"1 2    http://www.medsci.org  129  Changes in T/B  cell epitope s  Table 6 presented T cell epitopes and B cell  epitopes in Ag85A, Ag85B and Ag85C according to  the Immune Epitopes Database (IEDB)  (18).",OADS,/arxiv_data1/oa_pdf/41/bd/ijmsv12p0126.PMC4293177.pdf
1 2    http://www.medsci.org  130  T/B 6323  CGNGTPNELGGANIPAEFLE  Rv1886c  No No  Ag85B   T/B 8688  DIKVQFQSGGNNSPAVYLLD  Rv1886c  No No  Ag85B   T/B 10841  DWYSPACGKAGCQTYKWET F Rv1886c  TTC -CTC  F-L Ag85B   T/B 18700  GANIPAEFLENFVRSSNLKF  Rv1886c  GCC -GCG  No  Ag85B   T/B 18898  GCQTYKWET FLTSELPQWLS  Rv1886c  TTC -CTC  F-L Ag85B   T/B 21096  GLRAQDDYNGWDINTPAFEW  Rv1886c  No No  Ag85B   T/B 21797  GPSSDPAWERNDPTQQIPKL  Rv1886c  CCC -CCT  No  Ag85B   T/B 40165  LTSELPQWLSANRAVKPTGS  Rv1886c  No No  Ag85B   T/B 43332  NAVFNFPPNGTHSWEYWGAQ  Rv1886c  No No  Ag85B   T/B 45250  NNSPAVYLLDGLRAQDDYNG  Rv1886c  No No  Ag85B   T/B 49421  PSLIGLAMGDAGGYKAADMW  Rv1886c  No No  Ag85B   T/B 49872  PVGGQSSFYSDWYSPACGKA  Rv1886c  No No Ag85B   T/B 50442  QDAYNAAGGHNAVFNFPPNG  Rv1886c  No No Ag85B   T/B 52026  QQFIYAGSLSALLDPSQGMG  Rv1886c  No No  Ag85B   T/B 56895  SAMILAAYHPQQFIYAGSLS  Rv1886c  No No Ag85B   T/B 64079  THSWEYWGAQLNAMKGDLQS  Rv1886c  No No  Ag85B   T/B 67697  VANNTRLWVYCGNGTPNELG  Rv1886c  No No  Ag85B   T/B 72314  WDINTPAFEWYYQSGLSIVM  Rv1886c  No No  Ag85B   T/B 76584  YYQSGLSIVMPVGGQSSFYS  Rv1886c  No No  Ag85B   B 1522  AGGGHNGVFDFPDSG  Rv3804c  No No  Ag85A   B 3402  ANRHVKPTGSAVVGL  Rv3804c  No No  Ag85A   B 49333  PSDLGGNNLPAKFLE  Rv3804c  No No  Ag85A   B 51790  QPACRKAGCQTYKWE  Rv3804c  No No  Ag85A   B 70010  VMPVGGQSSFYSDWY  Rv3804c  No No  Ag85A   T 1546  AGGYKASDMWGPKEDPAWQR  Rv3804c  No No  Ag85A   T 3403  ANRHVKPTGSAVVGLSMAAS  Rv3804c  No No Ag85A   T 3422  ANSPALYLLDGLRAQDDFSG  Rv3804c  No No  Ag85A   T 6901  CQTYKWETF  Rv3804c  No No  Ag85A   T 8686  DIKVQFQSGGANSPALYLLD  Rv3804c  No No  Ag85A   T 10838  DWYQPACGKAGCQTYKWETF  Rv3804c  No No  Ag85A   T 18896  GCQTYKWETFLTSELPGWLQ  Rv3804c  No No  Ag85A   T 19646  GFVRTSNIKFQDAYNAGGGH  Rv3804c  No No  Ag85A   T 20979  GLLDPSQAMGPTLIGLAMGD  Rv3804c  No No  Ag85A   T 21093  GLRAQDDFSGWDINTPAFEW  Rv3804c  No No  Ag85A   T 21439  GNGKPSDLGGNNLPAKFLEG  Rv3804c  No No  Ag85A   T 21482  GNNLPAKFLEGFVRTSNIKF  Rv3804c  No No  Ag85A   T 21670  GPKEDPAWQRNDPLLNVGKL  Rv3804c  No No  Ag85A   T 21960  GQSSFYSDWY  Rv3804c  No No  Ag85A   T 25363  IANNTRVWVYCGNGKPSDLG  Rv3804c  GCC -GGC  A-G Ag85A   T 31902  KLIANNTRV  Rv3804c  GCC -GGC  A-G Ag85A   T 34823  LAIYHPQQFVYAGAMSGLLD  Rv3804c  No No Ag85A   T 40162  LTSELPGWLQANRHVKPTGS  Rv3804c  No No  Ag85A   T 41872  MKPDLQRALGATPNTGPAPQGA  Rv3804c  No No  Ag85A   T 43504  NDPLLNVGKLI ANNTRVWVY  Rv3804c  GCC -GGC  A-G Ag85A   T 44100  NGVFDFPDSGTHSWEYWG AQ Rv3804c  GCG -GGG  A-G Ag85A   T 49699  PTLIGLAMGDAGGYKASDMW  Rv3804c  No No  Ag85A   T 49870  PVGGQSSFYSDWYQPACGKA  Rv3804c  No No  Ag85A   T 50444  QDAYNAGGGHNGVFDFPDSG  Rv3804c  No No  Ag85A   T 52030  QQFVYAGAMSGLLDPSQAMG  Rv3804c  No No  Ag85A   T 52431  QSSFYSDWY  Rv3804c  No No  Ag85A   T 56884  SALTLAIYHPQQFVYAGAMS  Rv3804c  No No  Ag85A   T 64081  THSWEYWG AQLNAMKPDLQR  Rv3804c  GCG -GGG  A-G Ag85A   T 72312  WDINTPAFEWYDQSGLSVVM  Rv3804c  No No  Ag85A   T 73578  YDQSGLSVVMPVGGQSSFYS  Rv3804c  No No  Ag85A   T 103416  MQL VDRVRG  Rv3804c  GTT -GTC  No  Ag85A   T 103423  MSRRLVVGA  Rv3804c  No No  Ag85A   T 173920  AMGPTLIGLAMGDAG  Rv3804c  No No  Ag85A   T 173921  AMSGLLDPSQAMGPT  Rv3804c  No No  Ag85A   T 173924  AYNAGGGHNGVFDFP  Rv3804c  No No  Ag85A   T 173925  DSGTHSWEYWG AQLN  Rv3804c  GCG -GGG  A-G Ag85A   T 173926  FEWYDQSGLSVVMPV  Rv3804c  No No Ag85A   T 173927  FLEGFVRTSNIKFQD  Rv3804c  No No  Ag85A   T 173932  FSGWDINTPAFEWYD  Rv3804c  No No  Ag85A   T 173933  FVYAGAMSGLLDPSQ  Rv3804c  No No  Ag85A   T 173934  FYSDWYQPACGKAGC  Rv3804c  No No Ag85A   T 173935  GAQLNAMKPDLQRAL  Rv3804c  GCG -GGG  A-G Ag85A   T 173936  GGQSSFYSDWYQPAC  Rv3804c  No No  Ag85A   T 173937  GKAGCQTYKWETFLT  Rv3804c  No No  Ag85A   T 173938  GKLI ANNTRVWVYCG  Rv3804c  GCC -GGC  A-G Ag85A   T 173941  KEDPAWQRNDPLLNV  Rv3804c  No No  Ag85A,Non-OADS,/arxiv_data1/oa_pdf/41/bd/ijmsv12p0126.PMC4293177.pdf
"1 2    http://www.medsci.org  131  T 173943  KVQFQSGGANSPALY  Rv3804c  No No  Ag85A   T 173944  LLDGLRAQDDFSGWD  Rv3804c  No No Ag85A   T 173948  MGRDIKVQFQSGGAN  Rv3804c  No No Ag85A   T 173950  NNTRVWVYCGNGKPS  Rv3804c  No No  Ag85A   T 173953  PLLNVGKLI ANNTRV  Rv3804c  GCC -GGC  A-G Ag85A   T 174003  QTYKWETFLTSELPG  Rv3804c  No No Ag85A   T 174004  RAQDDFSGWDINTPA  Rv3804c  No No  Ag85A   T 174007  SELPGWLQANRHVKP  Rv3804c  No No Ag85A   T 174010  SPALYLLDGLRAQDD  Rv3804c  No No  Ag85A   T 174014  SWEYWG AQLNAMKPD  Rv3804c  GCG -GGG  A-G Ag85A   T 174016  TGSAVVGLSMAASSA  Rv3804c  No No Ag85A   T 174020  VFDFPDSGTHSWEYW  Rv3804c  No No  Ag85A   T 174022  WLQANRHVKPTGSAV  Rv3804c  No No  Ag85A   T 174023  WQRNDPLLNVGKLI A Rv3804c  GCC -GGC  A-G Ag85A   T 174024  WVYCGNGKPSDLGGN  Rv3804c  No No  Ag85A   T 174025  YHPQQFVYAGAMSGL  Rv3804c  No No Ag85A   T/B 17838  FSRPGLPVEYLQVPSPSMGR  Rv3804c  CCG -TCG   CCG -CCC  P-S  No  Ag85A   T/B 39011  LQVPSPSMGRDIKVQFQSGG  Rv3804c  No No Ag85A   *The CDS of Ag85A, Ag85B and Ag85C of M. Tuberculosis H37Rv strain has been used as the reference sequence.",Non-OADS,/arxiv_data1/oa_pdf/41/bd/ijmsv12p0126.PMC4293177.pdf
1 2    http://www.medsci.org  132    Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/41/bd/ijmsv12p0126.PMC4293177.pdf
"1 2      http://www.medsci.org  133  DISCUSSION   In this study, we chose 1 80 clinical MTBC strains  which were originated from a very large geographical  area and have different spoligotyping patterns  in  China; hence the data provided by them could be representativ e of genetic diversity that might be pr e- sent within China, at least to some extent.",Non-OADS,/arxiv_data1/oa_pdf/41/bd/ijmsv12p0126.PMC4293177.pdf
Genes in M. tuberculosis was assigned functional  categories according to Tubercul ist  (http://tuberculist.epfl.ch/ ).,OADS,/arxiv_data1/oa_pdf/41/bd/ijmsv12p0126.PMC4293177.pdf
1 2    http://www.medsci.org  134  likely to be under purifying selection.,Non-OADS,/arxiv_data1/oa_pdf/41/bd/ijmsv12p0126.PMC4293177.pdf
"1 2      http://www.medsci.org  135  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2015;  12(2):  135-140.  doi: 10.7150/ ijms.10453   Research Paper   Antipsychotics -Associated Serious Adverse Events in  Children : An Analysis of the FAERS Database   Goji Kimura  1, Kaori Kadoyama 1, J.B. Brown 2, Tsutomu Nakamura 3, Ikuya Miki 3, Kohshi Nisiguchi 3, 4,  Toshiyuki Sakaeda 1, 4 , and Yasushi Okuno 2  1.",Non-OADS,/arxiv_data1/oa_pdf/17/a3/ijmsv12p0135.PMC4293178.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/17/a3/ijmsv12p0135.PMC4293178.pdf
1 2    http://www.medsci.org  136  and quality of life more than FGAs [1].,Non-OADS,/arxiv_data1/oa_pdf/17/a3/ijmsv12p0135.PMC4293178.pdf
1 2    http://www.medsci.org  137  analyzed [14-18].,Non-OADS,/arxiv_data1/oa_pdf/17/a3/ijmsv12p0135.PMC4293178.pdf
1 2    http://www.medsci.org  138  Table  2.,Non-OADS,/arxiv_data1/oa_pdf/17/a3/ijmsv12p0135.PMC4293178.pdf
"1 2    http://www.medsci.org  139  ceptor of haloperidol and aripiprazole are higher, and  those of quetiapine and risperidone are lo wer [4, 21].",Non-OADS,/arxiv_data1/oa_pdf/17/a3/ijmsv12p0135.PMC4293178.pdf
1 2    http://www.medsci.org  140  8.,Non-OADS,/arxiv_data1/oa_pdf/17/a3/ijmsv12p0135.PMC4293178.pdf
http://www.pmda.go.jp/ich/e/e11_00_12_15e.pdf   20.,Non-OADS,/arxiv_data1/oa_pdf/17/a3/ijmsv12p0135.PMC4293178.pdf
http://www.pmda.go.jp/ich/e/e11_00_12_15e.pdf,Non-OADS,/arxiv_data1/oa_pdf/17/a3/ijmsv12p0135.PMC4293178.pdf
"1 2      http://www.medsci.org  141  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2015;  12(2):  141-145.  doi: 10.7150/ ijms.10483   Research Paper   Malignant Lymphomas in the Head and Neck Region –  a  Retrospective, Single -Center Study over 41 Years   Christian Walter1, Thomas Ziebart1, Keyvan Sagheb, Roman Kia Rahimi -Nedjat1, Asina Manz1, Georg  Hess2  1.",Non-OADS,/arxiv_data1/oa_pdf/8c/8e/ijmsv12p0141.PMC4293179.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/8c/8e/ijmsv12p0141.PMC4293179.pdf
1 2    http://www.medsci.org  142  50.8% [1].,Non-OADS,/arxiv_data1/oa_pdf/8c/8e/ijmsv12p0141.PMC4293179.pdf
1 2    http://www.medsci.org  143    Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/8c/8e/ijmsv12p0141.PMC4293179.pdf
"1 2    http://www.medsci.org  144  survival was not part  of this analysis, since further  staging and chemo -/ radiotherapeutic treatment was  not performed within the department of oral and  maxillofac ial surgery.",Non-OADS,/arxiv_data1/oa_pdf/8c/8e/ijmsv12p0141.PMC4293179.pdf
1 2    http://www.medsci.org  145  opme nt of a greater stage of lymphoma and a worse  prognosis.,Non-OADS,/arxiv_data1/oa_pdf/8c/8e/ijmsv12p0141.PMC4293179.pdf
"1 2      http://www.medsci.org  146  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2015;  12(2):  146-153.  doi: 10.7150/ ijms.7541   Research Paper   Utility of Kynurenic Acid  for Non-Invasive Detection of  Metastatic Spread to Lymph Nodes in Non -Small Cell  Lung Cancer   Dariusz Sagan1, Tomasz Kocki2, Samir Patel3, Janusz Kocki4   1.",Non-OADS,/arxiv_data1/oa_pdf/08/38/ijmsv12p0146.PMC4293180.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/08/38/ijmsv12p0146.PMC4293180.pdf
"1 2    http://www.medsci.org  147  identified as one of the factors contributing to su p- pression of specific anti -tumor immune response and  to an e scape of malignant cells from immune survei l- lance [1, 2, 3].",Non-OADS,/arxiv_data1/oa_pdf/08/38/ijmsv12p0146.PMC4293180.pdf
"1 2    http://www.medsci.org  148  Venous blood samples for measurements were  collected from peripheral vein in aseptic conditions,  after at least 12 hours of fasting.",Non-OADS,/arxiv_data1/oa_pdf/08/38/ijmsv12p0146.PMC4293180.pdf
1 2    http://www.medsci.org  149  Table 2.,Non-OADS,/arxiv_data1/oa_pdf/08/38/ijmsv12p0146.PMC4293180.pdf
1 2      http://www.medsci.org  150    Fig.,Non-OADS,/arxiv_data1/oa_pdf/08/38/ijmsv12p0146.PMC4293180.pdf
1 2    http://www.medsci.org  151    Fig.,Non-OADS,/arxiv_data1/oa_pdf/08/38/ijmsv12p0146.PMC4293180.pdf
"1 2    http://www.medsci.org  152  ucts of this metabolic route suppress antitumor r e- sponses and induce an immu noregulatory or an  anergic T cell phenotype at a systemic level [3, 8].",Non-OADS,/arxiv_data1/oa_pdf/08/38/ijmsv12p0146.PMC4293180.pdf
1 2    http://www.medsci.org  153  lating KYNA level measurement offers re liable pr e- operative non -invasive discrimination between N0  and N+ patients in NSCLC.,Non-OADS,/arxiv_data1/oa_pdf/08/38/ijmsv12p0146.PMC4293180.pdf
"12       http://www.medsci.org  154  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2015;  12(2):  154-162.  doi: 10.7150/ ijms.9964   Research  Paper   New Adipose  Tissue  Formation  by Human Adipose -  Derived  Stem  Cells  with Hyaluronic  Acid  Gel in  Immuno deficient  Mice  Shu-Hung  Huang1,2,3,4, Yun-Nan  Lin3, Su-Shin  Lee2,3,4, Chee -Yin Chai5, Hsueh -Wei Chang6, Tsai-Ming  Lin3,   Chung -Sheng  Lai2,3,4, Sin-Daw  Lin 2,3,4,  1.",Non-OADS,/arxiv_data1/oa_pdf/3c/0a/ijmsv12p0154.PMC4293181.pdf
This  is an open -access  article  distributed  under  the terms  of the Creative  Commons  License (http://creativecommons.org/  licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/3c/0a/ijmsv12p0154.PMC4293181.pdf
"12     http://www.medsci.org  155  because  it minimizes  the risk of operative  infections,   scarring,  and operative  costs, but also because  mult i- ple defective sites  can be filled  simultaneously.",Non-OADS,/arxiv_data1/oa_pdf/3c/0a/ijmsv12p0154.PMC4293181.pdf
"The most  popular  is  RESTYLANE® (Hyaluronic  acid gel, HA gel,  http://www.restylaneusa.com)  [30], a non- animal,   stabilized  hyaluronic  acid (NASHA)  produced by  fermentation  in equine  streptococci  cultures.",Non-OADS,/arxiv_data1/oa_pdf/3c/0a/ijmsv12p0154.PMC4293181.pdf
12     http://www.medsci.org  156  2.3.,Non-OADS,/arxiv_data1/oa_pdf/3c/0a/ijmsv12p0154.PMC4293181.pdf
"12     http://www.medsci.org  157  incubated  with  HA gel for 1,3,7 days.",Non-OADS,/arxiv_data1/oa_pdf/3c/0a/ijmsv12p0154.PMC4293181.pdf
12     http://www.medsci.org  158    Fig.,Non-OADS,/arxiv_data1/oa_pdf/3c/0a/ijmsv12p0154.PMC4293181.pdf
12     http://www.medsci.org  159    Fig.,Non-OADS,/arxiv_data1/oa_pdf/3c/0a/ijmsv12p0154.PMC4293181.pdf
12     http://www.medsci.org  160  ers to obtain  the appropriate  shapes  and dimensions   of reparative  tissues.,Non-OADS,/arxiv_data1/oa_pdf/3c/0a/ijmsv12p0154.PMC4293181.pdf
12     http://www.medsci.org  161  ising  approach  for developing  long -lasting  soft tissue   filler  that would  enable  the use of HA gel for autol o- gous  hASC  transplant.,Non-OADS,/arxiv_data1/oa_pdf/3c/0a/ijmsv12p0154.PMC4293181.pdf
12     http://www.medsci.org  162  54.,Non-OADS,/arxiv_data1/oa_pdf/3c/0a/ijmsv12p0154.PMC4293181.pdf
"12       http://www.medsci.org  163  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2015;  12(2):  163-176.  doi: 10.7150/ ijms.10826   Research Paper   Identification of Novel Compounds against  an R294K  Substitution of Influenza A (H7N9) Virus Using  Ensemble Based Drug Virtual Screening   Nhut Tran1,2, Thanh Van1,2, Hieu Nguyen 1, Ly Le1,2,  1.",Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
T his is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
"12     http://www.medsci.org  164  most effective ways to reduce the rate of infections  and deaths relating to influenza virus [8], vaccine is  unlikely to be effective in response to newl y emerging  influenza virus due to unavailability of new specific vaccines [9, 10].",Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
12     http://www.medsci.org  165  representative structures with the a id of linkage  method in GROMAC package.,OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
The TCMD library was downloade d from website http://tcm.cmu.edu.tw/.,OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
12     http://www.medsci.org  166  docking simulation using Lamarckian genetic alg o- rithm [56].,Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
"12     http://www.medsci.org  167  Results   Comparison of biding affinity of the crystal  structure of Anh ui and Shanghai virus to  defined inhibitors   The crystal structures of NA in Shanghai and  Anhui virus were selected for docking with Oselt a- mivir, Zanamivir, Peramivir, Laninarmivir and Sialic  acid.",Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
12     http://www.medsci.org  168  residue E120.,Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
12       http://www.medsci.org  169  Virtual screening and bioactivity analysis   Virtual screening helps us to identify potential  inhibitors for a target protein; the top hit identification  is collected with the aid of docking engine through  huge virtual structure libraries on a target protein.,Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
"12     http://www.medsci.org  170    Figure 4: Molecular dynamics simulations of NA in complex with ligands A) 7181, B) 7182, C) 10877, D) 40.",Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
12     http://www.medsci.org  171  Table 3: Binding affinity and molecular properties of top compounds.,Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
12     http://www.medsci.org  172,Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
"12     http://www.medsci.org  173    B/A: Binding affinity; MW: molecular weight; Hb- A: hydrogen bond acceptor, Hb -D hydrogen bond donor; Nrtb: number of rotatable bond",Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
12     http://www.medsci.org  174  Table 4: Free energy and their components (KJ/mol) of the NA in complex with ligands.,OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
12     http://www.medsci.org  175  3.,Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
12     http://www.medsci.org  176  multithreading.,Non-OADS,/arxiv_data1/oa_pdf/c5/be/ijmsv12p0163.PMC4293182.pdf
"12       http://www.medsci.org  177  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2015;  12(2):  177-186.  doi: 10.7150/ ijms.8988   Research Paper   High Producing Tumor Necrosis Factor Alpha Gene  Alleles in Protection against Severe Manifestations of  Dengue   Sing -Sin Sam1, Boon -Teong Teoh1, Karuthan Chinna2, Sazaly AbuBakar1  1.",Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
12     http://www.medsci.org  178  [6-8].,Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
12       http://www.medsci.org  179  Table 1.,Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
"12     http://www.medsci.org  180  dengue patients presented to UMMC, majority of  which were Malay (52.5%), followed by Chinese (17.4%), Indian (17.0%) and other ra ces (12.4%).",Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
12       http://www.medsci.org  181  Table 4.,Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
12     http://www.medsci.org  182  IL-12B genotypes and the distinctive clinic al prese n- tations of DHF/DSS as shown in Table 6.,Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
12     http://www.medsci.org  183   IL12B -3UTR AA/TNF -α -308GG  11.45  0.67-195.8  0.021    IL12B -3UTR AC/TNF -α -308GA+AA  0.08 0.02-0.30 0.002    IL12B -3UTR (AC+CC)/TNF -α -308GA+AA  0.09 0.03-0.32 <0.001    IL12B -3UTR (AC+CC)/IL -10 Non -GCC  0.10 0.01-0.78 0.007    IL12B (pro1+pro2)/TNF -α -308GA+AA  0.08 0.02-0.30 0.002    IL12B (pro1+pro2)/IL -10 Non -GCC  0.20 0.05-0.75 0.014   Increased AST  TNF -α -308GG  2.72 1.18-6.29 0.022    TNF -α -308GA  0.35 0.15-0.81 0.018    TNF -α -308GA+AA  0.37 0.16-0.85 0.022    TNF -α -308GA+AA/IL -10 Non -GCC  0.38 0.15-0.95 0.046    IL12B (pro1/pro2)/TNF -α -308GA+AA  0.27 0.09-0.82 0.026    IL12B -3UTR AC/TNF -α -308GA+AA  0.20 0.07-0.59 0.005   Increased ALT  TNF -α -308GG  2.92 1.34-6.38 0.009    TNF -α -308GA  0.32 0.14-0.70 0.007    TNF -α -308GA+AA  0.34 0.16-0.75 0.009    IL12B (pro1/pro2)  0.58 0.34-0.99 0.048    IL12B (pro1/pro1+pro2/pro2)  1.72 1.01-2.91 0.048    IL12B (pro1/pro2)/TNF -α -308GA/AA  0.29 0.10-0.88 0.032    IL12B -3UTR AC/TNF -α -308GA/AA  0.21 0.07-0.66 0.006   Hepatomegaly  IL12B (pro1/pro1)  2.24 1.24-4.06 0.010    IL12B (pro1/pro1)/TNF -α -308GG  2.08 1.12-3.86 0.026   Abdominal Pain  IL12B (pro1/pro2)/TNF -α -308 GA/AA  0.20 0.04-0.92 0.026    IL12B -3UTR AC/TNF -α -308 GA/AA  0.20 0.04-0.91 0.026   Alanine aminotransferase (ALT); Aspartate aminotransferase (AST); Odds ratio (OR); Confidence intervals (CI).,Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
12     http://www.medsci.org  184  -238A/lymphotoxin- alpha (LTA) -3 haplotype and  DHF with secondary DENV infection [42].,Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
12     http://www.medsci.org  185  possibility of early treatment with TNF -α or anti -IL-10  antibody for the prevention against severe outcome of  dengue.,Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
Revised 28 October 2013.  http://www.cdc.gov/dengue/epidemiology/   5.,Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
12     http://www.medsci.org  186  41.,Non-OADS,/arxiv_data1/oa_pdf/7b/8d/ijmsv12p0177.PMC4293183.pdf
"1 2      http://www.medsci.org  187  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2015;  12(2):  187-200.  doi: 10.7150/ ijms.10083   Review  Nanoparticle -Based Targeted Therapeutics  in  Head -And-Neck Cancer   Ting -Ting Wu, Shui -Hong Zhou   Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 310003,  China     Corresponding author : Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 310003,  China .",Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
This is an open- access article distributed under the terms of the Creative Common s License (http://creativecommons.org/  licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
1 2    http://www.medsci.org  188  Nonspecific distribution is an important factor  contributing to the side effects and poor clinical ou t- comes in conventional treatments.,Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
"1 2    http://www.medsci.org  189  is water insoluble, embed s within the  shell  of p oly- mersomes .",Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
1 2    http://www.medsci.org  190  1.2 Epidermal growth factor receptor (EGFR)  and Stat3   He et al.,OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
1 2    http://www.medsci.org  191  RNAi -based technology has shown great pote n- tial in targeted can cer therapy by suppressing the  expression of genes associated with tumor growth  [75].,Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
1 2    http://www.medsci.org  192  growth.,Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
1 2      http://www.medsci.org  193  Table 1.,Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
"1 2    http://www.medsci.org  194  for drug delivery, having a unique size, shape and  physical properties [120] .",Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
"1 2    http://www.medsci.org  195  current cli nical strategy for radiosensitization is use of  a combination of RT with chemotherapeutics, such as  docetaxel (Dtxl), carboplatin; however, this is associ-ated with unacceptable levels of systemic toxicity [135, 136] .",Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
"1 2      http://www.medsci.org  196  Polymeric nanoparticles have also attracted a  great deal of interest as potential nanocarriers due to  their stability in various environments, the ability to  load hydrophobic moieties, controlled drug release,  inexpensive and convenient manufacture, and bi ode- gradable properties [18, 148] .",Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
1 2    http://www.medsci.org  197  used commonly in pre -clinical RT.,Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
http://seer.cancer.gov/csr/1975_2011/ .,Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
1 2    http://www.medsci.org  198  25.,Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
1 2    http://www.medsci.org  199  84.,Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
1 2    http://www.medsci.org  200  140.,Non-OADS,/arxiv_data1/oa_pdf/cf/3f/ijmsv12p0187.PMC4293184.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f3/10/amep-6-019.PMC4293213.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances in Medical Education and Practice 2015:6 19–26Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  19OriginAl rEsEArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S6992 5leading teams during simulated pediatric  emergencies: a pilot study Ester h coolen1 Jos M Draaisma2 sabien den hamer3 Jan l loeffen2 1Department of Pediatric surgery,   Amalia children’s hospital,   radboud University Medical center,   2Department of Pediatrics, Amalia  children’s hospital, radboud  University Medical center,   3Department of communication  science, radboud University,   nijmegen, the netherlands correspondence: Ester h coolen   Department of Pediatric surgery,  radboud University Medical center,   PO Box  9101, nl-6500 hB nijmegen  (618), the netherlands   Email ester.coolen@radboudumc.n lPurpose:  Leadership has been identified as a key variable for the functioning of teams and as  one of the main reasons for success or failure of team-based work systems.",Non-OADS,/arxiv_data1/oa_pdf/f3/10/amep-6-019.PMC4293213.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/f3/10/amep-6-019.PMC4293213.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f3/10/amep-6-019.PMC4293213.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/29/bb/bctt-7-001.PMC4293214.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpBreast Cancer: Targets and Therapy 2015:7 1–8Breast Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/BCTT .S7273 7Factors associated with contralateral   preventive mastectomy Danny Yakoub1,2 eli avisar1,2,* T ulay Koru-sengul2,3,* Feng Miao2 stacey l Tannenbaum2 Margaret M Byrne1–3 Frederick Moffat1,2 alan livingstone1,2 Dido Franceschi1,2 1Division of surgical Oncology at  Department of surgery, 2sylvester  Comprehensive Cancer Center,   3Department of Public health  sciences, University of Miami – Miller  school of Medicine, Miami, Fl, Usa *These authors contributed equally to  this work Correspondence: eli avisar   Division of surgical Oncology, University  of Miami – Miller school of Medicine,  Jackson Memorial hospital/sylvester  Comprehensive Cancer Center,   1120 nW 14th street, CrB C232,   Miami, Fl 33136, Usa   Tel +1 305 243 4902   Fax +1 305 243 4907   email eavisar@med.miami.ed uIntroduction:  Contralateral prophylactic mastectomy (CPM) is an option for women who wish  to reduce their risk of breast cancer or its local recurrence.",Non-OADS,/arxiv_data1/oa_pdf/29/bb/bctt-7-001.PMC4293214.pdf
"Breast Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/breast-cancer---targets-and-therapy-journa lBreast Cancer: Targets and Therapy is an international, peer-   reviewed open access journal focusing on breast cancer research,  identification of therapeutic targets and the optimal use of preven - tative and integrated treatment interventions to achieve improved  outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/29/bb/bctt-7-001.PMC4293214.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/6e/37/amep-6-027.PMC4293215.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances in Medical Education and Practice 2015:6 27–34Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  27OriginAl rEsEArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S7583 0relationships between the quality of blended  learning experience, self-regulated learning,   and academic achievement of medical students:   a path analysis salah Eldin Kassab1 Ahmad i Al-shafei2 Abdel halim salem3 sameer Otoom4 1Department of Medical Education,   Faculty of Medicine, suez canal  University, ismailia, Egypt;   2Department of Physiology, college  of Medicine, King saud University,   riyadh, Kingdom of saudi Arabia;   3Department of Anatomy, college  of Medicine and Medical sciences,   Arabian gulf University, Manama,   Bahrain; 4royal college of surgeons in  ireland, Medical University of Bahrain  (rcsi Bahrain), Busaiteen, Bahrain correspondence: salah Eldin Kassab   Faculty of Medicine, suez canal  University, ring road, ismailia,   PO Box 41111, Egypt   Fax +20 64 320 8543   Email kassabse@gmail.co mPurpose:  This study examined the relationships between the different aspects of students’  course experience, self-regulated learning, and academic achievement of medical students in  a blended learning curriculum.",Non-OADS,/arxiv_data1/oa_pdf/6e/37/amep-6-027.PMC4293215.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/6e/37/amep-6-027.PMC4293215.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/6e/37/amep-6-027.PMC4293215.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinicoEconomics and Outcomes Research 2015:7 37–51ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  37ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S7418 1assessing the importance of predictors in  unplanned hospital readmissions for chronic  obstructive pulmonary disease Tzy-Chyi Yu1 huanxue Zhou2 Kangho suh1 stephen arcona1 1novartis Pharmaceuticals  Corporation, East hanover,    2KMK Consulting inc.,    Florham Park, n J, Usa Correspondence: Tzy-Chyi Yu   Outcomes Research Methods and  analytics, health Economics and  Outcomes Research, novartis  Pharmaceuticals Corporation,   One health Plaza, East hanover, nJ  07936-1080, Usa   Email amanda.yu@novartis.co mPurpose:  The all-cause readmission rate within 30  days of index admissions for chronic obstruc - tive pulmonary disease (COPD) was approximately 21% in the United States in 2008.",Non-OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
"Available from: http://www.academyhealth.org/files/ publications/ Reducing_Hospital_Readmissions.pd f. Accessed July 29, 2014.",Non-OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
Available from: http://online.wsj.com/news/articles/SB 1000142405274870428150457632516321862912 4.,Non-OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
Available from: http://newsroom.cigna.com/ article_display.cfm?article_id=122 2.,Non-OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
"Available from: http://www.hcup-us.ahrq.gov/ reports/statbriefs/sb172-Conditions-Readmissions-Payer.pd f. Accessed  August 15, 2014.",OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
"Available from: http://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions- Reduction-Program.htm l. Accessed July 29, 2014.",Non-OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
Available  from:  http://www.medpac.gov/documents/reports/Jun08_EntireReport.,OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
"Available from:  http://www.hcup-us.ahrq.gov/reports/statbriefs/sb121.pd f. Accessed  July 29, 2014.",OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
"Available  from: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.js p.  Accessed July 29, 2014.",OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
"Available from: http://www.cms.gov/ Medicare/ Quality- Initiatives-Patient-Assessment-Instruments/Hospital QualityInits/ Measure-Methodology.htm l. Accessed July 29, 2014.",Non-OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
Available from: http://ep.yimg.,Non-OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
Available from: http://fmwww.bc.edu/repec/bocode/d/domin.,Non-OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/40/99/ceor-7-037.PMC4293216.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e5/e1/aabc-8-001.PMC4293217.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances and Applications in Bioinformatics and Chemistry 2015:8 1–10Advances and Applications in Bioinformatics and Chemistry Dove press submit your manuscript | www.dovepress.co m Dove press  1OriginAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AABC.S7525 0Identification of highly conserved regions   in L-segment of Crimean–Congo hemorrhagic  fever virus and immunoinformatic prediction  about potential novel vaccine Arafat rahman Oany1 shah Adil ishtiyaq Ahmad1 Mohammad Uzzal hossain1 Tahmina Pervin Jyoti2 1Department of Biotechnology and  Genetic Engineering, Faculty of Life  Science, Mawlana Bhashani Science  and T echnology University, Santosh,   Tangail, Bangladesh; 2Biotechnology  and Genetic Engineering Discipline,   Life Science School, Khulna University,   Khulna, Bangladesh Correspondence: Arafat rahman Oany   Department of Biotechnology and  Genetic Engineering, Faculty of Life  Science, Mawlana Bhashani Science   and Technology University, Santosh,  Tangail 1902, Bangladesh   Tel +880 15 5881 9130   email arafatr@outlook.co mAbstract:  Crimean–Congo hemorrhagic fever (CCHF) is a tick-borne zoonotic viral disease with  a disease fatality rate between 15% and 70%.",Non-OADS,/arxiv_data1/oa_pdf/e5/e1/aabc-8-001.PMC4293217.pdf
"Advances and Applications in Bioinformatics and Chemistry Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com /advances-and-applications-in-bioinformatics-and-chemistry-journalAdvances and Applications in Bioinformatics and Chemistry is an inter - national, peer-reviewed open-access journal that publishes articles in the  following fields: Computational biomodeling; Bioinformatics; Compu - tational genomics; Molecular modeling; Protein structure modeling and  structural genomics; Systems Biology; Computational Biochemistry; Computational Biophysics; Chemoinformatics and Drug Design; In silico  ADME/Tox prediction.",Non-OADS,/arxiv_data1/oa_pdf/e5/e1/aabc-8-001.PMC4293217.pdf
Visit http://www.dovepress.com/testimonials.ph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e5/e1/aabc-8-001.PMC4293217.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/08/a2/ceor-7-065.PMC4293218.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinicoEconomics and Outcomes Research 2015:7 65–72ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  65ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S7626 9End-stage renal disease in autosomal dominant   polycystic kidney disease: a comparison   of dialysis-related utilization and costs   with other chronic kidney diseases steven M Brunelli1 Christopher M Blanchette2,3 ami J Claxton1 Debosree Roy2 sandro Rossetti3 Benjamin gutierrez3 1DaVita Clinical Research,   Minneapolis, M n, Usa;  2University of  north Carolina, Charlotte, n C, Usa;   3Otsuka america Pharmaceutical, inc.,   Princeton, nJ, Usa Correspondence: steven M Brunelli   DaVita Clinical Research,    825 south  8th street, suite  300,  Minneapolis, Mn, Usa   Tel +1 781 292 0901  Fax +1 877 683 2671  Email steven.brunelli@davita.co mBackground:  Autosomal dominant polycystic kidney disease (ADPKD) is the leading  inheri table  cause of end-stage renal disease (ESRD) and one of the leading causes of ESRD  overall.",Non-OADS,/arxiv_data1/oa_pdf/08/a2/ceor-7-065.PMC4293218.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/08/a2/ceor-7-065.PMC4293218.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/08/a2/ceor-7-065.PMC4293218.pdf
Available  from: http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid =29.,OADS,/arxiv_data1/oa_pdf/08/a2/ceor-7-065.PMC4293218.pdf
Available from: http://www.usrds.,Non-OADS,/arxiv_data1/oa_pdf/08/a2/ceor-7-065.PMC4293218.pdf
"Available from:  http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics- Trends-and-Reports/ReportsTrustFunds/Downloads/TR2013.pd f.  Accessed March  2, 2014.",OADS,/arxiv_data1/oa_pdf/08/a2/ceor-7-065.PMC4293218.pdf
"Available from: https://www.cms.gov/Regulations-and- Guidance/Guidance/Manuals/downloads/msp105c01.pd f. Accessed  May 16, 2014.",Non-OADS,/arxiv_data1/oa_pdf/08/a2/ceor-7-065.PMC4293218.pdf
"Available from: http://www.bls.gov/cpi/cpifact4.ht m.  Accessed May  28, 2014.",Non-OADS,/arxiv_data1/oa_pdf/08/a2/ceor-7-065.PMC4293218.pdf
"Available from:  http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics- Trends-and-Reports/CMS-Fast-Facts/index.htm l. Accessed May  19,  2014.",OADS,/arxiv_data1/oa_pdf/08/a2/ceor-7-065.PMC4293218.pdf
Available from: http://www.usrds.,Non-OADS,/arxiv_data1/oa_pdf/08/a2/ceor-7-065.PMC4293218.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8d/9c/dddt-9-313.PMC4293289.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2015:9 313–320Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  313Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S7770 2solid lipid nanoparticles loaded with iron  to overcome barriers for treatment of iron  deficiency anemia Khaled Mohamed hosny1,2 Zainy Mohammed Banjar3 amani h hariri4 ali habiballah hassan5 1Department of Pharmaceutics  and industrial Pharmacy, Faculty  of Pharmacy, King abdulaziz  University, Jeddah, saudi arabia;   2Department of Pharmaceutics  and industrial Pharmacy, Faculty  of Pharmacy, Beni suef University,   Beni suef, egypt; 3Department  of clinical Biochemistry, Faculty  of Medicine, King abdulaziz University,   Jeddah, saudi arabia; 4consultant  Obstetrics and gynecology, hera  general hospital, Makkah, saudi  arabia; 5Department of Orthodontics,   Faculty of Dentistry, King abdulaziz  University, Jeddah, saudi arabiaAbstract:  According to the World Health Organization, 46% of the world’s children suffer  from anemia, which is usually treated with iron supplements such as ferrous sulfate.",Non-OADS,/arxiv_data1/oa_pdf/8d/9c/dddt-9-313.PMC4293289.pdf
"The first one is that all are known to affect the gastrointestinal tract correspondence: Khaled Mohamed  hosny PO Box 80260, Department of  Pharmaceutics and industrial pharmacy,  Faculty of Pharmacy, King abdulaziz  University, Jeddah 21589, saudi arabia Tel +966 5 9272 2634 email kmhomar@kau.edu.s a Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Hosny et al Running head recto: Fe-SLNs for treatment of iron deficiency anemia DOI: http://dx.doi.org/10.2147/DDDT.S77702",Non-OADS,/arxiv_data1/oa_pdf/8d/9c/dddt-9-313.PMC4293289.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/8d/9c/dddt-9-313.PMC4293289.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/8d/9c/dddt-9-313.PMC4293289.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8d/6e/cia-10-183.PMC4293290.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2015:10 183–191Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  183OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S6877 9Comparison of strength training, aerobic training,  and additional physical therapy as supplementary  treatments for Parkinson’s disease: pilot study Alessandro Carvalho1,2 Dannyel Barbirato1 narahyana Araujo1 Jose Vicente Martins3 Jose luiz sá Cavalcanti3 T ony Meireles santos4 evandro s Coutinho5 Jerson laks1,2 Andrea C Deslandes1 1Centro de Doença de Alzheimer  e Outros Transtornos da Velhice,   Instituto de Psiquiatria, Universidade  Federal do rio de Janeiro, rio de  Janeiro, Brazil; 2Centro de estudo   e Pesquisa do envelhecimento,   Instituto Vital Brazil, rio de Janeiro,   Brazil; 3Instituto de neurologia  Deolindo Couto, Universidade Federal  do rio de Janeiro, rio de Janeiro,   Brazil; 4Departamento de educação  Física da Universidade Federal de  Pernambuco, Pernambuco, Brazil;   5Departamento de epidemiologia   e Métodos Quantitativos em saúde.",Non-OADS,/arxiv_data1/oa_pdf/8d/6e/cia-10-183.PMC4293290.pdf
"The progression of PD leads to an increasing inability to perform daily  activities, loss of independence, and a decreased quality of life, and it generates socio - economic and occupational impairments.3 Because of its complex and multifactorial  etiology, which combines, in many cases, genetic, environmental, and lifestyle fac - tors, PD is usually treated with pharmacological and surgical approaches, but these  treatments are not always completely effective.4 The motor impairment in PD patients caused by bradykinesia, rigidity, tremor,  and postural instability accelerates the decline in functional capacity, especially when  associated with decreased activity and with a sedentary lifestyle.5,6 Physical rehabilita - tion may be important for the maintenance and improvement of mobility, posture, and  balance in PD patients.7 Different modalities of nonpharmacological treatment such as Correspondence: Alessandro Carvalho rua Ministro gabriel de Piza 337/04/401  Pechincha, 22770-360 rio de Janeiro,  Brazil email aocarvalho@gmail.co m Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Carvalho et al Running head recto: Supplementary treatments for Parkinson’s disease DOI: http://dx.doi.org/10.2147/CIA.S68779",Non-OADS,/arxiv_data1/oa_pdf/8d/6e/cia-10-183.PMC4293290.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/8d/6e/cia-10-183.PMC4293290.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/8d/6e/cia-10-183.PMC4293290.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/03/85/copd-10-057.PMC4293291.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of COPD 2015:10 57–68International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  57OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S7265 0Efficacy and safety of once-daily glycopyrronium   in predominantly Chinese patients with   moderate-to-severe chronic obstructive   pulmonary disease: the GLOW7 study Chen Wang1 Tieying Sun1 Yijiang Huang2 Michael Humphries3 Lingyan Bai3 Lilly Li3 Qian Wang3 Pearl Kho4 Roz Firth4 Peter D’andrea5 1Beijing Hospital, Dongcheng District,   Beijing, People’s Republic of China;   2Hainan Provincial People’s Hospital,   Xiuying District, Haikou, People’s  Republic of China;  3Beijing Novartis  Pharma Co Ltd, Zhangjiang Hi-T ech  Park, Shanghai, People’s Republic of  China;  4Novartis Horsham Research  Centre, Horsham, West Sussex,   UK; 5Novartis Pharmaceuticals  Corporation, East Hanover, NJ, USA Correspondence:  Chen Wang   China-Japan Friendship Hospital, 2  Yinghua  Dongjie, Chaoyang District, Beijing,  100029, People’s Republic of China   Tel +86 139 0112 2992  email cyh-birm@263.ne tBackground:  Glycopyrronium is a once-daily (od) long-acting muscarinic antagonist for the  maintenance treatment of chronic obstructive pulmonary disease (COPD).",Non-OADS,/arxiv_data1/oa_pdf/03/85/copd-10-057.PMC4293291.pdf
Available from: http://www.goldcopd.org /.,Non-OADS,/arxiv_data1/oa_pdf/03/85/copd-10-057.PMC4293291.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-copd-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/03/85/copd-10-057.PMC4293291.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/03/85/copd-10-057.PMC4293291.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e8/b2/copd-10-095.PMC4293292.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of COPD 2015:10 95–109International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  95RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/COPD.S5447 3Managing comorbidities in COPD Georgios Hillas1 Fotis Perlikos1 Ioanna Tsiligianni2,3 Nikolaos Tzanakis2 1Department of Critical Care and  Pulmonary Services, University of  Athens Medical School, evangelismos  Hospital, Athens,  2Department of  Thoracic Medicine, University  Hospital of Heraklion, Medical School,   University of Crete, Crete, Greece;   3Department of General Practice,   University Medical Centre   of Groningen, Groningen,    The NetherlandsAbstract:  Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity  and mortality worldwide.",Non-OADS,/arxiv_data1/oa_pdf/e8/b2/copd-10-095.PMC4293292.pdf
"Available from: http://www.ginasthma.org/local/uploads/files/ AsthmaCOPDOverlap.pd f. Accessed September  14, 2014.",Non-OADS,/arxiv_data1/oa_pdf/e8/b2/copd-10-095.PMC4293292.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-copd-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/e8/b2/copd-10-095.PMC4293292.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e8/b2/copd-10-095.PMC4293292.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/91/ad/cia-10-147.PMC4293293.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2015:10 147–155Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  147OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S7444 5New-generation filler based on cross-linked  carboxymethylcellulose: study of 350 patients  with 3-year follow-up Mauro leonardis1 Andrea Palange2 1Department of Plastic Surgery,   Salvator Mundi International Hospital,   2Department of Aesthetic Medicine,   Fisiobios Clinic, Rome, ItalyPurpose:  In recent years there has been a growing interest in nonsurgical procedures for facial  rejuvenation.",Non-OADS,/arxiv_data1/oa_pdf/91/ad/cia-10-147.PMC4293293.pdf
"Consequently, alternative and/or  complementary products have been made available on the market today to potentially Correspondence: Mauro leonardis Salvator Mundi International Hospital,  Viale delle Mura Gianicolensi,   67 – 00100 Roma, Italy Tel +39 06 588961 Fax +39 06 6532859 email mleonardis@libero.i tJournal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Leonardis and Palange Running head recto: Clinical study of cross-linked carboxymethylcellulose filler DOI: http://dx.doi.org/10.2147/CIA.S74445",Non-OADS,/arxiv_data1/oa_pdf/91/ad/cia-10-147.PMC4293293.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/91/ad/cia-10-147.PMC4293293.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/91/ad/cia-10-147.PMC4293293.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/54/a9/dddt-9-419.PMC4293294.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2015:9 419–423Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  419LeTTeropen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S7788 1Letter to the editor: naltrexone sustained- release/bupropion sustained-release for the  management of obesity: review of the data to date Anna M Buehler Hospital Alemao Oswaldo Cruz,   Institute of Health education and  Sciences, Sao Paulo, BrazilDear editor I read with great interest the systematic review by Caixàs et al1 on the effect of  naltrexone sustained-release/bupropion sustained-release (NB) for the management  of obesity.",Non-OADS,/arxiv_data1/oa_pdf/54/a9/dddt-9-419.PMC4293294.pdf
"The treatment protocol and the coprimary outcome were the same as those used  by the other three Phase III trials described in detail by Caixàs et al.1 When we ana - lyzed the results in the diabetic population, diabetic patients taking NB had a greater  weight reduction ( -5.0% versus -1.8%; P0.001) and a higher proportion of patients  achieving 5% weight loss (44.5% versus 18.9%; P0.001).4Correspondence: Anna M Buehler Hospital Alemao Oswaldo Cruz, Institute  of Health education and Sciences, rua  João Juliao, 245, First floor, 01323-903,  Sao Paulo, SP, Brazil Tel +55 11 354 905 82 email abuehler@haoc.com.b r Journal name: Drug Design, Development and Therapy Article Designation: Letter Y ear: 2015 Volume: 9 Running head verso: Buehler Running head recto: Naltrexone sustained-release/bupropion sustained-release DOI: http://dx.doi.org/10.2147/DDDT.S77881",Non-OADS,/arxiv_data1/oa_pdf/54/a9/dddt-9-419.PMC4293294.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/54/a9/dddt-9-419.PMC4293294.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/54/a9/dddt-9-419.PMC4293294.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/16/4b/copd-10-111.PMC4293295.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of COPD 2015:10 111–123International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  111RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/COPD.S6775 8Profile of inhaled glycopyrronium bromide   as monotherapy and in fixed-dose combination  with indacaterol maleate for the treatment   of COPD Anoop Prakash1 K Suresh Babu2 Jaymin B Morjaria1,3 1Department of Respiratory Medicine,   Castle Hill Hospital, Cottingham,   2Department of Respiratory Medicine,   Queen Alexandra Hospital, Cosham,   Portsmouth,  3Department of  Academic Respiratory Medicine,    Hull Y ork Medical School, University  of Hull, Castle Hill Hospital,   Cottingham, UK Correspondence: Anoop Prakash   Department of Respiratory Medicine,  Castle Hill Hospital, Castle Road,  Cottingham, HU16  5JQ, UK   Tel +44 14 8262 6792  Fax +44 14 8262 3255  email anoop.prakash@hey.nhs.u kAbstract:  Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and  mortality.",Non-OADS,/arxiv_data1/oa_pdf/16/4b/copd-10-111.PMC4293295.pdf
"Available from: http://bidocs.boehringer-ingelheim.com/ BIWebAccess /ViewServlet .ser?docBase =renetnt&folderPath =/ Prescribing +Information/PIs/Combivent +Respimat/CMVTRSPT.pd f.  Accessed January  31, 2014.",Non-OADS,/arxiv_data1/oa_pdf/16/4b/copd-10-111.PMC4293295.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-copd-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/16/4b/copd-10-111.PMC4293295.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/16/4b/copd-10-111.PMC4293295.pdf
Available from: http://www.ema.europa.,Non-OADS,/arxiv_data1/oa_pdf/16/4b/copd-10-111.PMC4293295.pdf
Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/002430/WC500133769.,Non-OADS,/arxiv_data1/oa_pdf/16/4b/copd-10-111.PMC4293295.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/6f/94/copd-10-069.PMC4293296.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of COPD 2015:10 69–77International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  69OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S7352 1Questionnaire on switching from the tiotropium  handihaler to the respimat inhaler in patients  with chronic obstructive pulmonary disease:  changes in handling and preferences immediately  and several years after the switch soichiro hanada1 shota Wada1 Takeshi Ohno1 hirochiyo sawaguchi1 Masato Muraki1 Yuji T ohda2 1Department of respiratory Medicine  and allergology, nara hospital, Kinki  University Faculty of Medicine, Ikoma,   2Department of respiratory Medicine  and allergology, Kinki University  Faculty of Medicine, Osakasayama,   JapanBackground:  Tiotropium (Spiriva) is an inhaled muscarinic antagonist for patients with chronic  obstructive pulmonary disease (COPD), and is available in two forms: the HandiHaler and the  Respimat inhaler.",Non-OADS,/arxiv_data1/oa_pdf/6f/94/copd-10-069.PMC4293296.pdf
"Long-acting muscarinic antagonists are very important in the management of  chronic obstructive pulmonary disease (COPD).3 Tiotropium (Spiriva®) is a once-daily Correspondence: Masato Muraki Department of respiratory Medicine  and allergology, nara hospital, Kinki  University Faculty of Medicine, 1248-1  Otoda-cho, Ikoma, nara 630-0298, Japan Tel +81 743 770 880 Fax +81 743 770 890 email muraki@nara.med.kindai.ac.jpJournal name: International Journal of COPD Article Designation: original research Y ear: 2015 Volume: 10 Running head verso: Hanada et al Running head recto: Switching from HandiHaler to Respimat inhaler in COPD DOI: http://dx.doi.org/10.2147/COPD.S73521",Non-OADS,/arxiv_data1/oa_pdf/6f/94/copd-10-069.PMC4293296.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/6f/94/copd-10-069.PMC4293296.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/94/copd-10-069.PMC4293296.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c4/ce/copd-10-079.PMC4293297.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of COPD 2015:10 79–94International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  79OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S7309 2symptoms and impact of COPD assessed by an   electronic diary in patients with moderate-to-   severe COPD: psychometric results  from the shIne study Károly Kulich1 Dorothy l Keininger1 Brian Tiplady2 Donald Banerji3 1novartis Pharma ag, Basel,   switzerland; 2eresearch T echnologies  ltd, Peterborough, UK; 3novartis  Pharmaceuticals Corporation, east  hanover, nJ, UsaBackground:  Symptoms, particularly dyspnea, and activity limitation, have an impact on the  health status and the ability to function normally in patients with chronic obstructive pulmonary  disease (COPD).",Non-OADS,/arxiv_data1/oa_pdf/c4/ce/copd-10-079.PMC4293297.pdf
"Keywords:  QVA149, psychometric assessment, dyspnea, health status, patient-reported outcomes Introduction Symptoms, particularly dyspnea and activity limitation, have a profound impact on  the activities of daily life and health status in patients with COPD.1 The prevention  and control of symptoms are important elements in the management of COPD as the  goals have shifted towards optimizing symptom control and reducing future risks such  as exacerbations, hospital admissions, and deaths.1 These symptoms are frequently collected as a patient-reported outcome (PRO)  from either a questionnaire, diary, or clinical questionnaire.2,3 PROs are recognized Correspondence: Donald Banerji novartis Pharmaceuticals Corporation,  1 health Plaza, east hanover,  nJ 07936, Usa Tel +1 862 778 9521 email donald.banerji@novartis.co m Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Kulich et al Running head recto: Electronic diary for assessing symptoms of COPD DOI: http://dx.doi.org/10.2147/COPD.S73092",Non-OADS,/arxiv_data1/oa_pdf/c4/ce/copd-10-079.PMC4293297.pdf
Available from: http://www.goldcopd.org/guidelines-global-strategy- for-diagnosis-management.html.,Non-OADS,/arxiv_data1/oa_pdf/c4/ce/copd-10-079.PMC4293297.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/c4/ce/copd-10-079.PMC4293297.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c4/ce/copd-10-079.PMC4293297.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/4f/fe/cia-10-157.PMC4293298.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2015:10 157–174Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  157RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S5067 0Optimal management of breast cancer  in the elderly patient: current perspectives Olivia Le Saux1 Bertrand Ripamonti2 Amandine Bruyas3,4 Olivier Bonin4 Gilles Freyer1,4 Marc Bonnefoy4,5 Claire Falandry4,5 1Medical Oncology Unit, Lyon Sud  University Hospital, Hospices Civils  de Lyon, Pierre-Bénite, 2Gynaecology- Obstetrics Department, University  Hospital, Saint-etienne, 3Croix  Rousse University Hospital, Hospices  Civils de Lyon, Pierre-Bénite, 4Lyon  University, Lyon, 5Geriatric Unit, Lyon  Sud University Hospital, Hospices  Civils de Lyon, Pierre-Bénite, FranceAbstract:  Breast cancer (BC) is the most common female malignancy in the world and almost  one third of cases occur after 70 years of age.",Non-OADS,/arxiv_data1/oa_pdf/4f/fe/cia-10-157.PMC4293298.pdf
"In a  single-institution analysis by Sigh et al in a subgroup of elderly patients ( 70 years  of age) with lymph node-negative disease, BC appeared to be more aggressive, with a  greater risk of developing distant metastases compared with younger patients.13 Simi - larly, in another single-institution analysis by Wildiers et al smaller tumors seemed to  be associated with increased axillary lymph node involvement.14 The hypothesis made  by the authors was that small BCs in older patients have different behavior because  of decreased immune defense mechanisms related to aging.Correspondence: Claire Falandry Geriatrics unit, Centre Hospitalier Lyon  Sud, 69495 Pierre-Benite cedex, France Tel +33 4 78 86 15 80 Fax +33 4 78 86 57 27 email claire.falandry@chu-lyon.f r Journal name: Clinical Interventions in Aging Article Designation: Review Y ear: 2015 Volume: 10 Running head verso: Le Saux et al Running head recto: Breast cancer in the elderly patient DOI: http://dx.doi.org/10.2147/CIA.S50670",Non-OADS,/arxiv_data1/oa_pdf/4f/fe/cia-10-157.PMC4293298.pdf
Available from: http://clinicaltrials.gov/show/ NCT01564056.,Non-OADS,/arxiv_data1/oa_pdf/4f/fe/cia-10-157.PMC4293298.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/4f/fe/cia-10-157.PMC4293298.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/4f/fe/cia-10-157.PMC4293298.pdf
Avail - able from: http://clinicaltrials.gov/show/NCT00193011.,Non-OADS,/arxiv_data1/oa_pdf/4f/fe/cia-10-157.PMC4293298.pdf
Avail - able from: http://clinicaltrials.gov/show/NCT01104935.,Non-OADS,/arxiv_data1/oa_pdf/4f/fe/cia-10-157.PMC4293298.pdf
Available from:  http://clinicaltrials.gov/show/NCT01597414.,Non-OADS,/arxiv_data1/oa_pdf/4f/fe/cia-10-157.PMC4293298.pdf
Available from: http://clinicaltrials.gov/show/NCT00892814.,Non-OADS,/arxiv_data1/oa_pdf/4f/fe/cia-10-157.PMC4293298.pdf
Available from: http://clinicaltrials.gov/ show/NCT01803958.,Non-OADS,/arxiv_data1/oa_pdf/4f/fe/cia-10-157.PMC4293298.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d2/a0/ceor-7-073.PMC4293299.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinicoEconomics and Outcomes Research 2015:7 73–83ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  73ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S7526 3annual biologic treatment cost for new and  existing patients with moderate to severe plaque   psoriasis in greece Vassilis Fragoulakis1 Efklidis Raptis2 Elli Vitsou2 nikolaos Maniadakis1 1health services Organization and  Management, national school of  Public health, 2Pfizer hellas, athens,   greece Correspondence: V Fragoulakis   health services Organization and  Management, national school of Public  health, 196 alexandras avenue,   athens 11521, greece   Tel +30 210 646 7097   Fax +30 213 201 0194   Email vfragoulakis@esdy.edu.g rAim:  The aim of the present study was to estimate the annual per-patient cost of treatment with  adalimumab, etanercept, infliximab, and ustekinumab by response status for new and existing  patients with moderate to severe psoriasis in Greece.",Non-OADS,/arxiv_data1/oa_pdf/d2/a0/ceor-7-073.PMC4293299.pdf
"Available at: http://www.who.int/uv/faq/uvhealtfac/en/ index1.htm l. Accessed November 13, 2014.",OADS,/arxiv_data1/oa_pdf/d2/a0/ceor-7-073.PMC4293299.pdf
Available  at: http://www.ifpa-pso.org/getfile.ashx?cid =279366&cc =3&refid=18.,Non-OADS,/arxiv_data1/oa_pdf/d2/a0/ceor-7-073.PMC4293299.pdf
Available at: http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/d2/a0/ceor-7-073.PMC4293299.pdf
Available at: http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/d2/a0/ceor-7-073.PMC4293299.pdf
Available at:  http://www.moh.gov.gr/articles/times-farmakwn/deltia-timwn/1860- diorthwtiko-deltio-timwn-30-08-201 3.,Non-OADS,/arxiv_data1/oa_pdf/d2/a0/ceor-7-073.PMC4293299.pdf
Available at: https://www.nice.,Non-OADS,/arxiv_data1/oa_pdf/d2/a0/ceor-7-073.PMC4293299.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/d2/a0/ceor-7-073.PMC4293299.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d2/a0/ceor-7-073.PMC4293299.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/98/55/cia-10-175.PMC4293300.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2015:10 175–182Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  175OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S6785 4Ya-ling lee1,2 hsiao-Yun hu2,3 Pesus Chou2 Dachen Chu2,4,5 1Department of Dentistry, Taipei  City hospital, 2Institute of Public  health and Community Medicine  research Center, national Yang- Ming University, 3Department  of education and research, Taipei  City hospital, 4Department of health  Care Management, national  Taipei University of nursing and  health sciences, 5Department  of neurosurgery, Taipei City hospital,   Taipei, Taiwan Correspondence: Dachen Chu Taipei City hospital Zhongxing Branch,  no 145, Zheng Zhou road, Datong,  Taipei, Taiwan Tel +886 2 2552 3234 ext 1000 Fax +886 2 2552 1608 email DAD57@tpech.gov.t w Purpose:  To investigate the association between periodontal disease (PD) and acute  myocardial  infarction (AMI), and evaluate the effect of dental prophylaxis on the incidence rate (IR)  of AMI.",Non-OADS,/arxiv_data1/oa_pdf/98/55/cia-10-175.PMC4293300.pdf
"The initial presentation is  reversible gingivitis, which can be treated after biofilm removal.10–12 As PD progresses,  destruction of the periodontal connective tissue and alveolar bone ultimately lead to  tooth loss.13 Increased tooth brushing frequency has been found to reduce the serum  concentrations of C-reactive protein and fibrinogen, suggesting that the improvement  of periodontal conditions can reduce a patient’s systemic inflammatory status.14Dental prophylaxis decreases the risk  of acute myocardial infarction: a nationwide  population-based study in TaiwanJournal name: Clinical Interventions in Aging Journal Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Lee et al Running head recto: Dental prophylaxis reduces AMI risk DOI: http://dx.doi.org/10.2147/CIA.S67854",Non-OADS,/arxiv_data1/oa_pdf/98/55/cia-10-175.PMC4293300.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lDove pres s Clinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/98/55/cia-10-175.PMC4293300.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/98/55/cia-10-175.PMC4293300.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/47/0a/ijn-10-335.PMC4293364.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 335–345International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  335OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S7480 5Passive tumor targeting and imaging by using  mercaptosuccinic acid-coated near-infrared  quantum dots guimiao lin1 Xiaomei Wang1 Feng Yin2 Ken-Tye Y ong2 1The engineering lab of synthetic  Biology and research Institute  of Uropoiesis and reproduction,   school of Medicine, shenzhen  University, shenzhen, People’s  republic of china; 2school  of electrical and electronic  engineering, Nanyang Technological  University, singapore, singaporeAbstract:  In this paper, we demonstrate the preparation of monodispersed quantum dots (QDs)  as near-infrared (NIR) optical probes for in vivo pancreatic cancer targeting and imaging.",Non-OADS,/arxiv_data1/oa_pdf/47/0a/ijn-10-335.PMC4293364.pdf
"Keywords:  QDs, near-infrared, mercaptosuccinic acid, pancreatic cancer, tumor targeting Introduction Semiconductor nanocrystals, also known as quantum dots (QDs), are highly  luminescent nanoparticles with sizes ranging from 2 nm to 15 nm.1,2 QDs are composed  of hundreds to thousands of atoms that commonly belong to groups II–VI (eg, CdSe  and CdTe), groups III–V (eg, InP), groups IV–VI (eg, PbS and PbSe), or group VI  (eg, Si).3,4 QDs have several unique optical properties far superior to those of the organic  chromophores.5–8 For example, QDs have high molar extinction coefficients, broad  absorption bands, high quantum efficiency ( 50%), narrow emission spectra with  full width at half-maximum 50 nm, high resistance to photobleaching, and higher  excited state lifetimes.9,10 In addition to these features, it was demonstrated that QDs  are at least 15 times brighter than organic dyes using the same excitation conditions.11  These unique optical properties can be utilized to enhance the signal-to-background  ratio during microscopy imaging.12–14 Moreover, the QDs emission can be systemati - cally tuned to emit from the visible to near-infrared (NIR) spectral region by simply  manipulating their size, shape, composition, and structure.15–18 This optical tunability of  QDs facilitates their use in multiplexed and real-time imaging.19,20 It was also reported  that QDs can be used as a single probe for optical tracking studies in vitro, over a  few hours using either laser scanning confocal microscopy or total internal reflection  microscopy.21 In addition, QDs are potential candidates for two-photon imaging because  these particles have a relatively large absorption cross section when compared to some  organic dyes.22 Besides the unimodal imaging capability of functional QDs, other novel correspondence: Ken-Tye Yong school of electrical and electronic  engineering, Nanyang Technological  University, Block s2.2, level B2, Nanyang  link, singapore 639798, singapore email ktyong@ntu.edu.s g Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Lin et al Running head recto: Targeting and imaging of quantum dots in tumor DOI: http://dx.doi.org/10.2147/IJN.S74805",Non-OADS,/arxiv_data1/oa_pdf/47/0a/ijn-10-335.PMC4293364.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/47/0a/ijn-10-335.PMC4293364.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/47/0a/ijn-10-335.PMC4293364.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/cd/57/ijn-10-305.PMC4293365.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 305–320International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  305OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S7397 1Preparation, in vitro and in vivo evaluation of  polymeric nanoparticles based on hyaluronic acid- poly(butyl cyanoacrylate) and D-alpha-tocopheryl  polyethylene glycol 1000 succinate for tumor- targeted delivery of morin hydrate sarra abbad1,2 cheng Wang1 ayman Yahia Waddad1 huixia lv1 Jianping Zhou1 1Department of Pharmaceutics,   china Pharmaceutical University,   Nanjing, People’s republic of china;   2Department of Pharmacy, abou Bekr  Belkaid University, Tlemcen, algeriaAbstract:  Herein, we describe the preparation of a targeted cellular delivery system for morin  hydrate (MH), based on a low-molecular-weight hyaluronic acid-poly(butyl cyanoacrylate)  (HA-PBCA) block copolymer.",Non-OADS,/arxiv_data1/oa_pdf/cd/57/ijn-10-305.PMC4293365.pdf
"Keywords:  anti-tumor effect, hyaluronic acid, TPGS, morin hydrate, nanoparticles Introduction Morin hydrate (3,5,7,2 ′,4′-pentahydroxyflavone) (MH), a naturally occurring bioflavonoid  identified in a number of fruits, vegetables, and herbs of the Moraceae family, is  emerging as a potent therapeutic drug for different maladies, including cardiovascular  disease, diabetes mellitus, neurodegenerative disease, cancer, and inflammation.1,2  This flavonoid has been reported to induce apoptosis in a hepatocellular carcinoma  model and human cultured prostate cancer cells.3,4 Additionally, it inhibits the growth  of HL-60 cells and breast cancer-resistance protein (ABCG2)-mediated transport.5,6  correspondence: huixia lv/Jianping Zhou Department of Pharmaceutics,  china Pharmaceutical University,  24 Tongjiaxiang, Nanjing 210009,  People’s republic of china Tel +86 25 8327 1272 Fax +86 25 8330 1606 email lvhuixia@163.co m/ jianpingzhoucpu@yahoo.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Abbad et al Running head recto: Polymeric nanoparticles based on HA-PBCA and TPGS DOI: http://dx.doi.org/10.2147/IJN.S73971",Non-OADS,/arxiv_data1/oa_pdf/cd/57/ijn-10-305.PMC4293365.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/cd/57/ijn-10-305.PMC4293365.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/cd/57/ijn-10-305.PMC4293365.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/56/5f/ijn-10-347.PMC4293366.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 347–355International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  347OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S7124 5Treating cutaneous squamous cell carcinoma   using 5-aminolevulinic acid polylactic-co-glycolic  acid nanoparticle-mediated photodynamic therapy  in a mouse model Xiaojie Wang1,2,* lei shi2,* Qingfeng T u2 hongwei Wang3 haiyan Zhang2 Peiru Wang2 linglin Zhang2 Zheng huang4 Feng Zhao5 hansen luan5 Xiuli Wang2 1shanghai skin Diseases clinical  college of anhui Medical University,   2shanghai skin Disease hospital,   3huadong hospital, Fudan University,   shanghai, 4MOe Key laboratory  of Opto electronic science and  Technology for Medicine, Fujian  Normal University, Fuzhou, 5National  Pharmaceutical engineering research  center, china state Institute of  Pharmaceutical Industry, shanghai,   People’s republic of china *These authors contributed equally  to this studyBackground:  Squamous cell carcinoma (SCC) is a common skin cancer, and its treatment  is still difficult.",Non-OADS,/arxiv_data1/oa_pdf/56/5f/ijn-10-347.PMC4293366.pdf
"It might  be particularly suitable for large and multifocal lesions located on the face and external  genital area.2 Although ALA PDT shows some promise for the treatment of superficial  SCC,3 it is not currently recommended for the treatment of invasive SCC, mainly due  to the limited bioavailability of ALA in the skin tissue.4,5 Nanoparticles (NPs) might be a useful approach for delivering ALA in topical PDT,  since NPs might improve ALA stability and cutaneous penetration.6 An NP-delivery  system might also improve the selective accumulation of photosensitizer in the diseased  tissue.7 Our in vitro study suggested that the use of polylactic-co-glycolic acid (PLGA)  NPs could improve ALA delivery in human cutaneous SCC cells.8 The aim of this  in  vivo study was to evaluate the feasibility of ALA PLGA NP-mediated PDT for the  treatment of cutaneous SCC in a mouse model.correspondence: Xiuli Wang shanghai skin Disease hospital,  1278 Baode road, shanghai 200443,  People’s republic of china Tel +86 21 6183 3004 Fax +86 21 6183 3021 email xlwang2001@aliyun.co mJournal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Wang et al Running head recto: In vivo evaluation of ALA PLGA nanoparticles DOI: http://dx.doi.org/10.2147/IJN.S71245",Non-OADS,/arxiv_data1/oa_pdf/56/5f/ijn-10-347.PMC4293366.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/56/5f/ijn-10-347.PMC4293366.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/56/5f/ijn-10-347.PMC4293366.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8f/ba/ijn-10-321.PMC4293367.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 321–334International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  321OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S7773 1chitosan based atorvastatin nanocrystals: effect  of cationic charge on particle size, formulation  stability, and in-vivo efficacy Mallesh Kurakula1 aM el-helw2 Tariq r sobahi1 Magdy Y abdelaal1 1Polymer research lab, Department  of chemistry, Faculty of science, King  abdulaziz University, Jeddah, saudi  arabia; 2Department of Pharmaceutics,   Faculty of Pharmacy, King abdulaziz  University, Jeddah, saudi arabiaAbstract:  Cationic charged chitosan as stabilizer was evaluated in preparation of nanocrystals  using probe sonication method.",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/ijn-10-321.PMC4293367.pdf
"The oldest technique,  by physical modification of active pharmaceutical ingredient is a key strategy to  improve the solubility, especially for those moieties which exhibit dissolution rate  limited bioavailability.3 Nanosizing can be a non-specific approach to improve the  bioavailability but is a proven principle paradigm to render an ideal pharmaceutical  formulation.4 Atorvastatin (ATR) ([R-(R*,R*)]-2-(4-fluorophenyl)- β,δ-dihydroxy-5- (1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid,  calcium salt (2:1) trihydrate), is a synthetic statin, acting as lipid lowering agent correspondence: Mallesh Kurakula Polymer research lab; Department  of chemistry, Faculty of science, King  abdulaziz University, PO Box 80203,  Jeddah 21589, saudi arabia Tel +966 054 039 1082 email mallesh_kurakula@yahoo.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Kurakula et al Running head recto: Chitosan based atorvastatin nanocrystals DOI: http://dx.doi.org/10.2147/IJN.S77731",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/ijn-10-321.PMC4293367.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/ijn-10-321.PMC4293367.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/8f/ba/ijn-10-321.PMC4293367.pdf
Available from: http://www.ich.org/fileadmin/Public_Web_Site/ ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.,OADS,/arxiv_data1/oa_pdf/8f/ba/ijn-10-321.PMC4293367.pdf
"Available from:  http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/ Guidelines /Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pd f. Accessed  December 11, 2014.",OADS,/arxiv_data1/oa_pdf/8f/ba/ijn-10-321.PMC4293367.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by- nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/ (9 July 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/standards/ semanticweb/ (9 July 2013, date last accessed).",OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/ TR/2004/REC-rdf-primer-20040210/ (9 July 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/standards/techs/uri#w3c_all (9 July 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/standards/techs/owl#w3c all (9 July 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/standard- s/techs/sparql#w3c all (9 July 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/TR/ 2013/REC-sparql11-entailment-20130321/ (31 August 2013, date last accessed).",OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/ Submission/RDQL/ (9 July 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.ihtsdo.org/snomed-ct/ (9 July2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.cs.man.ac.uk/ /C24horrocks/obo/ (6 October 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.bioontol- ogy.org/wiki/index.php/OboInOwl:Main_Page (6 Octo-ber 2013, date last accessed).",OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/ DesignIssues/LinkedData.html (9 July 2013, date lastaccessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"https://dvcs.w3.org/ hg/gld/raw-file/default/bp/index.html (9 July 2013, datelast accessed).",OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/TR/2013/ NOTE-ld-glossary-20130627/ (9 July 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://patterns.dataincubator.org/book/ (31 August 2013, date last accessed).",OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/wiki/SweoIG/TaskForces/CommunityProjects/LinkingOpenData (9 July 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://datahub.io/group/lod- cloud (19 August 2013, date last accessed).",OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
http://www4.wiwiss.fu-berlin.,Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.ncbi.nlm.nih.gov/pubmed/ (9 July 2013, date last accessed).",OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://www.w3.org/ wiki/HCLSIG/LODD (6 September 2013, date lastaccessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
http://senselab.med.,Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
"http://dbpedia.org/About (6 September 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
http://www.imi.,Non-OADS,/arxiv_data1/oa_pdf/4d/40/bbt079.PMC4293377.pdf
13. http://www.gilead.com/news/press-releases/2013/6/gile-ad-announces-us-fda-priority-review-designation-for-sofos - buvir-for-the-treatment-of-hepatitis-c,Non-OADS,/arxiv_data1/oa_pdf/c0/cc/PDIA-31-22345.PMC4293381.pdf
"This is an Open Access article distributed under the terms of the CreativeCommons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the workproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/06/c4/ciu795.PMC4293395.pdf
Available at: http://www.who.int/tb/ country/en/ .,Non-OADS,/arxiv_data1/oa_pdf/06/c4/ciu795.PMC4293395.pdf
http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.,Non-OADS,/arxiv_data1/oa_pdf/6d/c4/dmcn0056-1117.PMC4293466.pdf
Inves- tigation of an Increase in the Incidence of Narcolepsy in Children and Adolescents in 2009 and 2010. http://healthupdate.gov.ie/wpcontent/uploads/2012/04/Final_Report_of_National_Narcolepsy_Study_Steering_Com- mittee-latest1.pdf (accessed 6 August 2012).,Non-OADS,/arxiv_data1/oa_pdf/6d/c4/dmcn0056-1117.PMC4293466.pdf
Published online 17 July 2013 and http://dx.doi.org/10.1016/j.sleep.2013.03.020 (accessed 21 August 2013).,OADS,/arxiv_data1/oa_pdf/6d/c4/dmcn0056-1117.PMC4293466.pdf
1: 1-3 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2015.28.1.1 |E d i t o r i a l| Complex Regional Pain Syndrome:  Time to Study the Supraspinal Role?,Non-OADS,/arxiv_data1/oa_pdf/cb/2d/kjpain-28-1.PMC4293501.pdf
"1: 11-21 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2015.28.1.11 | Original Article | Comparison of the Efficacy of Caudal, Interlaminar, and  Transforaminal Epidural Injections in Managing Lumbar Disc  Herniation: Is One Method Superior to the Other?",Non-OADS,/arxiv_data1/oa_pdf/b3/5e/kjpain-28-11.PMC4293502.pdf
Available at http://www.ich.org/filea- dmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1 0/Step4/E10_Guideline.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b3/5e/kjpain-28-11.PMC4293502.pdf
"1: 22-31 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2015.28.1.22 | Original Article | Comparative Study of the Effects of the Retrocrural Celiac  Plexus Block Versus Splanchnic Nerve Block, C-arm Guided,  for Upper Gastrointestinal Tract Tumors on Pain Relief and  the Quality of Life at a Six-month Follow Up Department of Anesthesia and Pain Relief, Tanta Cancer Institute,  *Department of Anesthesia and Surgical Intensive Care, Faculty of Medicine, Tanta University, Tanta, Egypt Amera H. Shwita, Yasser M. Amr*, and Mohammad I. Okab* Background: The celiac plexus and splanchnic nerves are targets for neurolytic blocks for pain relief from  pain caused by upper gastrointestinal tumors.",Non-OADS,/arxiv_data1/oa_pdf/ae/0c/kjpain-28-22.PMC4293503.pdf
"1: 32-38 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2015.28.1.32 | Original Article | A Pilot Study of the Correlation between the Numeric  Rating Scale used to Evaluate “Geop ” and  Questionnaires on Pain Perception Department of Anesthesiology and Pain Medicine, Soonchunhyang University Bucheon Hospital,  Soonchunhyang University College of Medicine, Bucheon, Korea Bon Sung Koo, Myung Jin Jung, Joon Ho Lee, Hee Cheol Jin, Jeong  Seok Lee, and Yong Ik Kim Background: The word “geop” is a unique Korean term commonly used to describe fright, fear and anxiety,  and similar concepts.",Non-OADS,/arxiv_data1/oa_pdf/5b/94/kjpain-28-32.PMC4293504.pdf
"1: 39-44 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2015.28.1.39 | Original Article | Comparison of Ramosetron Plus Dexamethasone with  Ramosetron Alone on Postoperative Nausea, Vomiting,  Shivering and Pain after Thyroid Surgery Department of Anesthesiology and Pain Medicine, Konkuk University School of Medicine, Chungju, *Department of  Anesthesiology and Pain Medicine, Wonkwang University College of Medicine, Iksan, Korea Myeong Jong Lee, Kyu Chang Lee, Hye Young Kim, Won Sang Lee, Wo n Jun Seo, and Cheol Lee* Background: Postoperative nausea and vomiting (PONV), po stanesthetic shivering and pain are common  postoperative patient complaints that can result in  adverse physical and psychological outcomes.",Non-OADS,/arxiv_data1/oa_pdf/20/92/kjpain-28-39.PMC4293505.pdf
"1: 4-10 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2015.28.1.4 | Review Article | Etifoxine for Pain Patients with Anxiety Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, Yangsan, Korea Yun Mi Choi and Kyung Hoon Kim Etifoxine (etafenoxine, StresamⓇ) is a non-benzodiazepine anxiolytic with an anticonvulsant effect.",Non-OADS,/arxiv_data1/oa_pdf/d7/10/kjpain-28-4.PMC4293506.pdf
"1: 45-51 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2015.28.1.45 | Original Article | A Comparison of Three Methods for Postoperative Pain  Control in Patients Undergoing Arthroscopic Shoulder Surgery Departments of Anesthesiology and Pain Medicine, *Orthopedic Surgery, †Emergency Medicine,  Jeju National University Hospital, Jeju, Korea Sun Kyung Park, Yun Suk Choi, Sung Wook Choi*, and Sung Wook So ng† Background: Arthroscopic shoulder operations (ASS) are often associated with severe postoperative pain.",Non-OADS,/arxiv_data1/oa_pdf/9d/1c/kjpain-28-45.PMC4293507.pdf
"1: 52-56 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2015.28.1.52 |C a s e  R e p o r t| Successful Treatment of Rectus Femoris Calcification with  Ultrasound-guided Injection: A Case Report 1Department of Rheumatology, Presbyterian Medical Center, Jeonju,  2Department of Anesthesiology and Pain Medicine, Wonkwang University Hospital, School of Medicine,  3Institute of Wonkwang Medical Science, 4Department of Anesthesiology and Pain Medicine, Na-eun Hospital, Iksan, Korea Myong Joo Hong1, Yeon Dong Kim2,3, Jeong Ki Park2, and Tai Ug Kang4 Painful periarticular calcification most commonly occurs within the rotator cuff of the shoulder and rarely  around the elbow, hip, foot, and neck.",Non-OADS,/arxiv_data1/oa_pdf/58/8d/kjpain-28-52.PMC4293508.pdf
"1: 57-60 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2015.28.1.57 |C a s e  R e p o r t| Spinal Cord Stimulation for Intractable Visceral Pain  Due to Sphincter of Oddi Dysfunction Department of Anesthesiology and Pain Medicine, Inje University Haeundae Paik Hospital, Busan, Korea Kang Hun Lee, Sang Eun Lee, Jae Wook Jung, and Sang Yoon Jeon Sphincter of Oddi dysfunction (SOD) is a syndrome of chronic biliary pain or recurrent pancreatitis due  to the functional obstruction of the pancreaticobiliary flow.",Non-OADS,/arxiv_data1/oa_pdf/94/93/kjpain-28-57.PMC4293509.pdf
"1: 61-63 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2015.28.1.61 | Brief Report | The Effect of Stellate Ganglion Block on Intractable  Lymphedema after Breast Cancer Surgery Department of Anesthesiology and Pain Medicine, School of Medicine, Ewha Womans University, Seoul, Korea Jin Kim, Hahck Soo Park, Soo Young Cho, Hee Jung Baik, and Jong  Hak Kim Lymphedema of the upper limb after breast cancer surg ery is a disease that carries a life-long risk and is  difficult to cure once it occurs despite the various treatments which have been developed.",Non-OADS,/arxiv_data1/oa_pdf/82/a6/kjpain-28-61.PMC4293510.pdf
1: 64-65 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2015.28.1.64 | Letters to Editor | Which Methods of Epidural Steroid Injections Is More  Effective in Reducing the Radicular Pain;  Transforaminal or Interlaminar?,Non-OADS,/arxiv_data1/oa_pdf/81/86/kjpain-28-64.PMC4293511.pdf
"REVIEW Korean J Intern Med 2015;30:1-5 http://dx.doi.org/10.3904/kjim.2015.30.1.1 Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgMethods for the morphological and functional  evaluation of microvascular damage in systemic  sclerosis Barbara  Ruaro1, Vanessa Smith2, Alberto Sulli1, Saskia Decuman2, Carmen Pizzorni1, and Maurizio Cutolo1 1Research Laboratory and  Academic Division of Clinical  Rheumatology, Department of  Internal Medicine, University  of Genova, Genoa, Italy;  2Department of Rheumatology,  Ghent University Hospital, Gent,  Belgium Received : August 29, 2014 Accepted: November 10, 2014 Correspondence to  Maurizio Cutolo, M.D.",Non-OADS,/arxiv_data1/oa_pdf/70/c9/kjim-30-1.PMC4293547.pdf
"1, January 2015  www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.1of different body sites [9-11].",Non-OADS,/arxiv_data1/oa_pdf/70/c9/kjim-30-1.PMC4293547.pdf
"Microcirculation in systemic sclerosis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.1The instrument comprises a heatable probe, an optic  fiber connector, an instrument that detects both tissue  perfusion and skin temperature, and a computer to  evaluate the data.",Non-OADS,/arxiv_data1/oa_pdf/70/c9/kjim-30-1.PMC4293547.pdf
"1, January 2015  www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.1in healthy subjects at the level of the fingertips, peri - ungual areas, and palms of the hands.",Non-OADS,/arxiv_data1/oa_pdf/70/c9/kjim-30-1.PMC4293547.pdf
Microcirculation in systemic sclerosis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.1laroscopic patterns in systemic sclerosis.,Non-OADS,/arxiv_data1/oa_pdf/70/c9/kjim-30-1.PMC4293547.pdf
"ORIGINAL ARTICLE Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:104-109 http://dx.doi.org/10.3904/kjim.2015.30.1.104INTRODUCTION Rheumatoid arthritis-associated interstitial lung dis - ease (RA-ILD), the most common manifestation of  rheumatoid lung disease [1], occurs more frequently in  patients with severe RA.",Non-OADS,/arxiv_data1/oa_pdf/b9/16/kjim-30-104.PMC4293548.pdf
RA-ILD with anti-TNF therapy www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.104several randomized controlled trials [4].,Non-OADS,/arxiv_data1/oa_pdf/b9/16/kjim-30-104.PMC4293548.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.104Despite the shorter duration of anti-TNF treatment, a  higher number of acute exacerbations of ILD following  anti-TNF therapy was observed in the nonsurvivor ver - sus survivor group (1.3 [range, 0 to 3] vs. 0.4 [range, 0 to  3], respectively; p = 0.012).",Non-OADS,/arxiv_data1/oa_pdf/b9/16/kjim-30-104.PMC4293548.pdf
"RA-ILD with anti-TNF therapy www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.1043, who received adalimumab for 2 months following 9  months of etanercept treatment, died of septic shock  following knee surgery.",Non-OADS,/arxiv_data1/oa_pdf/b9/16/kjim-30-104.PMC4293548.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.104creased following treatment with anti-TNF therapy ver - sus traditional DMARDs, but the proportion of deaths  attributable to RA-ILD was higher in patients treated  with anti-TNF agents [10].",Non-OADS,/arxiv_data1/oa_pdf/b9/16/kjim-30-104.PMC4293548.pdf
RA-ILD with anti-TNF therapy www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.104Diffuse alveolar hemorrhage after infliximab treatment  of Crohn’s disease.,Non-OADS,/arxiv_data1/oa_pdf/b9/16/kjim-30-104.PMC4293548.pdf
"LETTER TO THE EDITOR Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:110-113 http://dx.doi.org/10.3904/kjim.2015.30.1.110Departments of 1Internal  Medicine, 2Pathology, and  3Radiology, College of Medicine,  The Catholic University of Korea,  Seoul, KoreaCholangiocarcinoma with a paraneoplastic    leukemoid reaction mimicking a pyogenic liver   abscess Hyoju Ham1, Hee Yeon Kim1, Kyung Jin Seo2, Su Lim Lee3, and Chang Wook Kim1 Received : April 2, 2014 Revised : August 20, 2014 Accepted : September 11, 2014 Correspondence to  Chang Wook Kim, M.D.",Non-OADS,/arxiv_data1/oa_pdf/cf/51/kjim-30-110.PMC4293549.pdf
CCC with PLR mimicking liver abscess www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.110tion our initial diagnosis.,Non-OADS,/arxiv_data1/oa_pdf/cf/51/kjim-30-110.PMC4293549.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.110Figure 3 .",Non-OADS,/arxiv_data1/oa_pdf/cf/51/kjim-30-110.PMC4293549.pdf
"CCC with PLR mimicking liver abscess www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.110sive to antibiotics, thus favoring a diagnosis of malig - nancy.",Non-OADS,/arxiv_data1/oa_pdf/cf/51/kjim-30-110.PMC4293549.pdf
"LETTER TO THE EDITOR Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:114-117 http://dx.doi.org/10.3904/kjim.2015.30.1.114 Department of Medicine,  Samsung Medical Center,  Sungkyunkwan University School  of Medicine, Seoul, KoreaA functioning adrenal adenoma and pheochromo - cytoma in the same adrenal gland: two discrete    adrenal incidentalomas Ga Eun Park, Yoon Young Cho, Yun Soo Hong, Su Hoon Kang, Kyung Ho Lee, Hyun Woo Lee, and    Jae Hyeon Kim Received : December 7, 2013 Revised : May 31, 2014 Accepted : July 10, 2014 Correspondence to  Jae Hyeon Kim, M.D.",Non-OADS,/arxiv_data1/oa_pdf/3c/81/kjim-30-114.PMC4293550.pdf
Two discrete adrenal incidentalomas in same adrenal gland www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.114An overnight dexamethasone suppression test was  conducted t o assess cortical secretion to screen for en - dogenous Cushing syndrome.,Non-OADS,/arxiv_data1/oa_pdf/3c/81/kjim-30-114.PMC4293550.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.114cortical adenomas (Fig.",Non-OADS,/arxiv_data1/oa_pdf/3c/81/kjim-30-114.PMC4293550.pdf
Two discrete adrenal incidentalomas in same adrenal gland www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.114cm (Fig.,Non-OADS,/arxiv_data1/oa_pdf/3c/81/kjim-30-114.PMC4293550.pdf
"LETTER TO THE EDITOR Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:118-121 http://dx.doi.org/10.3904/kjim.2015.30.1.118Departments of 1Internal  Medicine, 2Radiology, and  3Surgery, Seoul National  University College of Medicine,  Seoul, KoreaAn insulinoma with an aberrant feeder from the  splenic artery detected by super-selective arterial  calcium stimulation with venous sampling Joon Ho Moon1, Eun Ky Kim1, Ah Reum Khang1, Hyo-Cheol Kim2, Jin-Young Jang3, and Young Min Cho1 Received : February 11, 2014 Revised : June 2, 2014 Accepted : July 10, 2014 Correspondence to  Young Min Cho, M.D.",Non-OADS,/arxiv_data1/oa_pdf/08/7d/kjim-30-118.PMC4293551.pdf
"An insulinoma with an aberrant feeder artery www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.118tests, were within normal ranges.",Non-OADS,/arxiv_data1/oa_pdf/08/7d/kjim-30-118.PMC4293551.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.118artery.",OADS,/arxiv_data1/oa_pdf/08/7d/kjim-30-118.PMC4293551.pdf
An insulinoma with an aberrant feeder artery www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.118cross-sectional anatomy.,Non-OADS,/arxiv_data1/oa_pdf/08/7d/kjim-30-118.PMC4293551.pdf
"LETTER TO THE EDITOR Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:122-124 http://dx.doi.org/10.3904/kjim.2015.30.1.122Departments of 1Internal Medicine  and 2Orthopedic Surgery, Wonju  Christian Hospital, Yonsei  University Wonju College of  Medicine, Wonju, KoreaExtranodal natural killer/T-cell lymphoma of the  tenosynovium of the hand Yoo Li Lim1, Hyun Sung Pack1, Jeong Eun Park1, Jin Rok Oh2, and Jee Hyun Kong1 Received : April 1, 2014 Revised : May 15, 2014 Accepted : June 13, 2014 Correspondence to  Jee Hyun Kong, M.D.",Non-OADS,/arxiv_data1/oa_pdf/ca/08/kjim-30-122.PMC4293552.pdf
NK/T cell lymphoma of tenosynovium www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.122Polymerase chain reaction for Epstein-Barr virus was  negative.,Non-OADS,/arxiv_data1/oa_pdf/ca/08/kjim-30-122.PMC4293552.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.122al.",Non-OADS,/arxiv_data1/oa_pdf/ca/08/kjim-30-122.PMC4293552.pdf
"LETTER TO THE EDITOR Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:125-128 http://dx.doi.org/10.3904/kjim.2015.30.1.125Department s of 1Radiation Oncol - ogy, 2Internal Medicine , 3Surgery ,  and 4Pathology , Chung-Ang  University Hospital, Seoul , KoreaOccurrence of colonic liposarcoma after    retroperitoneal liposarcoma Jin Hwa Choi1, In Gyu Hwang2, Seong Jae Cha3, Tae Jin Lee4, and Joung-Soon Jang2 Received : January 20, 2014 Revised : March 20, 2014 Accepted : June 23, 2014 Correspondence to  Joung-Soon Jang, M.D.",Non-OADS,/arxiv_data1/oa_pdf/22/0d/kjim-30-125.PMC4293553.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.125its.",Non-OADS,/arxiv_data1/oa_pdf/22/0d/kjim-30-125.PMC4293553.pdf
"An abdominal m etachronous liposarcoma http://dx.doi.org/10.3904/kjim.2015.30.1.125 www.kjim.orgpredictor of worse outcome, with a 5-year survival rate of  50%.",Non-OADS,/arxiv_data1/oa_pdf/22/0d/kjim-30-125.PMC4293553.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.1254.",Non-OADS,/arxiv_data1/oa_pdf/22/0d/kjim-30-125.PMC4293553.pdf
"Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgIMAGE OF INTEREST Korean J Intern Med 2015;30:129-130 http://dx.doi.org/10.3904/kjim.2015.30.1.129A 34-year-old woman presented with a  2-year history of anterior midline neck  swelling.",Non-OADS,/arxiv_data1/oa_pdf/06/f9/kjim-30-129.PMC4293554.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.129neck mass, it is important to differentiate ectopic thyroid  tissue from other causes, such as a thyroglossal duct cyst,  lipoma, lymph node, epidermoid cyst, and malignancies,  to prevent inappropriate excision.",Non-OADS,/arxiv_data1/oa_pdf/06/f9/kjim-30-129.PMC4293554.pdf
"Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgIMAGE OF INTEREST Korean J Intern Med 2015;30:131 http://dx.doi.org/10.3904/kjim.2015.30.1.131A 45-year-old female presented with  a facial rash for 2 weeks.",Non-OADS,/arxiv_data1/oa_pdf/15/bc/kjim-30-131.PMC4293555.pdf
"ERRATUMKorean J Intern Med 2015;30:132 http://dx.doi.org/10.3904/kjim.2015.30 .1.132   Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/81/42/kjim-30-132.PMC4293556.pdf
"pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2014;29:764-773 http://dx.doi.org/10.3904/kjim.2014.29.6.764 In the article cited above, the addition of “b” annotation would be needed in  Table 5 of the main text.",Non-OADS,/arxiv_data1/oa_pdf/81/42/kjim-30-132.PMC4293556.pdf
"REVIEW Korean J Intern Med 2015;30:17-22 http://dx.doi.org/10.3904/kjim.2015.30.1.17 Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgMajor changes and improvements of dialysis  therapy in Korea: review of end-stage renal    disease registry Dong Chan Jin Department of Internal Medicine,  College of Medicine, The Catholic  University of Korea, Seoul, Korea Received : October 19, 2014 Accepted: October 30, 2014 Correspondence to  Dong Chan Jin, M.D.",Non-OADS,/arxiv_data1/oa_pdf/ac/66/kjim-30-17.PMC4293557.pdf
"1, January 2015  www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.17DATA COLLECTION METHOD The ESRD registry committee of the KSN collected all  registry data by post mail until 1994, but subsequently  began collecting the data through an online Internet  program that opened in 2001 and was revised in 2013  (Table 1).",OADS,/arxiv_data1/oa_pdf/ac/66/kjim-30-17.PMC4293557.pdf
"Major changes of dialysis therapy in Korea www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.17undergoing HD and PD among those on renal replace - ment therapy was about 70% and 10%, respectively (Fig.",Non-OADS,/arxiv_data1/oa_pdf/ac/66/kjim-30-17.PMC4293557.pdf
"1, January 2015  www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.17MAJOR CHANGE 5: INCREASE IN AGED PA - TIENTS UNDERGOING DIALYSIS AND OVERALL  PATIENTS UNDERGOING LONG-TERM DIALYSIS Korea is one of the most rapidly aging countries world - wide.",Non-OADS,/arxiv_data1/oa_pdf/ac/66/kjim-30-17.PMC4293557.pdf
Major changes of dialysis therapy in Korea www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.17MISCELLANEOUS CHANGES Other observed miscellaneous changes were as fol - lows.,Non-OADS,/arxiv_data1/oa_pdf/ac/66/kjim-30-17.PMC4293557.pdf
"1, January 2015  www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.17the last two decades in Korea.",Non-OADS,/arxiv_data1/oa_pdf/ac/66/kjim-30-17.PMC4293557.pdf
Available from: http://www.jsdt.or.jp.,Non-OADS,/arxiv_data1/oa_pdf/ac/66/kjim-30-17.PMC4293557.pdf
"EDITORIAL Korean J Intern Med 2015;30:23-26 http://dx.doi.org/10.3904/kjim.2015.30.1.23 Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgIs tenofovir disoproxil fumarate an all-powerful  weapon in the treatment of chronic hepatitis B?",Non-OADS,/arxiv_data1/oa_pdf/6e/81/kjim-30-23.PMC4293558.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.23 imen.",Non-OADS,/arxiv_data1/oa_pdf/6e/81/kjim-30-23.PMC4293558.pdf
"TDF for antiviral-resistant CHB  http://dx.doi.org/10.3904/kjim.2015.30.1.23analysis of patients with double ADV resistance muta - tions, in whom the decrease in serum HBV DNA tended  to be slower in the TDF monotherapy group (–2.42 log10  IU/mL) than in the TDF + ETV group (–3.45 log10 IU/ mL).",Non-OADS,/arxiv_data1/oa_pdf/6e/81/kjim-30-23.PMC4293558.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.23 tenofovir monotherapy versus tenofovir plus entecavir  combination therapy in chronic hepatitis B patients with  genotypic resistance mutations to adefovir.",Non-OADS,/arxiv_data1/oa_pdf/6e/81/kjim-30-23.PMC4293558.pdf
"EDITORIAL Korean J Intern Med 2015;30:27-28 http://dx.doi.org/10.3904/kjim.2015.30.1.27 Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgCan improvements in our physiological     understanding yield information on the utility of  endothelial progenitor cell capture stents?",Non-OADS,/arxiv_data1/oa_pdf/1a/d4/kjim-30-27.PMC4293559.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.27 inferred in the absence of baseline information that  was not provided in the cited study.",OADS,/arxiv_data1/oa_pdf/1a/d4/kjim-30-27.PMC4293559.pdf
"EDITORIAL Korean J Intern Med 2015;30:29-31 http://dx.doi.org/10.3904/kjim.2015.30.1.29 Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgAssociation of metabolic syndrome with coronary  artery calcification Kyoung Hwa Ha1 and Dae Jung Kim1,2 1Cardiovascular and Metabolic  Disease Etiology Research Center,  2Department of Endocrinology  and Metabolism, Ajou University  School of Medicine, Suwon, Korea Received : December 11, 2014 Accepted: December 16, 2014 Correspondence to  Dae Jung Kim, M.D.",Non-OADS,/arxiv_data1/oa_pdf/49/64/kjim-30-29.PMC4293560.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.29 MetS and diabetes [12].",Non-OADS,/arxiv_data1/oa_pdf/49/64/kjim-30-29.PMC4293560.pdf
Metabolic syndrome and coronary calcification  http://dx.doi.org/10.3904/kjim.2015.30.1.29REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/49/64/kjim-30-29.PMC4293560.pdf
"ORIGINAL ARTICLE Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:32-41 http://dx.doi.org/10.3904/kjim.2015.30.1.32INTRODUCTION Over the past few decades, treatment of chronic hep - atitis B (CHB) patients has greatly improved with the  development of effective oral nucleos(t)ide analogues  (NAs), which inhibit reverse transcription of hepatitis B  virus (HBV) polymerase [1-3].",Non-OADS,/arxiv_data1/oa_pdf/45/45/kjim-30-32.PMC4293561.pdf
"TDF in CHB with multiple NAs failure www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.32when they are treated sequentially with less potent and  low genetic barrier drugs [7,8].",Non-OADS,/arxiv_data1/oa_pdf/45/45/kjim-30-32.PMC4293561.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.32Clinical and laboratory assessments Serum HBV DNA, HBeAg, ALT, creatinine and phos - phorus levels were assessed routinely every 3 months  during the TDF treatment.",Non-OADS,/arxiv_data1/oa_pdf/45/45/kjim-30-32.PMC4293561.pdf
"TDF in CHB with multiple NAs failure www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.32gorized into three groups according to HBV DNA levels  at baseline (2 to 4, 4 to 6, and  ≥ 6 log IU/mL), lower HBV  DNA levels were significantly associated with increased  CVR rates ( p < 0.001) (Fig.",OADS,/arxiv_data1/oa_pdf/45/45/kjim-30-32.PMC4293561.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.320.74190.89960.9665 0.5175 Months of treatment0 6 13 181.0 0.80.60.40.20.0 24 30 36 42 48 54Cumulative probaility of CVR HBV DNA group < 4 ≥ 4, < 6≥ 6 Months of treatment 0 6 13 181.0 0.80.60.40.20.0 24 30 36 42 48 54Cumulative probability of CVR  Months of treatment0 6 13 181.00.8 0.6 0.4 0.2 0.0 24Geneotype resistance LAM LAM/ADVLAM/ETV 30 36 42 48 54Cumulative probability of CVR TDFTDF + LAM or TDF + ETV Months of treatment0 6 13 181.0 0.80.60.40.20.0 24 30 36 42 48 54Cumulative probability of CVRFigure 1.",Non-OADS,/arxiv_data1/oa_pdf/45/45/kjim-30-32.PMC4293561.pdf
"TDF in CHB with multiple NAs failure www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.32had genotypic resistance to LAM/ADV/ETV, and one  reached a CVR 6 months after TDF plus LAM combi - nation therapy.",Non-OADS,/arxiv_data1/oa_pdf/45/45/kjim-30-32.PMC4293561.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.32level decline of 4.5 log copies/mL after median treatment  duration of 12 months [23].",Non-OADS,/arxiv_data1/oa_pdf/45/45/kjim-30-32.PMC4293561.pdf
TDF in CHB with multiple NAs failure www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.32 against HBV in patients with ETV resistance.,Non-OADS,/arxiv_data1/oa_pdf/45/45/kjim-30-32.PMC4293561.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.32progression: the impact of antiviral therapy.",Non-OADS,/arxiv_data1/oa_pdf/45/45/kjim-30-32.PMC4293561.pdf
TDF in CHB with multiple NAs failure www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.32study.,OADS,/arxiv_data1/oa_pdf/45/45/kjim-30-32.PMC4293561.pdf
"ORIGINAL ARTICLE Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:42-48 http://dx.doi.org/10.3904/kjim.2015.30.1.42INTRODUCTION Percutaneous coronary intervention (PCI) is an estab - lished treatment in patients with obstructive coronary  artery disease [1].",Non-OADS,/arxiv_data1/oa_pdf/51/d7/kjim-30-42.PMC4293562.pdf
"Impact of stent on coronary microvascular function www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.42DES implant site after an average of 6 months following  PCI, whereas this is not the case with BMSs [4-6].",Non-OADS,/arxiv_data1/oa_pdf/51/d7/kjim-30-42.PMC4293562.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.42ly described methods [11].",Non-OADS,/arxiv_data1/oa_pdf/51/d7/kjim-30-42.PMC4293562.pdf
Impact of stent on coronary microvascular function www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.42p = 0.034).,Non-OADS,/arxiv_data1/oa_pdf/51/d7/kjim-30-42.PMC4293562.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.42to determine the independent predictors of microvas - cular dysfunction after PCI.",Non-OADS,/arxiv_data1/oa_pdf/51/d7/kjim-30-42.PMC4293562.pdf
"Impact of stent on coronary microvascular function www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.42In a previous study [7], microvascular function did not  differ between patients who received a DES and those  who received a BMS.",Non-OADS,/arxiv_data1/oa_pdf/51/d7/kjim-30-42.PMC4293562.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.422.",Non-OADS,/arxiv_data1/oa_pdf/51/d7/kjim-30-42.PMC4293562.pdf
"ORIGINAL ARTICLE Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:49-55 http://dx.doi.org/10.3904/kjim.2015.30.1.49INTRODUCTION With the advent of thin-strut designs and biocompati - ble polymers, second- or third-generation drug-eluting  stents (DESs) have been demonstrated to have improved  safety and efficacy compared with first-generation DESs  [1-6].",Non-OADS,/arxiv_data1/oa_pdf/98/16/kjim-30-49.PMC4293563.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.49are limited data on the clinical impact of RFU CAG af - ter second- or third-generation DES implantation in  clinically stable patients with coronary artery disease.",OADS,/arxiv_data1/oa_pdf/98/16/kjim-30-49.PMC4293563.pdf
"Clinical impact of routine follow-up coronary angiography www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.49DM, ST-segment-elevation myocardial infarction, and  smoking patients were about 30%, 20%, and 50% in both  groups.",Non-OADS,/arxiv_data1/oa_pdf/98/16/kjim-30-49.PMC4293563.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.49confidence interval, 0.35 to 2.02) (Fig.",OADS,/arxiv_data1/oa_pdf/98/16/kjim-30-49.PMC4293563.pdf
"Clinical impact of routine follow-up coronary angiography www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.49outcome and the follow-up angiography group suffered  a twofold higher rate of revascularization, primarily due  to revascularization at follow-up angiography [7-16].",Non-OADS,/arxiv_data1/oa_pdf/98/16/kjim-30-49.PMC4293563.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.49low-up group and late catch-up in the clinical follow-up  group was also noted in our study.",Non-OADS,/arxiv_data1/oa_pdf/98/16/kjim-30-49.PMC4293563.pdf
Clinical impact of routine follow-up coronary angiography www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.4911.,Non-OADS,/arxiv_data1/oa_pdf/98/16/kjim-30-49.PMC4293563.pdf
"ORIGINAL ARTICLE Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:56-61 http://dx.doi.org/10.3904/kjim.2015.30.1.56INTRODUCTION Pulmonary paragonimiasis is a food-borne parasitic  disease of the lungs caused by the lung fluke Paragon - imus westermani  or other Paragonimus  species.",Non-OADS,/arxiv_data1/oa_pdf/22/01/kjim-30-56.PMC4293564.pdf
"Paragonimiasis masquerading as pleural tuberculosis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.56berculosis, lung cancer, and other pulmonary infections,  many patients with paragonimiasis face a considerable  burden of long-term hospitalization as well as unnec - essary procedures and treatments before receiving the  correct diagnosis [8-12].",Non-OADS,/arxiv_data1/oa_pdf/22/01/kjim-30-56.PMC4293564.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.56cases.",Non-OADS,/arxiv_data1/oa_pdf/22/01/kjim-30-56.PMC4293564.pdf
"Paragonimiasis masquerading as pleural tuberculosis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.56had a median age of 43 years and did not for the most  part exhibit signs of infection such as fever and periph - eral leukocytosis; therefore, we suspected pleural tuber - culosis rather than parapneumonic effusion and ma - lignancy.",Non-OADS,/arxiv_data1/oa_pdf/22/01/kjim-30-56.PMC4293564.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.56an exudate with a normal-to-low concentration of glu - cose, a pH of ~7.3 (occasionally < 7.2), and a predomi - nance of lymphocytes [18].",Non-OADS,/arxiv_data1/oa_pdf/22/01/kjim-30-56.PMC4293564.pdf
Paragonimiasis masquerading as pleural tuberculosis www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.562.,Non-OADS,/arxiv_data1/oa_pdf/22/01/kjim-30-56.PMC4293564.pdf
"REVIEW Korean J Intern Med 2015;30:6-16 http://dx.doi.org/10.3904/kjim.2015.30.1.6 Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgAvoiding or coping with severe hypoglycemia in  patients with type 2 diabetes Jae-Seung Yun and Seung-Hyun Ko Division of Endocrinology and  Metabolism, Department of  Internal Medicine, College of  Medicine, The Catholic University  of Korea, Seoul, Korea Received : December 6, 2014 Accepted: December 11, 2014 Correspondence to  Seung-Hyun Ko, M.D.",Non-OADS,/arxiv_data1/oa_pdf/6d/2b/kjim-30-6.PMC4293565.pdf
"Hypoglycemia in type 2 diabetes www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.6sleep quality, and the daily function of patients with  both type 1 and type 2 diabetes [8].",Non-OADS,/arxiv_data1/oa_pdf/6d/2b/kjim-30-6.PMC4293565.pdf
"1, January 2015  www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.6often observed, but these symptoms are not specific to  hypoglycemia; instead, they are the result of a percep - tion of the physiological changes caused by the central  nervous system-mediated sympathoadrenal discharge  triggered by hypoglycemia [18].",Non-OADS,/arxiv_data1/oa_pdf/6d/2b/kjim-30-6.PMC4293565.pdf
"Hypoglycemia in type 2 diabetes www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.6cemic event, and that 42% of hypoglycemic episodes  were asymptomatic.",Non-OADS,/arxiv_data1/oa_pdf/6d/2b/kjim-30-6.PMC4293565.pdf
"1, January 2015  www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.6The stress hormones that are secreted in response to  hypoglycemia increase blood viscosity and promote co - agulation, leading to endothelial dysfunction and the  release of inflammatory cytokines into the circulation.",Non-OADS,/arxiv_data1/oa_pdf/6d/2b/kjim-30-6.PMC4293565.pdf
"Hypoglycemia in type 2 diabetes www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.6changes in medication; however, 56% of hypoglycemic  events have an unknown cause [32].",Non-OADS,/arxiv_data1/oa_pdf/6d/2b/kjim-30-6.PMC4293565.pdf
"1, January 2015  www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.6nal hypoglycemia, especially those with pre-existing  ischemic heart disease or recurrent hypoglycemia, are  encouraged to perform SMBG more frequently, and  greater clinical attention is needed.",Non-OADS,/arxiv_data1/oa_pdf/6d/2b/kjim-30-6.PMC4293565.pdf
Hypoglycemia in type 2 diabetes www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.6Conflict of interest No potential conflict of interest relevant to this article  was reported.,Non-OADS,/arxiv_data1/oa_pdf/6d/2b/kjim-30-6.PMC4293565.pdf
"1, January 2015  www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.625.",Non-OADS,/arxiv_data1/oa_pdf/6d/2b/kjim-30-6.PMC4293565.pdf
Hypoglycemia in type 2 diabetes www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.648.,Non-OADS,/arxiv_data1/oa_pdf/6d/2b/kjim-30-6.PMC4293565.pdf
"1, January 2015  www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.6betes.",Non-OADS,/arxiv_data1/oa_pdf/6d/2b/kjim-30-6.PMC4293565.pdf
"ORIGINAL ARTICLE Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:62-72 http://dx.doi.org/10.3904/kjim.2015.30.1.62INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a  common, preventable, and treatable disease, charac - terized by limited airflow that is persistent, typically  progressive, and associated with chronic pulmonary  inflammatory responses to noxious particles and gas -es [1].",Non-OADS,/arxiv_data1/oa_pdf/86/ae/kjim-30-62.PMC4293566.pdf
Ozone exposure on emphysema model www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.62tional study reported that the mortality rate increased  to 2.5% in COPD patients with acute exacerbations of  COPD (AECOPD) [4].,Non-OADS,/arxiv_data1/oa_pdf/86/ae/kjim-30-62.PMC4293566.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.62ozone monitor (IN2000-L2-LC, IN USA Inc., Needham,  MA, USA), which can detect ozone concentrations be - tween 0 and 3 ppm.",Non-OADS,/arxiv_data1/oa_pdf/86/ae/kjim-30-62.PMC4293566.pdf
Ozone exposure on emphysema model www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.62A (0.1% formic acid in water) for 5 minutes.,Non-OADS,/arxiv_data1/oa_pdf/86/ae/kjim-30-62.PMC4293566.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.62than in group I (NS + NO).",Non-OADS,/arxiv_data1/oa_pdf/86/ae/kjim-30-62.PMC4293566.pdf
"Ozone exposure on emphysema model www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.62NO) compared with the other groups, and six spots that  had significantly lower optical densities in group I (NS +  NO) compared with the other groups, were selected for  analysis.",OADS,/arxiv_data1/oa_pdf/86/ae/kjim-30-62.PMC4293566.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.62O).",Non-OADS,/arxiv_data1/oa_pdf/86/ae/kjim-30-62.PMC4293566.pdf
Ozone exposure on emphysema model www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.62Table 1.,Non-OADS,/arxiv_data1/oa_pdf/86/ae/kjim-30-62.PMC4293566.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.62to induce lung inflammation related to pulmonary sur - factant D [23], and 3.0 ppm for 3 hours to induce airway  hyper-responsiveness [24].",Non-OADS,/arxiv_data1/oa_pdf/86/ae/kjim-30-62.PMC4293566.pdf
"Ozone exposure on emphysema model www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.62In conclusion, we developed an ozone-induced exac - erbation model in a smoking-induced emphysema lung,  and TBC1D5 was identified as a potential biomarker of  ozone-induced lung injury in emphysema.",Non-OADS,/arxiv_data1/oa_pdf/86/ae/kjim-30-62.PMC4293566.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.62DS.",Non-OADS,/arxiv_data1/oa_pdf/86/ae/kjim-30-62.PMC4293566.pdf
"ORIGINAL ARTICLE Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:73-81 http://dx.doi.org/10.3904/kjim.2015.30.1.73INTRODUCTION Metabolic syndrome (MetS), as characterized by insulin  resistance (IR), has recently gained considerable atten - tion due to the link among metabolic diseases, obesity,  and cardiovascular disease [1].",Non-OADS,/arxiv_data1/oa_pdf/52/a5/kjim-30-73.PMC4293567.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.73with MetS have a high risk of CAC [7,8].",Non-OADS,/arxiv_data1/oa_pdf/52/a5/kjim-30-73.PMC4293567.pdf
"Metabolic syndrome and coronary calcification www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.73(GE Healthcare, Tokyo, Japan).",Non-OADS,/arxiv_data1/oa_pdf/52/a5/kjim-30-73.PMC4293567.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.73the three sets of MetS criteria.",Non-OADS,/arxiv_data1/oa_pdf/52/a5/kjim-30-73.PMC4293567.pdf
"Metabolic syndrome and coronary calcification www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.73model was used to predict the presence of CAC, there  were no differences in C statistics among the three sets  of MetS criteria.",OADS,/arxiv_data1/oa_pdf/52/a5/kjim-30-73.PMC4293567.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.73sive and non-invasive techniques are available to measure  subclinical atherosclerosis [27].",Non-OADS,/arxiv_data1/oa_pdf/52/a5/kjim-30-73.PMC4293567.pdf
Metabolic syndrome and coronary calcification www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.73MetS and CAC [3].,Non-OADS,/arxiv_data1/oa_pdf/52/a5/kjim-30-73.PMC4293567.pdf
"1, January 2015 http://dx.doi.org/10.3904/kjim.2015.30.1.732 diabetes mellitus.",Non-OADS,/arxiv_data1/oa_pdf/52/a5/kjim-30-73.PMC4293567.pdf
Metabolic syndrome and coronary calcification www.kjim.org http://dx.doi.org/10.3904/kjim.2015.30.1.73diovascular events in people with type 2 diabetes: system - atic review and meta-analysis.,Non-OADS,/arxiv_data1/oa_pdf/52/a5/kjim-30-73.PMC4293567.pdf
"ORIGINAL ARTICLE Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2015;30:82-87 http://dx.doi.org/10.3904/kjim.2015.30.1.82INTRODUCTION Diabetic cystopathy (DC) is an important long-term  complication in patients with diabetes mellitus (DM); it  occurs in 30% to 80% of diabetics [1-4].",Non-OADS,/arxiv_data1/oa_pdf/7b/5e/kjim-30-82.PMC4293568.pdf
